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Oxidative stress is associated with a number of cardiovascular diseases such as atherosclerosis 
and pulmonary hypertension.  Previously, our group has shown that prostaglandin–F2α and 
hypoxia enhance total tyrosine phosphorylation, activate Src and cause SrcFK-dependent 
constriction. Combining these observations with the ROS-sensitivity of Src, lead me to 
investigate whether interaction between SrcFK and ROS makes a central contribution to 
vascular smooth muscle function.    
 
Intra-pulmonary Arteries (IPA) were dissected from rat lungs, protein was extracted and 
phosphorylation of known targets of Rho-kinase (MYPT-1) and MLCK (MLC20) as well as Src 
auto-phosphorylation (Tyr416) was measured. Protein-protein interactions were examined by 
immune-precipitation/co-immuno-precipitation. Contraction was measured in IPA mounted on 
a wire myograph. Primary smooth muscle cell lines, generated from IPAs were used to measure 
ROS production using the luminescent dye L-012 or were transfected with GFP-tagged RhoA 
or ARHGEF1 to visualise protein translocation in live cells.  
 
In this study, I demonstrate that U46619 and LY83583 induce ROS production in PASMCs. I 
also demonstrate that U46619 and LY83583 contractile responses in IPA are sensitive to both 
antioxidants and SrcFK inhibition. U46619, hypoxia and LY83583 also enhance SrcFK 
autophosphorylation, ROCK activity and MLC20 phosphorylation which are blocked by SrcFK 
inhibition, antioxidants (U46619 and LY83583) and mitochondrial inhibitors (hypoxia). 
Finally, U46619 and LY83583 promote reversible translocation of eGFP-RhoA or eGFP-
ARHGEF1 in a SrcFK dependent and ROS dependent manner. U46619 also enhanced co-
immunoprecipitation of ARHGEF1 with SrcFK. Taken together these results suggest SrcFK’s 
play a key role as ROS sensitive intermediates which enhance contractile responses via 
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Glossary of Terms 
U46619 (U46) – T-type prostanoid receptor agonist. 
LY83583 (LY) – A cell permeable quinolinedione and substrate for the oxidoreductase enzyme 
diaphorase. Therefore an intracellular superoxide generator 
Tempol – Antioxidant. 
Ebselen – Antioxidant. 
PP2 – A selective SrcFK inhibitor. 
L-NAME - An analogue of arginine that inhibits the production of nitric oxide (NO). 
Rotenone – Inhibits electron transfer from complex 1 of the electron transport chain. 
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1.1 Pulmonary Vasculature 
The pulmonary circulation begins when blood is pumped by the heart (right ventricle) into the 
main pulmonary artery, which immediately divides into the right and left pulmonary arteries 
supplying each lung. The blood is reoxygenated while passing through the pulmonary 
capillaries before re-entering the heart and being pumped around the body through the systemic 
vasculature.  
The pulmonary circulation receives the entire cardiac output of the right ventricle. It contains a 
high-density capillary network, thereby maximising gaseous exchange (CO2 to O2 and vice 
versa). Resistance of the pulmonary circulation is 10-15% of the systemic circulation. This is 
due to the vessels of the pulmonary microcirculation being short and relatively wide, with low 
levels of resting tone. The pulmonary circulation network is also numerous, so the total cross-
section is comparable to that of the systemic circulation. The sympathetic nervous system, 
myogenic or metabolic regulation have very little effect in regulating pulmonary resistance. 
The most important mechanism regulating pulmonary vascular tone is hypoxic pulmonary 
vasoconstriction (HPV), a process whereby pulmonary arteries constrict in response to hypoxia 
(systemic vessels typically dilate) thereby maximising the matching of perfusion to ventilation 
in the lungs.     
Understanding the pulmonary circulation is of vital importance as dysregulation within this 
system can lead to disease states such as pulmonary hypertension and eventually right heart 
failure. With this in mind, it is also important to investigate the basic signalling pathways in the 
pulmonary circulation so that they can subsequently be studied in more depth in disease states 




1.1.1 Pulmonary Hypertension  
 
Pulmonary hypertension (PH) is a term used to describe a wide spectrum of rare but lethal 
pulmonary hypertensive conditions that have different aetiologies but similar clinical 
presentation. The normal resting adult pulmonary pressure is ~16mmHg. However, PH patients 
have a mean pulmonary arterial pressure (mPAP) of >25 mmHg at rest or >30 mmHg during 
exercise.   
PH was classified initially as primary, if the cause was unknown and secondary if the cause can 
be identified. More complex classifications have been designed to enable the classification of 
various manifestations of PH based on pathological, functional and clinical characteristics, 
currently there are 5 groups 1,2. Group 1 PH, also known as pulmonary arterial hypertension 
(PAH), includes heritable and idiopathic PAH (hPAH, iPAH), which are associated with 
mutations in the bone morphogenetic receptor type II (BMPR-II). Groups 2-5 are forms of 
secondary PH. Group 2 is associated with left heart disease resulting in increased left atrial 
pressure that is transmitted to the pulmonary artery. Group 3 PH is due to lung diseases such as 
chronic obstructive pulmonary disease (COPD) which leads to chronic hypoxia 3. Pulmonary 
arteries (PA) constrict in response to alveoli hypoxia, termed hypoxic pulmonary 
vasoconstriction (HPV). This was initially described by von Euler-Lijestand in 19464  and aims 
to optimise ventilation perfusion by diverting blood away from poorly ventilated areas of the 
lung. HPV is considered vital in normal pulmonary vasculature, so long as it is short lived and 
highly localised. Chronic hypoxia triggers pulmonary vascular remodelling leading to 
pulmonary arterial hypertension followed by right ventricle hypertrophy 5-9. Group 4 PH 
includes chronic thromboembolic PH, and is mainly caused by pulmonary embolism. Group 5 
PH is associated with a heterogeneous set of conditions such as chronic myeloid leukaemia 
(CML) and thyroid disease. Secondary PH is managed by treated the cause of the underlying 




PH is characterised by pulmonary vascular remodelling due to increased pulmonary artery 
smooth muscle migration, proliferation and neomuscularisation 10,11. Subsequently, leading to 
increased pulmonary resistance. The causes of remodelling remain controversial however the 
RhoA/Rho-Kinase has been implicated in numerous aspects.  
The discovery that contraction of vascular smooth muscle, in addition to being regulated by 
intracellular Ca2+ concentration ([Ca2+]i), is also regulated via the monomeric G-protein RhoA 
and its downstream effector Rho-Kinase12,13. Furthermore, chronic hypoxia, which acts as a 
contributing factor to the development of pulmonary hypertension 14, is linked to enhanced 
RhoA/Rho-Kinase activity in PH 15. This has led to enormous interest in the effects of this 
pathway on vascular function. The RhoA/Rho-Kinase pathway, in addition to regulating the 
contractile responses of the vasculature via activation of G protein coupled receptor activation 
(GPCR), also exerts important effects on smooth muscle differentiation, proliferation and 
migration as well as on endothelium-dependent vasodilatation 16.  
As these processes are believed to contribute to PAH and non-PAH PH, regulation of Rho-
Kinase and inhibitors of RhoA/Rho-Kinase signalling within vascular smooth muscle have 
emerged as possible treatments for these conditions.
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1.2 Vascular Smooth Muscle 
Section Overview 
This section will give a brief overview of the structure and function of vascular smooth muscle 
particularly in relation to contraction. I will also describe a number of mechanism that regulate 
VSM contraction and the evidence for non-receptor tyrosine kinases in vascular function.   
 
Introduction 
Vascular smooth muscle cells (VSMC’s) are highly specialized cells that surround all hollow 
organs including blood vessels, airways, stomach, bladder, uterus and intestines. In blood 
vessels, VSMC’s main function is the regulation of blood pressure and regional blood flow 
distribution. VSMC’s within adult blood vessels proliferate at extremely low rates, however 
they express a unique collection of contractile proteins, ion channels and signalling molecules 
required for the cell’s contractile function, which is unique when compared to other cells type. 
VSMC’s retain extreme plasticity in phenotype in response to changes in local environment; 
for example, morphogenesis of blood vessels in response to vascular injury. The main function 
of VSMCs is contraction. During contraction, smooth muscle shortens and the diameter 
changes, which propels organ contents. Smooth muscle cells are not striated (as opposed to 
cardiac or skeletal muscle) giving rise to their smooth appearance. 
 
Activation of smooth muscle cells occurs in response to external stimuli such as hormones, 
paracrine signalling molecules and changes in local environmental factors, including PCO2, 
PO2, pH and ROS. Contractile force is therefore determined by variations of activation of the 
contractile system in all coupled cells. Smooth muscle filaments are composed of primarily 
alpha-actin (α-actin) which are anchored to dense bodies. As with all smooth muscle, 
contraction arises due to cross bridge cycling between actin and myosin. 
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1.2.1 Organisation of the Contractile Fibres  
The contractile apparatus of smooth muscle is composed of actin and myosin filaments. Myosin 
itself has a molecular weight of 520kDa and is formed of six polypeptide chains, two heavy 
chains and 2 pairs of light chains. The light chains can be further divided into 
“regulatory/functional” light chains 20kDa in size and “essential” light chains 17kDa in size.  
 
Actin is a globular multifunctional protein that forms part of the microfilaments, found in all 
eukaryotic cells. There are currently four known isoforms identified within smooth muscle; α 
and γ actin associated with “contractile” phenotype while β and γ are associated with 
“cytoskeletal” actin. Actin monomers are 43kDa globular proteins (g-actin) which contains 
binding sites for 2 actin monomers, thereby creating filamentous actin or F-actin. F-actin is a 
double stranded helical structure where the actin monomers are orientated in the same direction. 
Contractile microfilaments such as stress fibres contain alpha actinin, which ensures actin fibres 
are bundled together in parallel and creates space between them into which myosin fibres fit. 
Actin monomers are also polar which is vital as it contributes to their assembly but also in 
establishing the movement of myosin relative to actin. 
 
Two other proteins, calponin and caldesmon are key components of actin cytoskeleton and bind 
actin proteins. They are able to regulate actin filaments by crosslinking actin into networks as 
well as interacting with other structural proteins. Calponin and caldesmon can also inhibit the 





1.2.2 Smooth muscle contraction and regulation 
A key event that is essential for initiating smooth muscle contraction is the rise of intracellular 
calcium ([Ca2+]i). This can occur via release from intracellular stores such as the sarcoplasmic 
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reticulum (SR) 17 or via influx through voltage independent or dependent membrane channels 
18.  
Ca2+ release from stores occurs in response to activation of G-protein coupled receptor (GPCR) 
contractile agonists. This results in the activation of phospholipase c-β (PLCβ), and subsequent 
inositol triphosphate (IP3) and 1,2-diacyglycerol (DAG) mediated Ca2+ increase19,20. Increase 
in [Ca2+]i can also occur via capacitive Ca2+ entry otherwise known as store operated calcium 
entry21,22. Voltage independent pathways can also involve agonist-induced Ca2+ release through 
the activation of ryanodine receptors (RyR) found on the SR. This can occur via calcium 
induced calcium release, a process whereby calcium influx activates RyR and promotes release 
from the SR 23-25. Voltage dependent pathways occur via depolarisation (through attenuation of 
K+ channel conductance) of the plasma membrane resulting in the activation of voltage operated 
calcium channels (VOCCs) such as L-type Ca2+ channels26,27.  
Ca2+ can then form a complex with calmodulin. The Ca2+/calmodulin complex activates myosin 
light chain kinase (MLCK) which phosphorylates myosin light chain (MLC20) at position serine 
19. Myosin light chains are 20-kD regulatory subunits, that when phosphorylated, activate 
myosin. More specifically, this phosphorylation activates the myosin ATPase that provides the 
energy required to move the myosin head and promote cross bridge cycling between actin and 
myosin filaments and thereby contraction. 
The degree of force generated during smooth muscle contraction is determined by the net 
phosphorylation of MLC. This is a balance between MLCK and myosin light chain phosphatase 
(MLCP). MLCP dephosphorylates P-MLC converting it back to the inactive MLC (Fig 1.1). 
Following contraction, [Ca2+]i returns to basal levels which causes relaxation via plasma 
membrane Ca2+ ATPases (PMCA), sodium calcium exchangers (NCX), cytosolic binding 
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proteins and re uptake of Ca2+ into the SR via sarco/endoplasmic reticulum Ca2+ ATPase (Serca) 
28.   
Ca2+ Sensitization 
Ca2+ sensitization is a process whereby there is an increase in contractile force in response to 
contractile stimuli independent of changes in free cytosolic calcium 29.   
Ca2+ sensitization was initially observed in smooth muscle permeabilized with bacterial α-toxin 
30. This study revealed that [Ca2+]i does not always mirror the degree of MLC phosphorylation 
and contractile force. Therefore, contraction in smooth muscle can be enhanced by events that 
are independent of changes in [Ca2+]i.. 
Somlyo et al 31 suggested that MLCP is a G protein-regulated enzyme. This was based on Ca2+-
independent contractile effect of guanosine 5′-O-(3-thiotriphosphate) (GTPγS) on 
permeabilized smooth muscle. Subsequently, this was confirmed by demonstrating that GTPγS 
and agonists increased MLC phosphorylation independently of changes in [Ca2+]i, by inhibiting 
dephosphorylation of MLC12,30. These findings, along with demonstrating that pre-treatment of 
smooth muscle with adenosine 5′-O-(3-thiotriphosphate) (ATPγS) under Ca2+-free conditions 
caused thiophosphorylation of MYPT1 and increased the Ca2+ sensitivity of contractile force 
32, focused attention on MYPT1 as a Rho-Kinase substrate 33 and a key factor in Ca2+ 
sensitization. 
MLCP is a trimeric holoenzyme composed of three subunits, 38kDa catalytic subunit (PP1c), 
110 kDa non-catalytic myosin phosphatase targeting subunit (MYPT-1) and a 20kDa non-
catalytic subunit 34,35. There are three main ways in which MLCP is regulated; dissociation of 
its heterotrimeric structure, inhibition of inhibitory proteins such as CPI-17 and 
phosphorylation of MYPT-1 36. Phosphorylation of MYPT-1 is a major regulatory mechanism 
of MLCP. There are at least two known phosphorylation sites, which are related to the inhibition 
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of MLCP 36. Phosphorylation of MYPT-1 at Thr 696 (thr-697 in rat), is associated with MLCP 
inhibition 37. Kimura et al 33 first demonstrated that Rho-Kinase phosphorylates this site 
however a number of other kinases can also do this. These include zipper-interacting kinase 
(ZIPK) 38 and integrin-linked kinase (ILK) 39. Phosphorylation of MYPT-1 at Thr-850 is 
associated with MLCP disassociation and another key target of Rho-Kinase 40,41. 
In vascular smooth muscle, it has been suggested that phosphorylation of MYPT-1 at thr-850 
is the more significant site at inhibiting the actions of MLCP 41,42. Phosphorylation at this site 
has been shown to be sensitive to Rho-Kinase inhibition 41,43.  
DAG or Ca2+ can also activate protein kinase C (PKC) which in turn can also phosphorylate 
CPI-17 thereby inhibiting MLCP activity 44,45.  
Inhibition of MLCP is now known to occur primarily via activation of the RhoA / Rho-Kinase 
pathway in response to GPCR activation and plays a key role in Ca2+ sensitization 29,46,47 (Fig 
1.1). This will be explored in more detail in sections 1.6 and 1.7. 
Crosstalk between RhoA/ROCK and cytosolic Ca2+ 
RhoA/ROCK and cytosolic Ca2+ have distinct actions at promoting and enhancing VSM 
contraction. Until recently, Rho and Rho-kinase activation were considered to occur as a 
consequence of agonist binding. However, this assumption has been challenged,  Mita et 
al used high K+ to depolarize the caudal artery and found the contraction to be Rho-kinase 
sensitive and associated with inhibition of MLCP 48. A number of other studies have confirmed 
this observation and shown the activation of Rho-kinase by depolarization is Ca2+-dependent in 
vascular smooth muscle 49-52 . Thus it appears that Rho and Rho-kinase are activated by two 
pathways, one Ca2+-independent and one Ca2+-dependent. The exact mechanism of how Ca2+ 
activates Rho-Kinase remains to be elucidated however number of studies have provided some 
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clues as to potential mechanisms of Rho-Kinase regulation via membrane depolarisation and 
Ca2+ signalling.  
A study performed by Liu et al 53 recently reported that membrane depolarization causes a 
direct activation of G protein-coupled receptors leading to local Ca2+ release in smooth muscle. 
The authors demonstrate that membrane depolarization can induce RyR-mediated local Ca2+ 
release, leading to an increase in the activity of Ca2+ sparks and contraction in airway SMCs. 
The increased Ca2+ sparks are independent of VDCCs and the associated extracellular Ca2+ 
influx. This local Ca2+ release is attributed to direct activation of G protein-coupled M3 
muscarinic receptors in the absence of a ligand, which causes activation of Gq proteins and 
phospholipase C, leading to the generation of inositol 1,4,5-triphosphate (IP3). Subsequently 
promoting an initial Ca2+ release through IP(3) receptors and then further Ca2+ release via RyR2 
due to a local Ca2+-induced Ca2+ release process. These findings demonstrate an important 
mechanism for Ca2+ signalling but also has the potential of not only activating Gq signalling but 
also other heterotrimeric G proteins such as G12/13. 
Further evidence provided by Sakurada et al 54   demonstrated that depolarization with high 
KCl induced Rho activation and Rho kinase–dependent contraction, which are both 
Ca2+dependent in rabbit aortic VSM. Furthermore, a Ca2+dependent Rho activation also 
operates in VSM stimulated with noradrenalin and U46619, coupled to Gq and G12/13. The 
authors suggest that Rho activity is likely regulated by both G12/13 and Gq/Ca2+ and suggest that 
the Ca2+-dependent Rho activation may involve Ca2+ and calmodulin stimulation of RhoGEF 
as Rho activation was inhibited by the calmodulin inhibition. Furthermore, there are known 
examples for calmodulin regulation of GEFs of the other small GTPases such as the Ras-GEFs 
Ras-GRF 1 and 2 which possess an IQ motif that act as calmodulin-binding site, were shown 
to be activated by Ca2+-influx in an IQ motif-dependent manner 55. It is therefore entirely 
possible that calmodulin may also activate RhoGEFs. 
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More recently, Janssen et al 56 sought to examine the contribution of voltage-dependent 
Ca2+ influx and Rho/ROCK signalling in the responses to high-millimolar KCl, making 
comparisons between TSM and BSM as well as among porcine, bovine, and human airways. 
The authors show that KCl caused substantial contractions in tracheal preparations which were 
sensitive to the removal of external Ca2+ or the selective L-type Ca2+ channel blocker 
nifedipine; porcine bronchial preparations were much less sensitive, and bovine bronchi were 
unaffected by 1 μM nifedipine. Interestingly, the authors demonstrate that KCl-induced 
contractions were also sensitive to two structurally different ROCK inhibitors: Y-27632 and 
HA-1077. Furthermore, the inhibitory effects of nifedipine and the ROCK inhibitors were not 
additive suggesting that they are art of the same pathway. KCl also stimulated Rho and ROCK, 
which was suppressed by nifedipine or by removal of external Ca2+. KCl-induced [Ca2+]I influx 
was not affected by Y-27632 but was reversed by NiCl2 or by BAPTA-AM. The authors 
conclude that KCl acts through stimulation of Rho and ROCK, secondary to voltage-dependent 
Ca2+ influx. The authors speculate that depolarization and/or Ca2+ influx increases the activity 
of Rho GTPase-activating protein which in turn would result in activation of ROCK 29. Other 
groups have also shown that ion channels to form large complexes with a wide variety of 
kinases and these complexes promote the interactions between the channels and enzymes is a 
prerequisite for signalling via those enzymes57. 
Conversely, it has also been suggested that RhoA/Rho-kinase signalling affects agonist-induced 
Ca2+ mobilization. This was shown by Ito et al who demonstrate that receptor-operated Ca2+ 
influx is inhibited by Rho-Kinase inhibition 58. In another study, Shabir et al reported that Rho-
Kinase activity without agonist stimulation, modulates myogenic contraction in both a Ca2+ 
dependent and independent manner 59.  
What all these studies show is the diverse and highly complex nature of signalling events over 
and above the canonical signalling events demonstrated in figure 1. Further investigation will 
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be required to elucidate the mechanism(s) underlying this voltage- and/or Ca2+ dependent 
activation of the Rho/ROCK signalling pathway. 
Figure 1.1: 
 
Figure 1.1: The major pathways involved in smooth muscle contraction.  
Upon agonist stimulation of GPCRs, contraction occurs due to an increase in free cytosolic 
Ca2+. Furthermore, sensitivity of the contractile machinery via activation of the RhoA/Rho-
Kinase pathway can also occur, thereby, enhancing contractile force without the associated rise 
in free cytosolic Ca2+. How these pathways are activated can be found in the main text.   
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1.2.3 Non-receptor tyrosine kinase in vascular function 
 
Non-receptor tyrosine kinases (NRTKs) are cytoplasmic enzymes which act as important 
intermediates following activation of receptor tyrosine kinases (RTK) and G protein-coupled 
receptors (GPCR). These pathways are vital for contractile function, differentiation, survival, 
apoptosis and proliferation 60. There is also strong evidence linking NRTK signalling to 
regulating vascular tone, increased intracellular Ca2+ levels 61 and Ca2+ sensitization 62.   
A number of reports have linked NRTKs in modulating levels of free cytosolic Ca2+ and 
membrane potential. Touyz et al 63 demonstrated that in VSMC from human resistance arteries, 
angiotensin II induced a transient rise in [Ca2+]i, which was shown to be associated with a rise 
in IP3 via tyrosine phosphorylation of phospholipase γ1 (PLC-γ1) 64,65. Furthermore, L-type 
voltage-gated Ca2+ channel in VSMC are believed to be activated by tyrosine phosphorylation 
66. Wijetunge et al 67 was able to demonstrate that voltage-gated Ca2+ current is blocked by the 
tyrosine kinase inhibitors tyrphostin 23 and genistein. Liu and Sperelakis68 also demonstrated 
that genistein, decreased the open time and increased the closed time of single L-type 
Ca2+channels in rat portal vein cells.  
NRTK have been implicated in regulating Ca2+ activated K+ (BKCa) current in VSM. Genistein 
and lavendustin A both enhance BKCa current in rat tail artery cells, and tyrphostin A25 inhibit 
single channel currents during inside out patches69. More recently, Nagaraj et al70 proposed that 
the Src-family kinases (SrcFK) is a crucial factor controlling potassium channels, acting as a 
cofactor for setting a negative resting membrane potential in hPASMCs.  Taken together, these 
results demonstrate that NRTK have multiplicity of functions in regulating Ca2+ levels and 
membrane potential.   
Several early studies, before the development of specific NRTK inhibitors, have also suggested 
that NRTK play an important role in Ca2+ sensitisation.  These studies often used inhibitors 
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such as genistein to determine the role of tyrosine phosphorylation in smooth muscle 
contractility 71,72. Subsequently, genistein reversibly inhibited contraction in alpha-toxin 
permeabilized smooth muscle preparations, demonstrating a role for protein tyrosine 
phosphorylation in Ca2+ sensitization73. Alpha-toxin permeabilization allows for the control of 
intracellular concentrations of some important factors required for the contraction, particularly 
calcium. By clamping the Ca2+ concentration at a constant level, factors that affect the 
sensitivity of the contractile machinery to Ca2+, such as MLCP can be investigated. Skinned 
smooth muscle preparations effectively performs the same function as clamping Ca2+ 
concentration, except, the plasma membrane no longer maintains the ionic gradient necessary 
for maintaining the membrane potential. This allows for the control of calcium and other ions, 
therefore, intracellular signalling can be investigated without the influence of transmembrane 
currents 74. 
Further evidence for the role of NRTK in Ca2+ sensitization has been shown in studies carried 
out by Toma et al 75 who demonstrated the effects of tyrosine kinase inhibitors on the 
contractility of rat mesenteric resistance arteries. Ohanian et al 76 demonstrated the involvement 
of tyrosine phosphorylation in endothelin-1-induced calcium-sensitization in rat small 
mesenteric arteries and Matinez et al 77 who investigated the involvement of protein kinase C, 
tyrosine kinases, and Rho-Kinase in Ca2+ handling of human small arteries. Furthermore, Sasaki 
et al 78 also demonstrated that TKIs, inhibited agonist- and GTPγS-enhanced Ca2+ sensitisation 
in skinned rabbit mesenteric artery.  
GTPγS is a non-hydrolyzable G-protein-activating analog of guanosine triphosphate (GTP) and 
can mimic the Ca2+ sensitizing effects of receptor agonists. This prevents the GTP binding 
proteins from being inactivated, and allows the cellular processes and regulation to be 
investigated 79-81.  
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More recently, a number of studies using SrcFK specific blockers PP1 and PP2, have 
demonstrated a direct role of SrcFKs in contractile function 7,41,82,83. Nakao et al 82 first provided 
evidence for the role of the SrcFK member, Fyn, in Ca2+ sensitization of coronary artery 
contraction mediated by the sphingosylphosphorylcholine (SPC)-Rho-Kinase pathway. Knock 
et al 41 demonstrate for the first time that agonist-mediated, Rho-Kinase-dependent Ca2+ 
sensitization but not basal Rho-Kinase activity in rat pulmonary artery requires SrcFK activity. 
Knock et al 7 further demonstrated a direct role of SrcFKs in the acute contractile response to 
hypoxia in small pulmonary arteries of rat. Finally, Shaifta et al 83 recently showed that SrcFKs 
mediates Ca2+ sensitization in airway smooth muscle (ASM), while Src and focal adhesion 
kinase (FAK) together and individually influence multiple Ca2+ pathways. SrcFKs will be dealt 
with in more detail in sections 1.4, 1.5 and 1.6.  
1.3 Reactive oxygen Species 
 
Section overview 
Reactive oxygen species (ROS) are generated through the incomplete reduction of molecular 
oxygen. ROS are produced in healthy vascular tissue in response to a range of vasoconstrictor 
agonists and under hypoxic conditions which contribute to cellular functions. During hypoxic 
challenge, pulmonary arteries tend to constrict, a term commonly known as hypoxic pulmonary 
vasoconstriction (HPV). HPV is beneficial if it is short lived and highly localised, minimising 
the shunt effect. Global hypoxia throughout the lung can lead to pulmonary hypertension as this 
will cause constriction of the whole pulmonary circulation, thus increasing total pulmonary 
artery pressure and putting strain on the right heart. 
 
This section will detail: what ROS are, how ROS are produced and the key players involved in 
their regulation. It will briefly detail why ROS are believed to act as key secondary messenger 
molecules mediating vascular smooth muscle contraction in response to multiple stimuli. This 
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will be followed by section 1.4, where I describe the evidence for protein kinases, in particular 
tyrosine kinases, as redox sensitive intermediates, in response to ROS production.     
What are ROS? 
Reactive oxygen species (ROS) are reactive molecules derived from molecular oxygen. They 
are diffusible, short-lived molecules that can reversibly oxidise proteins, lipid, ion channels and 
transcription factors within biological systems 84. Initially, ROS were thought to occur solely 
as damaging bi-products of metabolism, however, they are now being recognised as bona fide 
second messengers in normal cellular function. ROS mediate responses such as gene 
expression, growth, survival/apoptosis, migration, adhesion and inflammation. However, ROS 
also modulate smooth muscle contractility 85, which will be the main focus of my PhD thesis.  
 
There are several ROS species including superoxide (O2•-), hydrogen peroxide (H2O2), 
peroxynitrite (OONO-), and the hydroxyl radical (OH•), which are produced in biological 
systems. O2•- also reacts with NO, forming peroxynitrite (ONOO-). It has been suggested that 
peroxynitrite (ONOO-), modifies proteins through nitration or S-nitrosylation86, although this 
is thought to be too indiscriminate to be of physiological relevance 87. O2•- can pass through the 
membrane via anion channels and is believed to act as a major intermediate in contractile 
function and Rho-Kinase activation 88,89. Knock et al 88 have shown that superoxide has very 
specific targets in pulmonary artery, independently of H2O2, namely activation of Rho-Kinase. 
  
O2•- is converted to H2O2 by superoxide dismutase (SOD) 90. H2O2 can also be produced by 
NADPH oxidase enzymes directly before O2•- leaves the enzyme 91. H2O2 has received the most 
attention because of its higher stability compared to O2•- and due to its membrane permeability. 
It is important to note that not only does H2O2 act on adjacent targets, but because it is relatively 
stable, it can also serve paracrine functions. H2O2 is destroyed by catalase or glutathione 
peroxidise (by reduction to H2O), but can be converted to hydroxyl radical (OH•) by the Fenton 
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reaction (catalysed by Fe2+). As with peroxynitrite, hydroxyl radical is not thought to play a 
physiological role due to its extremely short half-life and highly reactive nature 87,92 .   
 
1.3.1 How are ROS produced? 
ROS production is tightly controlled by cytosolic or membrane-bound oxido-reductase 
enzymes including; NADPH oxidase, xanthine oxidase, cyclooxygenase, lipoxygenase, nitric 
oxide (NO) synthase, heme oxygenase, peroxidases and within the mitochondrial electron 
transport chain (complex I/III) (ETC). The main function of the ETC is to transfer electrons 
along the chain thus creating a proton gradient for the formation of ATP. However, when 
protons “leak” from the ETC, mainly from complex III, this generates ROS which mediates 
hypoxic pulmonary vasoconstriction (HPV) 93,94. As mentioned, ROS can be produced by a 
variety of means, however I will focus specifically on NADPH oxidase and mitochondrial ETC 
ROS production. 
1.3.2 NADPH Oxidase 
 
NADPH Oxidases (NOX) proteins are a family of 7 membrane-associated, multiunit enzymes 
that catalyse the reduction of molecular oxygen using NADPH as an electron donor.  Electrons 
are transferred from NADPH down an electrochemical gradient first to flavin adenine 
dinucleotide (FAD), then through the NOX heme groups and finally across the membrane to 
oxygen, forming O2•- 95,96. In addition to these subunits, certain NOX enzymes contain EF-hand 
motifs at the N-terminus, allowing for the binding of Ca2+. A limited number of NOX enzymes 







Expression of NOX 
There are a number of NOX family members. However their expression, structure and ROS 
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Table 1.1: NOX Isoforms  
Details NOX isoforms, expression, subunits present and what species of ROS each subunit is 
believed to produce.   
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General Mechanism of NOX activation  
 
ROS are produced in healthy tissue in response to a wide variety of vasoconstrictor agonists 
including angiotensin 116, endothelin 117,118 and thrombin 119. 
NOX activation occurs via calcium or protein–protein interactions and involves all NOX 
enzymes, with the exception of NOX4, which is constitutively active 120 and NOX5 and the 
DUOX enzymes which are directly calcium dependent 121,122.  Therefore control of NOX1, 
NOX2, and NOX3 is primarily achieved through alterations of the cytosolic proteins in 
response to stimuli such as GPCR activation.  
In short, the activity of NOX1-3 in response to constrictor stimuli promotes translocation of 
p67phox 123 which binds to its NOX subunit. This binding is not strong and requires the adaptor 
proteins, active p47phox bound to p22phox 124,125 to augment p67phox to its NOX subunit. This 
function of p47phox is governed by phosphorylation, which occurs during activation of the 
oxidase 124,126. The small GTPase Rac also binds to p67phox 127, thereby allowing for full NOX 
activity. In the case of NOX1 and 3, these are most highly activated by the p47phox and p67phox 
homologues, NOXO1 and NOXA1.  
NOX4 is generally thought of being constitutive active therefore protein levels determine 
NOX4 activity and ROS production 128. A growing number of studies suggest that NOX4 might 
also be acutely activated in response to agonist stimulation, but analysis of these papers show 
very mixed picture. 
Finally, the physiological functions of NOX5 and DUOX1-2 are just emerging 129. Due to the 
presence of EF hand motifs, the first stimulus identified to increase NOX5 activity was calcium. 
  
Due to expression profile data already shown in table 1, NOX1, 2 and 4 are expressed in smooth 
muscle. NOX1 is known to be activated by angiotensin II (AngII) 130 and upregulated in Dahl 
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salt-sensitive rats131. More recently, Shaifta et al 99 demonstrated that NOX1 is essential in the 
generation of ROS for the contraction potentiating actions of sphingosylphosphorylcholine 
(SPC) in mesenteric arteries. Here, using mice lacking gp91phox (NOX2) or p47phox, the 
organizer subunit for NOX2 and NOX1, potentiation was the same in vessels from WT and 
gp91phox2/2 mice, it was absent in mice lacking p47phox. NOX4 is thought to be constitutively 
active and responsible for basal ROS production 132,133. This strongly suggests that activation 
of NOX1 and consequent generation of ROS are essential for the potentiating actions of SPC. 




The Mitochondria acts as another major source of cellular O2•- produced as a by-product of 
incomplete oxidative phosphorylation 136. In particular, complexes I 137, II 138 and III 139 of the 
mitochondrial respiratory chain “leak” electrons during respiration to form O2•-. From complex 
I and II, O2•- is released into the matrix where due to the high concentration of antioxidants, 
ROS is rapidly broken down, whereas complex III139 can release O2•- from both sides of the 
inner mitochondrial membrane (figure 1.2). Antioxidants such as SOD2 (MnSOD) and catalase 
found in the mitochondria, rapidly breakdown or sequester O2•- and H2O2 to reduce reactivity 











Figure 1.2: Mitochondrial ETC complexes can generate superoxide from multiple sites  
Complex I and II release ROS primarily into the matrix compartment, where manganese 
superoxide dismutase (MnSOD) converts superoxide to hydrogen peroxide (H2O2). Hydrogen 
peroxide is further broken down by catalase to water. Complex III can generate ROS which is 
rapidly released into the intermembrane space. Superoxide can enter the cytosol via anion 
channels or converted to hydrogen peroxide and diffuse across the membrane. 
 
Hypoxia 
It is believed that hypoxia promotes ROS production from the mitochondria. This is known as 
the ROS hypothesis140,141. At first glance, this seems counter-intuitive, since the production of 
superoxide is dependent on the availability of O2 as an electron acceptor. However, there are a 
number of factors which favour the release of ROS from the mitochondria.  
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Activation of mitochondrial potassium channels have been described to enhance ROS 
production. Marshall et al 102 first described the activation of NAD(P)H Oxidase (NOX) and 
increased superoxide production under hypoxic conditions. More recently, a link between NOX 
and the mitochondria has been described in endothelial cells. Here, Dikalov et al 142 describe 
how angiotensin II activates NOX2 which enhances ROS production subsequently activating 
ROS sensitive PKCɛ. PKCɛ phosphorylates and activates the mitochondrial ATP-sensitive 
potassium channels (mitoKATP) which increased the production of mitochondrial ROS 143,144 
via reverse electron flow102.  
Recently, the Rieske iron-sulphur protein (RISP), which transfers one electron from ubiquintol 
at the outer ubinquintol-binding site to cytochrome c forming ubisemiquinone, which 
subsequently transfers an electron to cytochrome b. Ubisemiquinone has been shown to transfer 
electrons to molecular oxygen and produce superoxide. Knockdown or over-expression of RISP 
has been shown to inhibit or increase hypoxia induced ROS production94,145,146. 
The degradation of ROS is tightly regulated by antioxidant enzymes and cellular REDOX 
buffers 87 which rapidly breakdown ROS thereby reducing the chance of oxidative damage. 
  
1.3.4 Antioxidant enzymes 
 
The redox state of vascular tissues is controlled by oxidative stimuli and antioxidant enzymes 
such as SOD, catalase and glutathione redox buffers. The cell is normally kept in a reduced 
state however when this balance is shifted in favour of oxidation (oxidative stress)147, this can 
affect cellular signalling pathways and promote disease states such as hypertension 116 and 
reperfusion injury 148. These proteins are key in preventing damage from oxidative stress. It is 
important to note, that antioxidant enzymes/proteins also function beyond protecting the cell 
from oxidative damage. They are also key in ‘normal signalling’, being involved in the 
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termination and localisation of normal ROS bursts which could be involved in regulating 
oxidative signalling.   
In response to physiological stimuli there is an increase in ROS production which is regulated 
and occurs in specific micro domains. This is different from oxidative stress as during oxidative 
stress there is an imbalance between the production of free radicals and the ability of the body 
to counteract or detoxify their harmful effects.   
Superoxide dismutase (SOD)  
There are 3 SODs found in mammalian cells, (SOD1, SOD2, and SOD3).  SODs convert O2•- 
to H2O2. SOD1, a Cu/Zn SOD, is expressed in the cytoplasm, SOD2 (manganese containing) is 
also known as mitochondrial manganese SOD because of its localization. Finally, SOD3 (also 
Cu/Zn containing), which is secreted and then bound to the outer plasma membrane. Deletion 
of SOD has been implicated in a number of disease states 149. 
Catalase  
Catalase, catalyses the breakdown of H2O2 to water and O2. Catalase contains 4 heme groups. 
The heme-iron is initially oxidized by H2 O2 to form molecular oxygen and water 150. Catalase 
expression is high in many tissues however catalase null mice develop normally 151. 
Cellular Redox Buffers 
 
Cellular redox buffers are buffer systems located within the cell that control levels of ROS thus 
protecting the cell from oxidative damage e.g. oxidative modification of proteins. There are 
three main redox buffers: Glutathione (GSH), Thioredoxins (Trx) and Peroxiredoxins (Prx).   
Glutathione  
GSH is considered the main redox buffer in a cell because of the large amount of reducing 
equivalents supplied by GSH 152 (glutathione present in cells at mM concentrations). GSH 
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molecules are easily oxidized to form GSH disulfide (GSSG), which is then reduced back to 
GSH by the reaction with GSH reductase (GR).  
Reduced glutathione (GSH) can donate H+ and e- to ROS such as O2•- but forms a reactive GS. 
But 2 GS react together to form GSSG (oxidised glutathione). Glutathione peroxidase catalyses 
2GSH + H2O2 → GSSG. 2 GSH are regenerated from GSSG by glutathione reductase, utilising 
NADPH as a reducing agent 
The intracellular thiol redox status is described as the ratio of reduced to oxidized forms, 
GSH/GSSG, showing 100 or more at the steady state but decreasing to 10 or less under 
oxidative stress conditions 153,154. 
Thioredoxins  
Thioredoxins (Trx) are a group of ubiquitous antioxidant enzymes, found in organisms ranging 
from archae to mammals which contains two cysteines in the redox active centre 155. They 
regulate the function of target proteins through oxidoreductase activity. Trx couples with Trx-
dependent peroxidases (Prxs) to scavenge hydrogen peroxide (H2O2) and peroxynitrite along 
with catalyzing the reduction of disulfide bonds 156-158. Organisms have developed their 
specialized subset of Trxs, which are located in various cellular compartments. For instance, 
some Trxs are abundant in the cytosol 159, while others are translocated to the nucleus 160,161 or 
mitochondria, associated with the cell membrane 162 or secreted to the extracellular environment 
163. 
Peroxiredoxins 
Peroxiredoxins (Prx) are thiol-specific antioxidant proteins, also termed the thioredoxin 
peroxidases. Prxs exert their protective antioxidant role in cells through their peroxidase activity 
via redox-active cysteines whereby scavenging hydrogen peroxide, peroxynitrite and a wide 
range of organic hydroperoxides (ROOH) which are reduced and detoxified 164-168. Along with 
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Trx, Prx are also able to catalyse the reduction of disulphide bonds. Although located primarily 
in the cytosol, Prxs are also found within mitochondria, peroxisomes, nuclei and membranes, 
and, in at least one case, exported 164 . Prxs are produced at high levels in cells and compose 
0.1–0.8% of the soluble protein in other mammalian cells 169. 
Glutathione Peroxidase (GPX) 
Gpx promotes the breakdown of H2O2 and lipid hydroperoxides to water or corresponding 
alcohols using reduced glutathione (GSH) 170. Gpx is thought to play a more critical protective 
antioxidant role in the cardiovascular system than catalase 171. Gpx knockout mice exhibit 
increased susceptibility to ischemia–reperfusion injury 172. 
These systems along with enzyme systems already discussed, offer a powerful antioxidant 
defence mechanisms.  
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Protein function can be altered by oxidative modification of amino acid residues, especially 
cysteine. At “physiological” levels of ROS, this oxidative modification may be limited to 
specific cysteine residues found on key proteins involved in cellular signal transduction which 
may alter their function and interactions with other proteins. Some of these include membrane 
channels such as K+ channels and Ca2+ channels, tyrosine phosphatases and protein kinases. 
  
Amongst the latter are the Src family of non-receptor tyrosine kinases (SrcFK) which may be 
activated through direct oxidative modification, while tyrosine phosphatases are inhibited 
leading to a net increase in phosphorylation. The eponymous member of the kinase family, Src, 
is of particular interest as a signalling molecule involved in proliferation and migration along 
with regulating multiple signalling pathways in smooth muscle contraction.  
 
In this section, I will describe the relationship between ROS production (agonists and hypoxia) 
and activation of NRTK, specifically SrcFK, and how this relates to smooth muscle contraction.   
 
Introduction 
Non-receptor tyrosine kinases (NRTKs) are cytoplasmic enzymes which act as important 
intermediates following activation of receptor tyrosine kinases (RTK) and G protein-coupled 
receptors (GPCR). 
Although both types of tyrosine kinases are primarily known for their roles in cell growth and 
proliferation, studies by Di Salvo et al 173,174 and Hollenberg’s et al 72,175 suggested that NRTK 
also play an important role in vasoconstriction in response to G protein coupled receptors 
(GPCR) activation. This idea was suggested from observations that tyrosine kinase inhibitors 
(TKI) attenuated vasoconstrictor-induced contraction. Furthermore, activation of GPCR caused 
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tyrosine phosphorylation of multiple cellular proteins.There is now an increasing body of 
evidence indicating that tyrosine phosphorylation is an important proximal signalling 
mechanism following contractile stimuli, many of which also increase ROS production, 
including angiotensin II (Ang II), endothelin-1 (ET-1), and thrombin 84,116,118,119. While most of 
the above involve activation of NADPH oxidase, there is evidence that ROS derived from 
mitochondria play an important signalling role. A specific example of the latter is hypoxic 
pulmonary vasoconstriction (HPV), where it has been proposed that the initial stimulus is 
hypoxia-induced elevation of mitochondrial ROS production 94,140,176 as discussed in section 
1.3.3.  
Furthermore, increased ROS levels have been shown to increase tyrosine phosphorylation in 
vascular tissue 72,177,178. Evidence for a role of NRTK in GPCR-mediated vasoconstriction has 
come from numerous studies which have shown that TKI or tyrosine phosphatase inhibitors 
such as sodium orthovanadate can inhibit or enhance vasoconstriction. Furthermore, two 
previous studies using broad-spectrum tyrosine kinase blockers (genistein and tyrphostin) 
suggested that tyrosine kinases were involved in HPV179,180, however due to the non-specificity 
of these TKI, the kinase involved was unknown.  
Finally, a number of early studies using non-specific TKI such as lavendustin A and tyrphostin 
47 been reported to see an increase rather than inhibit tyrosine phosphorylation. This disparity 
is due to the poor selectivity of these early non-specific TKI, and explains how using non-
specific TKIs can exert opposing effects 181-184. More recent, selective SrcFK inhibitors such as 




1.4.1 Non-receptor tyrosine kinase (NRTK) 
 
Many NRTKs are localised in the cytoplasm however some are anchored to the cell membrane 
via myristoylation and palmitoylation. In general, NRTKs contain SH2 and SH3 domains which 
are examples of non-catalytic domains involved in protein-protein interaction188. The Src 
Homology 2 (SH2) interacts with phospho tyrosine residues and Src Homology 3 (SH3) which 
interacts with proline rich sequences. The majority of NRTKs have a catalytic domain which is 
held in an inactive state through intramolecular bonds. However, the catalytic domain can be 
activated via auto-phosphorylation or via phosphorylation by another kinase 189, thereby 
opening the kinase domain. An example of this being activation of integrins, which bind ECM 
ligands subsequently activating SrcFK via activation of focal adhesion kinase (FAK) leading to 
further downstream signalling 190. 
1.4.2 Kinase regulation by ROS 
 
Protein kinases modify the function of target proteins by catalysing phosphorylation of tyrosine, 
threonine and/or serine residues.  There are a number of protein kinases implicated in smooth 
muscle constriction, including receptor tyrosine kinases (e.g., epidermal growth factor-receptor 
[EGF-R] and platelet-derived growth factor-receptor [PDGF-R]), SrcFK, PKC, mitogen-
activated protein kinases (MAPKs), and Rho-Kinase 191, many of which are prime targets for 
redox regulation.  
 
Importantly, responses to physiological stimuli and changes in protein kinase activity are 
blocked by antioxidants. This suggests that ROS act as intermediate signalling molecules 
between stimulus and downstream effectors, such as kinases. This is consistent with the 
knowledge that exogenously applied ROS from xanthine/xanthine oxidase or quinones such as 
LY83583 88,151 promote vasoconstriction. Vascular beds where externally applied ROS promote 
constriction include aorta192 , pulmonary artery88,193,194 and coronary artery195. ROS-mediated 
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vasoconstriction is inhibited by nonspecific tyrosine kinase inhibitors (e.g., genistein)192, 
specific inhibitors of SrcFK 41,196 and Rho-Kinase inhibitors 88,192,197.  
Exogenous ROS can also cause relaxation, depending on the vascular bed and the nature of any 
pre constriction 88,198. Snetkov et al 89 demonstrated that O2•- promotes Rho-Kinase-dependent 
Ca2+ sensitization in pulmonary but not mesenteric arteries. In both arterial types, K(V) channels 
are shown to be open, however this only results in relaxation in mesenteric. This indicates that 
Rho-Kinase mediated Ca2+ sensitization is having an overriding effect in the pulmonary arteries 
which is not mirrored in the mesenteric arteries. Suggesting, a fundamental difference in what 
signalling pathways have a greater influence over vascular tone in different vascular beds. 
It is clear that ROS play an important role in vascular function. As mentioned, there are a 
number of ways in which kinases can be activated or inhibited by oxidation. This can occur 
through oxidation or nitrosylation of redox-sensitive cysteines found within the kinase or via 
regulatory proteins such as tyrosine phosphatases87,199. It has also been suggested that nitration 
or nitrosylation of tyrosine residues by peroxynitrite may also prevent tyrosine phosphorylation 
86, it is unknown how tightly regulated this process is 87.    
  
1.4.3 Src-Family Kinases (SrcFK) 
 
SrcFKs are a group of closely related NRTKs including the eponymous member Src 200. SrcFKs 
have a molecular weight between 52-62kDa possessing six distinct and functional domains 201 
(Figure 1.3). There are nine members of SrcFKs which have been well characterised in 
mammalian cells 200. The most widely expressed members of the Src family include c-Src, Fyn, 
Yes, Lyn, Hck, Blk, Fgr and Frk 202. Our laboratory has shown that Src, Fyn and Yes are highly 
expressed in rat intra-pulmonary arteries (IPA) and cultured pulmonary arterial smooth muscle 
cells (PASMCs) at both the mRNA and protein levels41. Furthermore, Src has been shown to 





Figure 1.3: SrcFK Structure 
The domain structure of Src family kinases. The Src kinase architecture consists of four 
domains: the unique region, which varies among family members, followed by the SH3 
(protein-protein interactions), SH2 (binds to phospho tyrosine residues on other proteins or 
within same protein. The auto inhibitory site (Tyr 527) is required to be de phosphorylated 
followed by phosphorylation at (Tyr 416) for Src to be activated unless another protein disrupts 
the internal SH2 (tyr527) binding). These sites are indicated. Finally the SH4 domain is 
important for membrane targeting. 
 
SrcFK exists either in a folded inactive form or an open active form. Src contains two important 
phospho-tyrosine residues, one in the kinase activation loop (tyr-416 in humans) and one in the 
C-terminal regulatory domain (tyr-527 in humans). The inactive form is kept folded by binding 
of the Src Homology 2 (SH2) domain with the phosphorylated tyr-527. This is stabilized by 
internal binding of the Src Homology 3 (SH3) domain with the proline-rich linker region 203. 
Src is activated by de-phosphorylation of tyr-527 or by proteins binding to the phospho-tyrosine 
residues or proline-rich regions, such as the platelet-derived growth factor-receptor (PDGF-R) 
203. This results in the autophosphorylation of tyr-416 in the kinase domain, thereby fully 
activating the kinase. Tyr-416 may be further phosphorylated within the SH2 domain, by PKC, 
further destabilizing internal binding and activating Src 203. Src inactivation occurs through 





1.4.4 SrcFK regulation by ROS 
 
SrcFK can be a target for either direct redox regulation and/or regulation indirectly through 
redox modification of associated proteins, such as tyrosine phosphatases. 
Contractile stimuli that generate ROS have been shown to activate SrcFK. This has been 
demonstrated in studies that measure Src activity directly, or use tyr- 418 phosphorylation as a 
measure of activity. These stimuli include hypoxia/reoxygenation 7,204,205, stretch 195, growth 
factors 206, and GPCR agonists 99,116-118,207. Activation of Src in response to GPCR agonists is 
linked to NOX activity 193,208 and in response to hypoxia, mitochondrial ROS 204. Src is also 
activated by exogenous H2O2 in various tissues including vascular smooth muscle, at 
concentrations believed to be within the physiological range 209-211. However, Src has been 
shown to be inactivated by H2O2 212. The latter study used 20 mM H2O2 as an oxidizing agent, 
which would be considered higher than physiological range of ROS. Therefore, Src may be 
activated by physiological levels of ROS however inactivated at higher concentrations.  
In addition, since the primary trigger for HPV is believed to be an increase in mitochondrial 
ROS production 94, it is interesting to note that hypoxia enhances Src activity 7,204, while Src 
inhibition, inhibits HPV 7. Thus, SrcFKs are prime targets for hypoxia-induced ROS as part of 
the mechanism of HPV.  
Direct Redox Regulation of SrcFK 
SrcFK proteins contain cysteine residues, cys-245 in the SH2 domain and cys-487 in the kinase 
domain, which have been shown to be redox sensitive to lipoxygenase-derived ROS at focal 
adhesions 213. This study showed that Src activation was bi-phasic, the first phase involving 
dephosphorylation of tyr-527 mediated by protein tyrosine phosphatase (PTP), and the second 
phase involving oxidation of cys-245 and cys-487, resulting in enhanced Src activation. 
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Alternatively, SrcFK may also be activated through oxidation of as yet unidentified cysteine 
residues by either H2O2 or NO 211. 
Indirect Redox Regulation of SrcFK 
Exogenous ROS, peroxynitrite, and stimuli that can increase ROS production, increase cellular 
tyrosine phosphorylation, indicating that either PTP are inhibited or kinases are activated, or 
both 177,214. All PTPs contain cysteine residues in their catalytic domains that are essential for 
catalytic activity. These cysteine residues has low pKa values and are therefore more sensitive 
to oxidation than cysteine residues of most other proteins199.  
PTPs can reverse tyrosine phosphorylation of downstream targets and are able to de-
phosphorylate both tyr-527 and tyr-418 of Src. Therefore, the redox state of the cell and 
sensitivity of PTPs expressed will affect tyrosine phosphorylation. Currently, the PTPs that 
regulate SrcFK are unknown, however tyr-527 has been shown to be de-phosphorylated by the 
cytosolic phosphatases PTP1-B, SHP-1, SHP-2 PTP-a and CD45, with some reports also 
suggesting that PTP-BL and CD45 can de-phosphorylate Src at tyr- 418 212,215,216. 
 
Positive feedback between Src activation and ROS production 
Src has been implicated as part of a positive feedback loop involved in enhancing ROS 
production 217-219. Src has been shown to be upstream of serine phosphorylation of p47phox in 
response to angiotensin II, suggesting an intermediate kinase such as PKC 220. In endothelial 
cells, Src mediates tyrosine phosphorylation of p47phox 126. Furthermore, Ang II activates NOX 
which subsequent activates Src in a ROS-dependent manner, subsequently through 
transactivation of the EGF-R, activates rac-1, which is required for assembly and activation of 
NOX 219. Finally, as discussed in the section 1.3.3, Dikalov et al 142 has shown the role of PKC 
and SrcFK in ROS induced ROS release. Interestingly, PKC and Src are themselves redox-
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sensitive, giving rise to the possibility of positive feedback-mediated amplification and further 
signalling92. 
1.5 G-protein coupled receptors and smooth muscle regulation 
Section Overview 
Ca2+ sensitization in response to constrictor stimuli occurs primarily through the activation of 
the monomeric G protein RhoA and its principle effector Rho-Kinase. Rho-Kinase enhances 
constriction by phosphorylating the myosin phosphatase targeting subunit (MYPT-1), thereby 
inhibiting myosin phosphatase activity and enhancing myosin light chain phosphorylation. 
Previous studies have shown that constriction induced by agonists and hypoxia in pulmonary 
arteries involves activation of both RhoA and Rho-Kinase. Furthermore, it has been suggested 
that SrcFKs contributes to constriction though activation of RhoA/Rho-Kinase. The key 
proteins involved in RhoA/Rho-Kinase activation that are phosphorylated by Src are unknown. 
Logical targets are guanine nucleotide exchange factors (RhoGEFs) which promote exchange 
of GDP to GTP on RhoA, causing activation.  
 
So far, I have outlined the evidence for ROS being produced in response GPCR stimulation but 
also under hypoxic conditions. Here, I discuss the evidence for SrcFK being a key component 
of GPCR signalling.  
 
Introduction 
Contraction occurs in response to a number of stimuli, one such stimuli is agonist-induced 
activation of GPCR. Heterotrimeric G proteins (Gα, Gβ/Gγ subunits) are molecular switches 
that turn on intracellular signalling cascades in response extracellular stimuli. 
 
There are approximately 460 non-olfactory receptors encoded in the mammalian genome 221 
which are activated by a broad spectrum and diverse ligands including neurotransmitters and 
hormones222,223. Upon activation, GPCRs undergo a conformational change which activates 
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heterotrimeric G proteins by promoting the exchange of GDP/GTP associated with the Gα 
subunit. This leads to the dissociation of Gβ/Gγ from Gα. These become free to act upon their 
downstream effectors and thereby initiate unique intracellular signalling responses. After the 
signal is terminated (via intrinsic GTPase activity, RGS proteins or ligand disassociation), GTP 
of Gα-GTP is hydrolysed to GDP and Gα becomes inactive (Gα-GDP), which leads to its re-
association with the Gβ/Gγ dimer to form the inactive heterotrimeric complex224.  
1.5.1 Heterotrimeric G Proteins 
 
GPCRs are characterised by having a seven-transmembrane domain containing an extracellular 
N terminal and a cytoplasmic c terminal 225. The characteristics and class of GPCRs will not be 
described here in extensive detail. There are four basic families of guanine nucleotide-binding 
proteins (G-Proteins) involved in smooth muscle contraction. These are characterised 
depending on their G-protein α-subunit; Gαs, GαI/Go, Gαq/G11 and Gα12/13. 226.  
 
There are three main classes of G-proteins which are involved in mediating smooth muscle 
contraction; GI/Go, Gq/G11 and G12/13. Receptors which are coupled to Gq/G11 activate PLCβ, 
stimulate IP3 mediated release of [Ca2+]i from the SR and DAG mediated Ca2+ influx from 
membrane bound channels 227. Activation of receptors coupled to GI/Go can promote contraction 
due to inhibition of adenylyl cyclase and decreased protein kinase A (PKA) signalling 29. This 
counteracts smooth muscle relaxation promoted by activation of Gs which stimulates the PKA 
pathway by enhancing the activity of adenylyl cyclase which increases levels of cyclic AMP 
(cAMP) which in turn activates PKA and promotes relaxation 228. Finally, receptors coupled to 
G12/13 act via Rho guanine nucleotide exchange factors (RhoGEFs) specifically the RGS domain 
containing RhoGEFs (p115 RhoGEF, PDZ-RhoGEF and LARG-RhoGEF) 229,230 (these will be 
discussed in greater detail in section 1.7.4). This results in the activation of RhoA via exchange 
of GDP to GTP and subsequent activation of Rho-Kinase mediated calcium sensitization 
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29,46,231. Rho-Kinase can also promote actin polymerization 232 as well as play a pivotal role in 
a number of other functions. 
 
1.5.2 SrcFK activation by Heterotrimeric G-proteins  
 
Activation of Src by G-proteins is just one of the many events following receptor stimulation 
233. Activation of Src by GPCRs can be direct, via association with the intracellular receptor 
domain of the GPCR or indirectly via other means, such as oxidative modification 234.  
During my project, I used an agonist called U-46619 (U46). U46 is a thromboxane mimetic that 
induces vasoconstriction via activation of the TP receptor. This has been previously shown to 
involve Ca2+ sensitization231,235,236 as well as increase intracellular calcium 231,237,238. TP 
receptors are widely distributed in a variety of cell types including smooth muscle239-242. The 
TP receptor is known to be coupled to Gq and stimulate DAG/IP3 secondary messenger 
system243. More recently, the TP receptor has also been found to be coupled to G12/13244. 
Activation of G12/13 is known to regulate RhoGEF proteins which are upstream of RhoA/Rh-
Kinase 245. U46 is a potent vasoconstrictor in IPA’s and highly efficient at promoting 
vasoconstriction in IPA.  
An essential question is how SrcFK are being activated by U46, which G-protein is involved 
and how it activates SrcFK?  
Early experiments demonstrated that SrcFKs could be activated by a number of G-protein-
coupled-receptors (GPCRs), including the lysophosphatidic acid (LPA1, LPA2, LPA3)246-
248, α2A adrenergic249, M1 muscarinic 249, M2 muscarinic250,  PAR-1251 and PAR-2252, ETA253 
and AT1254 . Src activation by GPCRs coupled has predominantly been shown to be linked to 
pertussis toxin-sensitive Gi/o family G proteins, like the LPA, and is inhibited by proteins that 
sequester Gβγ subunits. However, Gq/11-coupled receptors like the AT1 receptors can also 
mediate Gα subunit-dependent Src activation.  
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Several GPCRs including the TP receptor255 contain consensus SH3 domain-binding motifs 
within their third intracellular loops or C-terminal tails. The β3 adrenergic receptor is an 
example where receptor activation promotes the formation of a complex between Src and the 
receptor 256.  Similar result have also been demonstrated with the purinergic P2Y2 receptor 257. 
Direct interactions between Src and the TP receptor have not been shown. However, it is 
entirely possible Src can directly interact with the TP receptor due to the presence of its SH3 
domain binding motifs found on both proteins.  
Numerous studies also suggest that direct interactions between Src and Gᾳ subunits may 
regulate SrcFK activity. Incubation of Src with GTP-γS-bound Gαs and GᾳI results in a 
significant increase in Src activation 258. Gα12 has also been shown to activate Src via 
recruitment of HSP90 which increased paracellular permeability in response to thrombin 259. 
Furthermore, overexpression of Gᾳ11 enhanced SrcFK activity leading to enhanced JNK and 
p38 MAPK activity which is blocked by the SrcFK inhibitor, PP2 and CSK overexpression 260. 
Finally, the Gβγ complex which was originally believed to act as docking proteins for Gᾳ 
subunits has been found to act as a key intermediate responsible for the activation of Src 246,261. 
These findings suggest that SrcFK may function as G-protein-regulated effectors particularly 
with receptors that are bound to these subunits. 
Signalling through GPCRs is regulated by arrestins. Arrestins bind to the receptors which 
prevents further G-protein activation. β-arrestins have been shown to function as signal 
transducers whereby β-arrestin 1 and β-arrestin 2 can bind directly to Src and recruit it to 
agonist-occupied GPCRs. The formation of β-arrestin:Src complexes on desensitized GPCRs 
appears to promote a 'second wave' of GPCR signalling 262.  
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ROS have also been implicated in signalling pathways initiated by other vasoconstrictor 
agonists, including angiotensin II and endothelin263 coupled to PLC via Gq. Activation of 
Gq/PLC is known to be coupled to enhanced Src and PKC activity. 
SrcFK has not been shown to be regulated directly by Ca2+ however other kinases such as 
protein-tyrosine kinase 2 (PYK2) 264 or PKC92, which associate with SrcFK, are regulated by 
Ca2+. As mentioned, the TP receptor is known to be coupled to Gq and stimulate 
DAG/IP3 secondary messenger system243 and increase Ca2+, therefore it is possible that this 
increase in calcium can activate PYK2 or PKC to further activate SrcFK and promote 
signalling. 
 
1.6 Rho-associated coiled-coil Kinase protein family (Rho-Kinase)  
 
Section Overview 
Rho-Kinase is a serine/threonine kinase and a member of the AGC family of kinases, activated 
by the monomeric G-protein, RhoA 16. Leung and colleagues were the first to identify Rho-
Kinase as an effector for the GTPase Rho265. Rho-Kinase has since emerged as an important 
factor in organisation of the actin-myosin cytoskeleton as well as an important regulator of cell 
contraction, motility, morphology, cell division, metabolism and gene expression 16,266,267. 
Until now, I have detailed the evidence for SrcFK acting a ROS-sensitive intermediate and key 
component of GPCR signalling. This section, I will primarily describe the evidence implicating 
SrcFK as an upstream mediator of Rho-Kinase. 
 
1.6.1 Expression of Rho-Kinase 
 
There are two known isoforms of Rho-Kinase expressed in the mammalian system: ROCK1 
and ROCK2. Rho-Kinase proteins are ubiquitously expressed however, ROCK2 is highly 
expressed in the brain and skeletal muscle 268-270. Both ROCK1 and ROCK2 are expressed in 
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VSM271. ROCK2 predominantly regulates VSMC contractility by directly binding to and 
phosphorylating the myosin-binding subunit of myosin phosphatase 272. 
1.6.2 Structure and activation of Rho-Kinase   
 
Rho-Kinase is comprised of an amino-terminal or (N-terminal) catalytic domain, a central 
coiled-coil domain, a Rho-Binding domain (RBD) and a carboxyl-terminal (C-terminal) 
domain. The C-terminal has a pleckstrin homology (PH) domain containing a cysteine rich 
region of which the function is unknown 16,273. The PH domain is involved in protein 
localisation and serves as a site for protein-protein interactions 274 (Figure 1.4). 
Figure 1.4 
 
Figure 1.4: Rho-Kinase structure  
Structure of Rho-Kinase. The structure of Rho-Kinase comprised of a Kinase domain, coiled 
coil domain containing a Rho-Binding domain and a pleckstrin homology (PH) domain 
containing a cysteine rich area. 
 
 
The structure of Rho-Kinase is such whereby the coiled-coil domain acts as an auto inhibitory 
domain and the PH domain targets the protein to the membrane. This setup ensures that the 
kinase domain of Rho-Kinase is inhibited when unstimulated. Rho-Kinase is activated by GTP-
bound RhoA which binds to the coiled-coil domain, compromising the binding between the c- 
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terminal region and the kinase domain thereby freeing/activating the kinase 16. Rho-Kinase is 
not known to be directly regulated by other kinases or ROS.   
1.6.3 Evidence for SrcFK Upstream of Rho-Kinase 
There is an increasing amount of evidence implicating SrcFKs in agonist- induced Ca2+ 
sensitization. Many contractile stimuli, including various GPCR agonists, hypoxia and 
exogenous ROS activate RhoA/Rho-Kinase in VSM and there is pharmacological evidence that 
this is partly mediated via SrcFK7,41,82,264.  
Nakao et al 82 first demonstrated that crosstalk between NRTK and Rho-Kinase may underlie 
Ca2+sensitisation. In this report, sphingosylphosphorylcholine (SPC) enhanced contraction of 
pig coronary artery strips with a minimal rise in [Ca2+]i. SPC-induced contraction was blocked 
by the SrcFK inhibitor PP1 and by the S-palmitoylation inhibitor EPA, which inhibits S-
palmitoylation of SrcFKs thereby inhibiting their ability to anchor to the cell membrane. These 
VSMC preparation expressed both Src and Fyn, and SPC was able to promote translocation of 
Fyn, but not Src, to the plasma membrane. SPC was also able to enhance translocation of Rho-
Kinase to the membrane, which was again inhibited by PP1 and EPA. This suggests a direct 
role for Fyn in promoting membrane translocation of Rho-Kinase, thought to be a crucial step 
in which it promotes Ca2+ sensitisation.  
More recently, Knock et al 41 evaluated the role of SrcFK in Ca2+-sensitization-dependent 
prostaglandin F2α (PGF2α)-mediated contraction in rat small distal pulmonary arteries. This 
report demonstrates that the SrcFK -selective inhibitors, SU6656 and PP2, both selectively 
inhibit PGF2α-induced but not direct Ca2+-induced contraction in α-toxin-permeabilized rat 
pulmonary artery. Also, SU6656 and PP2, inhibited PGF2α-mediated but not basal 
MLC20 phosphorylation at ser-19, suggesting the involvement of SrcFK only during 
stimulation of G-protein-coupled receptors. Furthermore, PGF2α enhanced MYPT-1 
phosphorylation at thr-855 (target for Rho-Kinase) was inhibited by SU6656 although 
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phosphorylation was unaffected, again suggesting that the involvement of SrcFK only during 
stimulation of G-protein-coupled receptors. Existing kinase inhibitors cannot easily distinguish 
between Src, Fyn, or Yes, all 3 of which are highly expressed in IPA. To distinguish which 
family member is involved in Ca2+ sensitization, these kinases do differ in the way that they are 
post-translationally modified, Src is dual myristoylated, whereas both Fyn and Yes are also 
palmitoylated275. Knock et al demonstrate that the non-selective acylation inhibitor 2-
bromopalmitate, but not the selective palmitoylation inhibitor EPA 41,276, inhibited PGF2α-
mediated Ca2+ sensitization. Subsequently, this report tentatively suggested that the eponymous 
member Src is in fact involved in PGF2α-mediated Ca2+-sensitization in rat IPA and not Fyn as 
suggested by Nakao et al82. Finally, this study concludes by demonstrating that SrcFKs act 
upstream of Rho/Rho-Kinase in response to PGF2α. The SrcFK inhibitor SU6656 and the Rho-
Kinase inhibitor Y27632 were not additive with respect to both inhibition of PGF2α-induced 
MYPT-1 and MLC20 phosphorylation and inhibition of the associated PGF2α-induced 
contraction. Furthermore, translocation of Rho-Kinase in PASMC, a process that is important 
for its activation, was reversed by pre-treatment with SU6656, indicating that the movement of 
Rho-Kinase in response to stimulation by PGF2α was likely to be mediated by SrcFK. This 
study for the first time demonstrated that agonist-mediated, Rho-Kinase-dependent Ca2+-
sensitization, but not basal Rho-Kinase activity, in rat pulmonary artery requires SrcFK activity. 
Another study by Knock et al 7 investigated the role of SrcFK in HPV. Prior to this 
investigation, a specific role of SrcFKs in HPV and the contractile pathway was unknown. This 
study provides the first direct evidence for a role or roles of SrcFKs in HPV and supportive 
evidence for the importance of Ca2+ sensitization in the sustained phase of the contraction. This 
study confirms that hypoxia both activates SrcFK and enhances PP2-sensitive tyrosine 
phosphorylation of multiple protein targets, coupled with the inhibition of HPV by both SU6656 
and PP2, are suggestive of an active role of these kinases in HPV. In this study, Rho-Kinase-
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mediated MYPT-1 phosphorylation was inhibited by SU6656, and hypoxia-induced 
translocation of Rho-Kinase in PASMCs was completely prevented by siRNA knockdown 
of Src and strongly inhibited by knockdown of Fyn. Therefore, SrcFKs are clearly involved in 
the upstream regulation of hypoxia-mediated Rho-Kinase activity. In addition to an 
involvement in Ca2+ sensitization, it was also found that the SrcFK inhibitor PP2 blocks the 
hypoxia-mediated [Ca2+]i response in IPAs. The results suggest a direct role for SrcFKs in the 
acute contractile response to hypoxia in small pulmonary arteries of rat. Since SrcFK inhibitors 
block both hypoxia-mediated Rho-Kinase-dependent MYPT-1 phosphorylation and the 
hypoxic [Ca2+]i response in IPAs, we may speculate that SrcFKs may act upstream of both key 
pathways to MLC20 phosphorylation and contraction.  
Currently, the direct link between agonists/hypoxia and ROS through SrcFK has not yet been 
made.  
 
1.7 Ras Homolog gene family member (RhoA)  
 
Section Overview 
In addition to heterotrimeric G-proteins as discussed above, another class of G-proteins exist 
classified as monomeric G proteins. These are structurally different from heterotrimeric G 
proteins as they are composed of one unit rather than α, β and γ subunits.  
This section, I will discuss the Rho GTPases (RhoA) family, giving an overview of their 







1.7.1 RhoA Expression and activation 
 
The Rho GTPases form a subgroup of the Ras superfamily of 20- to 30-kD GTP-binding 
proteins that have been shown to regulate a wide spectrum of cellular functions. These proteins 
are ubiquitously expressed comprise at least 10 distinct proteins: RhoA, B, C, D, and E; Rac1 
and 2; RacE; Cdc42Hs, and TC10 and are involved in a number of signalling pathways such as 
cell proliferation, cytoskeletal dynamics and contraction277. 
RhoA in particular has been shown to be highly expressed in smooth muscle 278,279 and mediate 
its effects primarily through Rho-Kinase 280-282. RhoA is activated in smooth muscle in response 
to multiple stimuli including G-protein coupled receptors 218,283-285, growth factors 286,287, 
cytokines and chemokines 288, extracellular matrix 289 and hypoxia 117,290,291 and  mediates a 
number of cellular processes such as growth and proliferation 292,293, migration 292,294, 
inflammation 293 and excitation contraction coupling29,47,295. 
It is because of this multiplicity of functions in addition to having an important role in normal 
vascular homeostasis, dysregulation or over activation of the RhoA/Rho-Kinase pathway has 
been shown to be involved in disease processes 296,297.  
Although much is known about the proteins that are immediately upstream of RhoA, these are 
numerous and varied and form a large network of signalling pathways in response to numerous 
stimuli. Key components are tyrosine kinases 298,299, tyrosine phosphatases 300 and reactive 
oxygen species (ROS) 207,301.  
1.7.2 Regulation of RhoA activation and inactivation  
Although our understanding is still incomplete, much is now known about how RhoA activity 
is controlled. Like all G-proteins, RhoA acts as a molecular switch, i.e. RhoA is inactive when 
bound to guanosine diphosphate (GDP) and active when bound to guanosine triphosphate 
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(GTP). RhoA is therefore activated by stimuli that promotes the exchange of GDP for GTP and 
inhibited upon stimulation of intrinsic GTPase activity. 
The activity of RhoA is determined by 3 types of regulatory proteins: Guanosine nucleotide 
dissociation inhibitors (GDIs) 302,303, guanosine nucleotide exchange factors (GEFs) 29,304,305 
and GTPase activating proteins (GAPS) 306. 
Activation of RhoA is associated with its translocation from the cytosol to the membrane in 
response to contractile agonists 46,197. RhoA then inserts into the membrane which is achieved 
through post-translational modification whereby a lipid tail is added by acyltransferase enzymes 
307 and GDP is exchanged for GTP. Inactive cytosolic RhoA-GDP is bound to GDIs 302,303 which 
prevent RhoA activation in 2 ways, firstly, by covering the lipid tail preventing its insertion into 
the plasma membrane and secondly, preventing nucleotide exchange by competing for the 
nucleotide binding site with GEFs303. At the membrane, GEFs catalyse the exchange of GDP 
to GTP by increasing the rate of nucleotide dissociation, this allows the binding of the more 
abundant GTP 306,308 (Fig 1.5).  Finally, all G-proteins contain intrinsic GTPase activity, which 
cleaves the bound GTP, generating GDP and inorganic phosphate. This activity is enhanced by 
GAPs 306. It has also been suggested that GDIs may also prevent GAPs from binding to active 












Figure 1.5  
  
Figure 1.5: Canonical regulation of RhoA.  
Cyclical activation/inaction of RhoA by nucleotide exchange, GTPase activity and cytosolic 
segregation. The details of which can be found in the text. 
 
 
Understanding how Rho proteins are activated and inactivated has largely focused on regulatory 
proteins such as GEFs and GAPs. However, recent in vitro studies have indicated that GTPases 
may also be directly regulated by redox agents. Lander et al 310 were the first to show this with 
another monomeric G-protein, Ras; NO treatment of recombinant Ras increased the proportion 
of GTP-bound Ras and endogenous NO activated Ras in human T cells. Furthermore, 
Campbell's group also identified a distinct redox-active motif located in the phosphoryl-binding 
loop of the Rho family (RhoA, Rac1, and Cdc42) 311. More recently, Aghajanian et al 312 
demonstrated that RhoA can be directly activated by ROS in cells and that ROS-mediated 
activation of RhoA can induce cytoskeletal rearrangement. By using cysteine to alanine 
mutants, Aghajanian et al demonstrate that ROS-mediated activation of RhoA is dependent on 
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cysteines 16 and 20. Taken together, these findings indicate that ROS-mediated RhoA 
activation is another potential regulatory mechanism for the control of VSM function. 
 
1.7.3 GAPS + GDI’s 
 
Expression and function of RhoGAPs in arteries have been poorly investigated probably 
because RhoGEFs are considered as primary and major regulators of Rho GTPase activity. 
However, in the absence of any stimulus, siRNA-mediated silencing of ARHGAP35 (also 
known as p190-RhoGAP or p190-A), ARHGAP1 (p50-RhoGAP), MYO9B (Myr5), or 
ARHGAP26 (GRAF) in vascular smooth muscle cells leads to an increase RhoA activity, 
indicating the expression and the function of these RhoGAPs 313.  
GDIs inhibit RhoA activity by preventing the insertion of the C-terminal lipid tail into the 
plasma membrane. There are three GDI isoforms in mammals (RhoGDI1, RhoGDI2 and 
RhoGDI3) with RhoGDI1 being the most widely expressed 314. Like GAPS, GDIs have not 
been widely studied in VSM.   
 
RhoGDIs were initially characterized as simply Rho GTPase inhibitors; however, recent work 
indicates their function is a lot more complex309. A number of signalling pathways which lead 
to the phosphorylation of either the Rho GTPase or to RhoGDI have been shown to regulate 
RhoGDI–Rho GTPase interactions 315,316. An example being, phosphorylation of Ser96 on the 
C terminus of GDI-1 by PKC 317, stimulates RhoA dissociation. Additionally, Src 
phosphorylation of RhoGDI, appears to decrease in the ability of RhoGDI to form a complex 
with Rho GTPases leading to enhanced Rho GTPase activity 318. Subsequently, these reports 










RhoGEFs are a highly diverse group of proteins with at least 70 expressed in the human genome 
compared to 22 different Rho proteins. This discrepancy suggests that in response to 
environmental changes, the preferential activation of certain RhoGEFs may occur, 
subsequently activating RhoA. A number of possibilities have been described, 1) RhoGEFs 
have tissue-restricted expression and function more efficiently in a particular environment; 2) 
different upstream signals use different RhoGEFs to activate Rho proteins, therefore the 
RhoGEFs involved are probably different according to upstream stimuli and 3) RhoGEFs not 
only activate Rho proteins but may also, influence the downstream pathways which are 
activated depending on where in the cell the Rho protein is activated by the GEF, which may 
in turn depend on where that particular GEF was located 319. The potential tissue-restricted 
expression of RhoGEFs suggests that they may also be involved in different functions of Rho-
proteins such as cell cycle progression, migration, actin polymerisation, cell-cell adhesion and 
exo/endocytosis 299,304-306,320-325. Expression profiles have established that a number of these 
RhoA-specific GEFs are expressed in the vasculature319 with VSM-RhoGEF (ARHGEF15) 
being specific to vascular smooth muscle320. Selective targeting of tissue-specific GEFs 
therefore may be of therapeutic benefit. 
 
Most RhoGEFs are of the DBL-RhoGEF family and contain two conserved domains, DBL 
homology (DH domain) which is the site of catalytic activity and a pleckstrin-homology (PH 
domain) which acts as an auto inhibitory domain 306,326. The PH domain may direct localization 
of the GEF by associating with phosphatidylinositol-phosphatase (e.g. PIP3). There are also 
RhoGEFs that are known to activate nucleotide exchange by structurally unrelated non-DH 




The signalling pathways which activate RhoGEFs are determined by their binding domains. 
Some GEFs can be activated directly by heterotrimeric G-Proteins through their RGS domain, 
others such as the Vav family possess a src-homology-2 (SH2) and/or src-homology-3 (SH3) 
domain. This allows for interactions with tyrosine kinases (resulting in tyrosine 
phosphorylation of the GEF).  
 
RhoGEFs can be considered key molecules in RhoA activity. The following descriptions will 
be limited primarily, but not exclusively, to RGS domain containing RhoGEFs known to 
activate RhoA and be tyrosine phosphorylated.  
 
There are three RGS domain containing RhoGEFs, ARHGEF1 (p115-RhoGEF), ARHGEF11 
(PDZ-RhoGEF), and ARHGEF12 (LARG which are expressed in both conductance and 
resistance arteries of rat or mouse 328,329. However, the most abundant RhoGEF in arterial 
smooth muscle cells is the specific RhoA GEF p63RhoGEF (ARHGEF25, GEFT) 319,330,331.  
 
The first link between heterotrimeric G-proteins and the monomeric small GTPase Rho was 
established when ARHGEF1 (p115RhoGEF) was initially discovered 230,332. Two additional 
RhoGEFs, ARHGEF11 (PDZ-RhoGEF) and ARHGEF12 (LARG) (leukaemia-associated 
RhoGEF) were identified as members of the p115RhoGEF family according to sequence 
similarity229,333-335. ARHGEF1 (p115-RhoGEF) localizes throughout the cytosol, and rapidly 
translocates to the plasma membrane upon GPCR-activation of Gα12/13, or expression of 
constitutively active Gα12/13mutants 308,336. ARHGEF12 (LARG) is reported to be distributed 
throughout the cytoplasm in most cells. ARHGEF11 (PDZ-RhoGEF) also localizes to the 
cytosol in some cell types also in the cytosol, but in others at the cell periphery or near the 
plasma membrane where it interacts with cortical actin. Activation of ARHGEF11 (PDZ-




ARHGEF1, ARHGEF11 and ARHGEF12 are directly activated by Gα12 or Gα13 which are 
coupled to a wide range of vasoconstrictor receptors 304,319,325,340,341. More recently, ARHGEF1 
has been shown to play a major role in Gαq linked Ang II-induced RhoA activation in vascular 
smooth muscle cells and Ang II-induced regulation of arterial tone and hypertension in rats or 
mice 325. Whereby, ARHGEF1 is activated by phosphorylation by the non-receptor tyrosine 
kinase, Janus kinase 2 (JAK2), downstream of AT1 receptor stimulation. Interestingly, in this 
study, ARHGEF1 was not activated by ET-1, U46619 or noradrenaline, which is surprising 
since this GEF has also been shown to be activated directly by Gα12/13 which is coupled to 
ETA and ETB, TXA2 and adrenergic receptors (α1) 342. Ang II has also been shown to activate 
ARHGEF1 in human peripheral blood mononuclear cells304. The authors conclude that 
ARHGEF1 may mediate Ang-II induced RhoA activation in humans. Additionally, 
ARHGEF12 has also been shown to be activated by Gαq 343 and ARHGEF25 (p63RhoGEF) is 
also responsible for the activation of RhoA by Gαq protein in response to phenylephrine (PhE) 
and endothelin (ET-1) 330. Furthermore, activation of RhoA by 5-HT and sphingosine 1-
phosphate in vascular smooth muscle cells is mediated by ARHGEF12 344. Activation of 
ARHGEF11 (PDZ-RhoGEF) and ARHGEF12 (LARG) has also been also been shown to be 
associated with tyrosine phosphorylation 324,345. Finally, the Vav sub-family of GEFs, are the 
only GEFs that possess a SH-2 domain which allows their binding to tyrosine kinases such as 
Janus Kinase (JAK) or SrcFK leading to tyrosine phosphorylation 322. Until recently, 325, they 
were the only GEFs to demonstrate that tyrosine phosphorylation was a requirement for 
activation.   
 
It has been hypothesised that SrcFKs may be involved in Ca2+ sensitization through upstream 
regulation of RhoA via GEF phosphorylation 346, but this currently has not been shown. Several 
RhoA-specific GEFs (ARHGEFs) are expressed in VSM 319 that are activated by G12/13 and/or 
by tyrosine phosphorylation which may be promoted by ROS347. Indeed, RhoGEFs are known 
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to be phosphorylated and activated by three other non-receptor tyrosine kinases, focal adhesion 
kinase (FAK), protein tyrosine kinase 2 (PYK2) or Janus kinase (JAK) 299,325,348. There is no 
evidence to suggest that these three kinases are themselves directly ROS sensitive however they 
are activated by GPCR agonists in a NOX dependent manner as well as exogenous ROS 349-351 
and through Src mediated tyrosine phosphorylation 352,353. JAK also required ROS-dependent 
activation of PYK2354. 
 
Although the function of the RhoGEFs expressed in arteries is unknown for most of them, it 
should be noted that they are shown to be involved in vasoconstrictor-induced RhoA 
signalling activation. 
 
1.8 Global Aims 
 
Vascular function can be altered by oxidative modification of key proteins involved in cellular 
signal transduction, thereby altering their functions and interaction with other proteins. 
Amongst these, Src Family Kinases (SrcFK) which may be directly activated by oxidative 
modification, while opposing tyrosine phosphatases are inhibited, may contribute to net 
increases in tyrosine phosphorylation and altered vascular function. Previous results within my 
group has shown that prostaglandin–F2α and hypoxia enhance total tyrosine phosphorylation, 
activate Src and cause SrcFK-dependent constriction. Combining these observations with the 
ROS-sensitivity of Src lead to the proposal that the interaction between SrcFK and ROS makes 
a central contribution to vascular smooth muscle function.    
Overall my objective is to determine the role of agonist induced ROS generation in the 
physiological regulation of vascular tone and the signalling pathways in pulmonary arteries.  
Specifically, I will test the following hypotheses:  
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(1) ROS are key secondary messenger molecules mediating vascular smooth muscle 
contraction in response to multiple stimuli and Src-family kinases have a critical role as 
ROS-sensitive intermediaries in these signalling pathways. 
(2) The GPCR agonist U46619 and exogenous ROS activate SrcFK, which subsequently 
activates RhoA and Rho-Kinase. This involves interactions with Rho guanine nucleotide 
exchange factors, notably ARHGEF1. 
 
The following schematic (Figure 1.6) indicates potential pathways that will be investigated 





Figure 1.6: Schematic of the signalling pathways that I investigated during my PhD.  
I demonstrated that the NRTK, Src, will act as a ROS sensitive intermediate potentially 
activating the RhoA/Rho-Kinase pathway via direct or indirect interactions with ARHGEF1.
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This chapter will detail the methodologies used throughout my PhD. Suitable techniques were 
used to measure contractile response in rat intra pulmonary arteries (IPA). In addition, 
luminescence was used to measure reactive oxygen species (ROS) production and suitable 
molecular techniques were used to investigate interactions between ROS, Src-FK, RhoA, Rho-
Kinase and ARHGEF1. 
2.2 Source of tissue 
 
Small Pulmonary arteries were dissected from Rat lung tissue.  
Small Intra Pulmonary arteries (IPA) were used in functional studies to measure functional 
responses to contractile agonists (see section 2.4). IPAs were also used in 
immunoprecipitation/co-immunoprecipitation and immunoblotting studies to investigate 
protein interactions as well as target protein activity (see section 2.6). 
Pulmonary arterial smooth muscle cells (PASMCs) were generated by digesting the complete 
pulmonary arterial tree and then used to measure ROS production (see section 2.7.5 – 2.7.11) 
or visualise eGFP-tagged RhoA or eGFP-tagged ARHGEF1 translocation in live cells (see 
section 2.8). 
2.2.1 Tissue Isolation for functional studies 
 
Male Wistar rats (~250g) were sacrificed by lethal overdose of sodium pentobarbital 
(100mg/Kg), intraperitoneal (ip).  
Lungs were dissected from the thorax of the rat and immediately placed into cold physiological 
saline solution (PSS) pH 7.4. PSS composition (mM): 118NaCl, 24 NaHCO3, 1 MgSO4, 4 KCl, 
5.56 D-glucose, 0.434 NaH2PO4, 1.8 CaCl2. IPAs were dissected from either the upper or 
middle lobes on the right side of the lung, or the upper lobe on the left side of the lung and 
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cleaned of any parenchyma and surrounding tissue. Subsequently, IPAs were cut into segments 
approximately 1mM in length and placed immediately in ice-cold PSS solution. 
Maintaining tissue in a viable state for in vitro contraction experiments 
Following tissue extraction, it is important to maintain the tissue in a viable state. The tissue is 
therefore kept in a solution that is both isotonic and within physiological pH range (pH7.35-
pH7.45). Throughout my studies using intact tissue, I used Physiological salt solution (PSS). 
However, Phosphate-Buffered Saline (PBS) was used when investigating ROS measurements 
in pulmonary arterial smooth muscle cells (PASMCs).  
PSS is a bicarbonate buffer that closely resembles blood serum for both pH and tonicity. PSS 
usually contain 0.9% NaCl dissolved in one litre of water, because NaCl dissociates completely 
into two ions – sodium and chloride – 1 molar NaCl is 2 osmolar. Therefore, PSS usually 
contains 154 mOsmol/L of Na+ and Cl− equating to 308 mOsmol/L. It has a slightly higher 
degree of osmolarity (i.e. more solute per litre) than blood which has a normal range between 
270-290 mOsmol/L. However, this difference is not great enough to affect the osmotic pressure 
gradient. 
pH is also another key factor which has to be maintained within the system. Blood pH is 
between 7.35 - 7.45 therefore this has to be maintained within our buffer. In normal physiology, 
blood pH is maintained primarily by the lungs via CO2 regulation and the kidneys by 
bicarbonate (HCO3-) regulation.  
The buffer has a pH of 7.4 and is maintained at this by gassing with 95% air, 5% CO2. The CO2 
reacts with H2O to form H2CO3 (carbonic acid). Carbonic acid will disassociate to produce 
HCO3- and H+ ion. Since the buffer contains bicarbonate, any excess H+ from tissue metabolism 
will react with bicarbonate to form carbonic acid. This is fully reversible with a high capacity 
to maintain pH so small changes will not have a great effect on pH.  
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2.2.2 Agonist, ROS generator and inhibitor Selection 
 
U-46619 (U-46) and LY83583 (LY) were used to elicit contractile responses in functional 
studies or enhance phosphorylation responses/protein interactions of key proteins in 
immunoblotting studies. As well as promoting reversible translocation of key proteins in 
PASMCs.  
U-46619 (U-46) was used throughout my investigations as it is a stable analogue of 
thromboxane A2 (TXA2), and a T Prostanoid receptor (TP receptor) agonist243,355. In our hands 
is a more effective vasoconstrictor in IPA than phenylephrine (PE), angiotensin II, (Ang II) or 
endothelin, (ET-1) 356. 
LY83583 (6-anilino-5,8-quinolinequinone) (LY) is a quinolinedione357 which has previously 
been used by our group as an intracellular superoxide generator 88,89. Here, 10µmol/L LY83583 
was shown to be inhibited by dicoumarol (10µmol/L), a blocker of the intracellular 
NADPH:quinone oxidoreductase enzyme diaphorase, in both MA and PA 89. LY83583 ROS 
production was also shown to be sensitive to superoxide dismutase (SOD) and not catalase, 
suggesting that the ROS produced is superoxide as measured by changes in luminescence. This 
is important as there are opposing theories about the role of superoxide and H2O2 in smooth 
muscle function (see introduction).  
Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl) is an antioxidant which was selected 
as it is a cell-membrane permeable, water-soluble compound belonging to the nitroxide class 
of SOD mimetics358. It is able to dismutate superoxide catalytically, hydrogen peroxide by 
catalase-like actions, and limit the formation of hydroxyl radicals by Fenton reactions 358. 
Tempol has been shown to reduce oxidative stress in obese rats 359, and other models where 
oxidative stress is prevalent 360.  
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Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) is another antioxidant selected as it is a 
structurally different from tempol however contains similar potent anti-oxidant properties. 
Ebselen has been described as a lipid soluble organo-selenium compound which mimics 
glutathione peroxidase activity 361,362. It has also been shown to react with the thioredoxin 
system and has been described as an excellent substrate for thioredoxin reductase (TrxR)363. 
Furthermore, ebselen has been shown to rapidly react with ROS generated during ischemia or 
reperfusion 364,365.     
PP2 was selected as it is a well-known SrcFK inhibitor used extensively within our laboratory 
7,41,83. 
2.3 Functional Measurements 
 
Contractile measurements were carried out using a single channel Mulvany-Halpern small 





















Figure 2.1: Main components of a Mulvany-Halpern small vessel wire myograph 
Shows a single channel Mulvany-Halpern small vessel wire myograph (Model 320A) used 
throughout my studies. Vessels are mounted on wires and compounds added while tension is 
being measured.                                             
 
2.3.1 Theory behind Force Measurement (Myography) 
 
Background 
Until the mid-1970s, most information about the mechanical, morphological and 
pharmacological properties of vascular smooth muscle was investigated using large vessels, the 























experiments and histological examinations. Due to the size of smaller vessels this discouraged 
investigators from undertaking mechanical experiments.  
Myography was first developed by Mulvany and Halpern 366-369 and allowed small vessels to 
be mounted on a myograph. This allowed measurements of isometric responses particularly in 
investigating contractile properties of vascular vessels 7,88,89,191. This differs from other methods 
as both ends of each mounting wire will be secured under tension without having to manipulate 
the vessels segment with dissecting equipment.  
The arteries of interest used throughout my studies are the lateral side branch small IPA, 
approximately 150–500 μm internal diameter. These arteries were used as they constrict in 
response to hypoxic stimulus 7,370,371, an important determinant for pulmonary arteries. 
Furthermore, these arteries contain high VSM content of VSM therefore allowing for 
measureable responses on a wire myograph. Finally, from a technical aspect, these arteries are 
large enough to mount on a myograph with minimal damage thus maximising responses to 
stimuli.    
Key component parts of a Myograph 
The myograph itself is an instrument used to investigate contractile properties of small proximal 
resistance vessels. It comprises of two metal jaws, one of which is attached to a force transducer 
the other to a micrometer arm. A force transducer converts tension into voltage. The myograph 
force transducer is a strain gauge connected to a Wheatstone bridge, amplifier and interface 
connected to a PC. This allows the force generated by the vessel to be recorded in real time e.g. 
In response to U46619, the artery contracts, this alters the electrical resistance of the strain 
gauge which is shown in real time on the PC using myodaq software. Finally, there are 100 
points measured per second however this is averaged 100 to 1 so there is 1 point per second 
showing. This helps reduce signal to noise ratio.  
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A micrometer arm is also attached and can be adjusted manually. This allows us to manually 
stretch the vessel over small distances to achieve a desired tension. The myograph is also kept 
at 37OC by a built-in heater. Each preparation has its own individual gas inlet and suction for 
solution replacement. 
Measuring Isometric Force 
In smooth muscle, Ca2+ dependent phosphorylation of MLC20 promotes cross bridge cycling 
between actin and myosin filaments. This results in greater force generation and shortening of 
smooth muscle 29.  
If a muscle is prevented from shortening when activated, the muscle will express its contractile 
activity by pulling against its attachments and developing force in response to stimuli. This type 
of contraction is termed isometric (meaning “same length”). When conditions are arranged so 
the muscle can shorten and exert a constant force while doing so, the contraction is called 
isotonic (meaning “same force”). 
2.4 Mounting of IPA’s 
 
IPA’s were mounted onto a wire myograph by carefully inserting stainless steel wires (40µm) 
through the lumen of the arteries. During this period, arteries were immersed in PSS. The wires 
were tightly secured to mounting jaws by 4 screws. The wires were kept parallel at all times. 
The wires were wrapped clockwise around the screws, the screws were then tightened thereby 
tightening the wires. The jaws were adjusted using the micrometer arm and force measure by 






Figure 2.2:  
 
Figure 2.2: Shows the mounting of Pulmonary arteries onto a wire myograph  
IPAs were mounted using stainless steel wires kept parallel at all times. These were secured by 
4 screws. IPAs can be stretched using the micrometer and the force measured by the transducer. 
 
2.4.1 Length Tension relationship and Normalization   
 
Length tension relationship is the relationship between a muscles length and the isometric 
tension (force) which is generated when fully activated. During muscle activity, particularly at 
longer lengths, tension depends on passive stretch of the tissue along with active force generated 
by muscle fibres when stimulated. When the passive contribution is subtracted and only the 
active force generated is considered, the relationship between force and length will depend on 
active cross bridge cycling between actin and myosin.   
Therefore before the start of any experiment it is important to perform a “Normalisation” step. 
There are 3 main reasons why this is important, the first being that elastic vessels size has to be 
clearly defined, the sensitivity to agonists or indeed antagonists is dependent on the amount 
ofstretch, finally any active responses is dependent on stretch which is why it is important to 
set the preparation of internal circumference to give a maximal response. 
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The aim of the “normalisation procedure” is to stretch the segment to the optimum of the length 
tension curve thereby maximising cross bridges between actin and myosin. Therefore, 
maximising the effect of stimulus on contraction.  
2.4.2 Stretching and challenging with KPSS 
 
IPA’s were stretched until a tension of ~3.0mN was maintained for each vessel. This stretching 
procedure was required for determining the ‘active’ length tension relation in IPA’s. This has 
been examined previously within the laboratory 88,89,372 . For rat IPA of the size used in this 
study, it was determined that a resting tone of ~3.0mN is approximately at the point on the 
length tension relationship curve that is optimum for the generation of active tension upon 
pharmacological stimulation. Active tension was tested after periods of incrementally increased 
stretch by repeatedly challenging IPA’s with KPSS treatment for ~3minutes (KPSS is made by 
equimolar substitution of KCl for NaCl in PSS). This process occurred at least 3 times, the 
arteries were then allowed to rest before the start of the experiment. This process is 













Figure 2.3: Illustration of Normalization Procedure and KPSS challenges 
(A) A stepwise normalization procedure and (B) three challenges with KPSS. Following the 
third challenge with KPSS, IPAs were washed and left to rest for ~30 minutes. 
 
2.4.3 Antioxidant and Kinase inhibitor dose response to KPSS and U46619 
contractile responses 
 
In order to determine the contribution of endogenous ROS to agonist-induced contraction, I 
examined the effects of the ebselen, tempol on sub-maximal contractile responses induced by 
the TP receptor selective agonist U46619 in IPA. I also confirmed that U46619-induced 
contraction is partially dependent on SrcFK activity using the SrcFK antagonist, PP2. In order 
to confirm the potential effects of DMSO alone, cumulative dose responses were performed 







tempol and PP2 in the presence of KPSS. This ensured that the concentration of drugs used 
along with the volume of vehicle control had no non-specific effect on contractile function.  
Following a series of stretches, three KPSS challenges were performed in IPAs. A resting period 
of ~30 mins was given to allow each IPA to return to basal tonic levels. IPA’s were then 
challenged with a fourth KPSS challenge and the contraction was allowed to plateau after ~25 
minutes incubation. A cumulative dose response to ebselen (0.1-10μM), tempol (0.1-3mM), 
PP2 (1-30μM) or (d) DMSO (0.5-14.5μL) was performed.  
The above protocol was then performed, but the IPA’s were challenged with U46619 (100nM) 
instead of a fourth KPSS. A cumulative dose response to (a) ebselen (0.1-10μM), (b) tempol 
(0.1-3mM), (c) PP2 (1-30μM) or (d) DMSO (0.5-14.5μL) was performed.  
2.4.4 Effect of antioxidants and kinase inhibitor in IPA on exogenous ROS 
contractility 
 
LY83583-derived superoxide has been shown to directly constrict IPA at 10µM 88. However, 
the concentration of LY83583 (1μM) used in this study does not itself cause contraction of 
IPA88 but causes an enhancement of 2nM U46619 response which is approx. 10% of KPSS in 
amplitude. The effect of antioxidants, ebselen (10μM), tempol (3mM), SrcFK inhibitor PP2 
(30μM) and DMSO (5µL) (as a vehicle control) were investigated on contractile responses to 
exogenous ROS enhanced contractile responses.  
Following the initial normalisation procedure, a control response was performed whereby 
U46619 (~2nM) was incubated with IPA for 10 minutes. 1μM LY83583 was added to the IPA 
for 10 minutes resulting in an enhancement of contraction. IPAs were then washed 3 times in 
PSS and allowed to rest for ~30 minutes. This was then repeated again. This controls for any 
potential run-down with time which could potentially influence the responses to U46619 and 
LY83683.    
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In separate IPAs, an initial control response was performed. This was followed by pre-
incubation of ebselen (10μM), tempol (3mM), PP2 (30μM) or DMSO (5μL) with IPAs for 10 
minutes before re applying U46619 and LY83583. Incubation with DMSO allowed me to 
control for any potential effect DMSO could have on contractile function thus ensuring any 
effect seen was due to the presence of the drug and not due to the presence DMSO.  
2.4.5 Effect of inhibiting NOS on agonist induced and ROS enhanced 
contractile responses 
 
In order to eliminate the role of nitric oxide in the effects of antioxidants and PP2 on U46619-
induced contraction and to eliminate the possibility that the enhancing effect of LY83583 on 
U46619-induced contraction was as a result of nitric oxide scavenging response by superoxide, 
these experiments were repeated in the presence of L-NAME. 
A normalisation procedure was initially performed followed by a resting period of ~30 mins.  L-
NAME (300nM) was then incubated with IPAs for ~20mins. U46619 (100nM) was 
subsequently added and a cumulative dose response to antioxidants, PP2 or DMSO was 
performed as discussed in an earlier section. 
The effect of L-NAME on exogenous ROS was also investigated. An initial control response 
was performed and IPA’s were subsequently allowed to rest. L-NAME (300nM) was then 
incubated with the IPAs for ~20mins followed by U46619 (100nM) and 1μM LY83583 
exposure. 
2.4.6 Effect of Mitochondrial inhibitors on U46 induced contraction 
 
In order to determine that myxothiazol and rotenone were acting downstream of mitochondrial 
electron transport chain, U46619 induced contractile responses were performed in the presence 
and absence of myxothiazol, rotenone and DMSO.   
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Following stretching, challenging with KPSS, IPAs were given a rest period for 30 minutes. A 
first control response was carried out whereby U46619 (100nM) was incubated with the IPA 
for 10 minutes. The IPAs was then washed 3 times in PSS and left to rest for 30 minutes. IPAs 
were then pre-incubation with DMSO (5μL), myxothiazol (100nM) and rotenone (100nM) for 
15min. U46619 (100nM) was then re-applied.   
2.5 Immuno/ Co-immunoprecipitation 
 
Background 
Immunoprecipitation (IP) is a commonly used technique for antigen detection and purification. 
Co–immunoprecipitation (CO-IP) is an extension of IP and is based on the potential of IP 
reactions to capture a target i.e. antigen as well as other molecules that are bound to the target. 
Therefore depending on the focus of the experiment, the experiment could be 
immunoprecipitation (primary target - antigen) or co-immunoprecipitation (secondary targets 
– interacting proteins). 
The principle is straightforward: the antibody can be crosslinked onto a beaded support where 
an antibody-binding protein is immobilized (such as protein A or G which are high affinity IgG 
ligands and bind to the Fc region of antibodies effectively immobilising the antibody capture 
site outward).  
The lysate is then added to the antibody complex and the antigen is captured along with any 
other attached macromolecules. Any proteins not captured are then washed away. After 
capturing the antigen, the antigen complex is eluted from the support (the antibody may also be 
eluted from the support depending on the denaturing buffer). The solute is then analysed by 
SDS-PAGE followed by western blot detection to verify the identity of the antigen and other 




2.5.1 Pulmonary artery isolation for CO-IP and immunoblotting studies 
 
Homogenates were prepared from IPAs. The complete arterial tree was dissected from the upper 
lobes from the right and left side of the rat lung. All parenchyma and any other surrounding 
tissue was cut free. The tissue was completely submerged in cold PSS throughout the entire 
dissection process. Dissection was performed on a Sylgard dissecting dish. 
For western blot samples, the arterial tree was cut longitudinally through the main branch 
thereby ensuring an equal number of side branches for each sample. For IP samples, a complete 
arterial tree was used per sample to ensure enough protein was extracted. After dissection, the 
arterial trees were immediately transferred into a 1.5ml eppendorf tube containing 1mL of PSS 
and kept on ice.   
2.5.2 Protein extraction consideration 
  
Protein was extracted from IPA to measure phosphorylation responses or protein-protein 
interactions in response to stimuli/inhibitors.  
Due to the structure of tissue compared to cells e.g. tissue samples, which contains higher levels 
of extracellular proteins such as collagen and elastin, mechanical force as well as the addition 
of a lysis buffer was required to extract protein.  
Another issue is that membrane proteins are hydrophobic therefore a detergent is required to 
extract these proteins 373. The choice of detergent will vary between CO-IP and western blot 
analysis and will be discussed in the next section.  
Furthermore protein degradation by protease enzymes during extraction will occur therefore 
the addition of a protease inhibitors to the lysis buffer is required.  
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Many of the proteins that I investigated were phosphorylated (indicating their activity) therefore 
phosphatase inhibitors were also added to stop any de-phosphorylation by phosphatases which 
may also be present during extraction.  
2.5.3 Lysis buffers 
 
The choice of lysis buffer depends upon the type of tissue, where the protein is situated and 
whether you want to maintain protein interactions. For protein extraction in tissue for western 
blot analysis, SDS lysis buffer was used. SDS is anionic and a very effective surfactant that can 
solubilise almost all proteins. It disrupts non-covalent bonds within and between proteins; 
completely denaturing proteins.  
Non-ionic detergents (NP-40 or Triton) were considered however nonionic detergents are 
considered mild surfactants as they break protein-lipid, lipid-lipid interactions but not protein-
protein interactions. They do not denature proteins. This means that proteins are solubilised in 
their native and active form and retain their protein interactions. Non-ionic detergents are used 
mainly for immunoprecipitation and co-immunoprecipitation.  
I used a Triton based buffer instead of NP40 for IP/CO-IP studies. I did initially try extracting 
protein with NP-40 but was unable to extract enough protein for western blot analysis. I 
therefore used Triton which allowed me to extract enough protein from my samples. 
2.5.4 Sample Tissue Treatment and protein extraction 
 
Treatment and protein extraction method was performed differently which is detailed below.  
Western blot Analysis 
Arteries were equilibrated for a 15 minute period during which they were incubated in PSS (pH 
7.4) and maintained at a temperature of 37oC while being continuously gassed with 
5%CO2/95% air. Following equilibrium, U46619 (100nM) and 1μM LY83583 time controls 
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were performed. This was followed by investigating the effect of 15 minute pre-incubation with 
ebselen, tempol, PP2 or DMSO on U46619 induced phosphorylation responses. 
Hypoxia 
The effect of hypoxia on protein phosphorylation was also investigated. Following 
equilibration, arteries were pre incubated with 1nM U46619 for 15 minutes. The gassing was 
subsequently changed to 1% O2/5% CO2/Nitrogen for 1 or 5 minutes depending on the protein 
of interest. This was again followed by investigating the effect of pre-incubating myxothiazol 
(100nM), rotenone (100nM) or DMSO (5µL) for 15 minutes prior to U46 or 1 or 5 minute 
hypoxic exposure.    
Immuno Precipitation 
Arteries were equilibrated for a 15 minute period during which they were incubated in PSS (pH 
7.4) and maintained at a temperature of 37oC while continuously gassed with 5%CO2/95% air. 
Following equilibrium, IPA’s were then treated with U46619 (100nM) for 15 minutes. 
 
Following treatment, IPA’s was immediately snap frozen in liquid nitrogen. The frozen tissue 
was pulverised using a Bessman Tissue Pulveriser (Spectrum Laboratories), which was cooled 
in liquid nitrogen.  
Samples prepared for western blot analysis: Pulverise tissue was transferred into 70μl of 
1xSDS lysis buffer containing 0.1M Tris HCl (pH6.8), 2% SDS, 1% phosphatase inhibitor 
cocktails 2 and 3 (Sigma) and 1% protease inhibitor (Sigma). This was immediately vortexed 
mixed for 1 minute at room temperature to extract protein from the tissue. The resulting mixture 
was then centrifuged at 10g for 3 minutes, the supernatant was collected and pipetted into a 
clean Eppendorf.  
Samples prepared for IP/CO-IP studies: Pulverise tissue was transferred into 70μl of 1% 
Triton X-100 lysis buffer containing 20 mM Tris HCl (pH8.0), 1% Triton X-100, 137mM NaCl, 
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2mM EDTA, 1% phosphatase inhibitor cocktails 2 and 3 (Sigma) and 1% protease inhibitor 
(Sigma). This was immediately vortexed mixed at room temperature for 10 seconds at room 
temperature followed by 50 seconds kept on ice. This was repeated 12 times and ensured 
enough protein was extracted from my sample. The resulting mixture was then centrifuged at 
13g for 10 minutes at 4OC, the supernatant was collected and pipetted into a clean Eppendorf.  
2.5.5 IP/CO-IP 
 
Protein was extracted as previously discussed for immediate western blot, however for IP/Co-
IP a triton based lysis buffer was used to extract protein from tissue.  
IP/CO-IP was performed using a Pierce™ Crosslink Magnetic IP/CO-IP Kit (8805) was used. 
Initially a 1X modified coupling buffer was prepared for each IP reaction. 25µL of Pierce 
protein A/G Magnetic Beads were then aliquoted into a microcentrifuge tube and the beads 
were then collected using a magnetic stand for 1 minute at room temperature. The storage 
solution was discarded and 500µL of 1X modified coupling buffer was added to each tube 
gently mixed and incubated for 1 minute at room temperature on a rotating platform. The beads 
were collected using a magnetic stand and this stage was repeated.  
An antibody solution was then prepared. The antibody was diluted 1:20 in coupling buffer, 
+lysis buffer and ultrapure water giving a final antibody concentration of 5µg per IP.100µL of 
prepared antibody solution was added to the beads, mixed and incubated on a rotating platform 
for 15 minutes at room temperature with vortex mixing every 5 minutes. The beads were then 
collected using a magnetic stand. 
1X modified coupling buffer was then added to each tube, gently mixed and the beads collected 
using a magnetic stand. The supernatant was then discarded and 1X modified coupling buffer 
was added to each tube and gently vortexed. The beads were then collected using a magnetic 
stand, the supernatant discarded, and this stage was repeated.     
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Bound antibodies were then crosslinked to protein A/G using a cross linker solution containing 
2.5µL of 20X coupling buffer, 4µL of 0.25mM DSS and 43.5µL of ultrapure water. This was 
added to the beads and incubated for 30 minutes at room temperature on a rotating platform. 
The beads were then collected using a magnetic stand and the supernatant discarded. Elution 
buffer was then added to the beads and gently mixed for 5 minutes at room temperature on a 
rotating platform. The beads were then collected using a magnetic stand and the supernatant 
discarded. This was repeated 2 more times. Cold IP lysis/wash buffer was then added to the 
beads and gently vortex mixed. The beads were then collected with a magnetic stand and the 
supernatant was discarded. This was repeated one more time. 
The lysate solution was diluted to 210µL with IP lysis/wash buffer. 70µL of diluted lysate 
solution was added to each tube containing crosslinked magnetic beads and incubated overnight 
at 4oC on a rotating platform. The beads were then collected using a magnetic stand the unbound 
sample (supernatant) was saved for analysis. The beads were then washed three times using IP 
lysis/wash buffer followed by a single wash using ultrapure water. The beads were then 
collected using a magnetic stand and elution buffer was added to each mixture and left to 
incubated for 5 minutes at room temperature on a rotating platform. The elution buffer has a 
low pH (pH2.0), the low pH condition allows the disassociation of the antibody-antigen 
interactions however if left for prolonged periods of time can disassociated the antibody and 
protein A/G interactions. Therefore, 7µL of neutralizing buffer is added. 
2.5.6 Measurement of Protein content by Bicinchoninic Acid Assay 
 
Following protein extraction, a bicinchoninic acid assay was performed. This ensured the 
amount of protein loaded into a polyacrylamide gel is standardized across all my samples. 
A bicinchoninic acid assay (BCA) also known as a Smith assay was performed on each tissue 
homogenate as described by Smith et al 1985 374. This is a popular colorimetric detection 
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method for quantifying total protein which combines the reduction of Cu2+ to Cu+ by protein in 
an alkaline medium with the highly selective and sensitive colorimetric detection of the cuprous 
cation (Cu+) by Bicinchoninic Acid.   
The BCA assay was chosen because it has a number of advantages of other colorimetric assays 
such as Lowry 375 and Bradford 376 assays. These include greater reagent stability, increased 
sensitivity, decreased protein: protein variation and it is compatible with samples that contain 
up to 5% detergent (surfactants).  
The Lowry method 375 involves the reaction of copper ions with peptide bonds and the oxidation 
of aromatic protein residues under alkaline conditions (Biuret test). This method was not used 
because the reaction method is not well understood. Also the method is intolerant towards 
compounds such as Mg2+, K+, EDTA and Tris 376. 
The Bradford assay is a more sensitive method than the Lowry method with less drawbacks 376. 
However, the main disadvantage the Bradford assay has is that it is incompatible with the 
percentage of detergent used to solubilise proteins. This will cause the reagent to precipitate 
even at low levels. Furthermore, the coomassie dye present is highly acidic therefore a small 
number of proteins cannot be measured due to poor solubility. Coomassie dyes also offer 
greater protein variation.  
The BCA method is also not perfect as it is not compatible with high concentrations of SDS. 
To overcome this, tissue homogenates were diluted in cell lysis prior to performing a BCA 
assay.       
Protein samples (tissue homogenates including the unbound fraction of IP/CO-IP samples but 
not the bound fraction) were diluted 1:4 in 1x lysis buffer (Invitrogen). This ensured that the 
protein concentration remained within the standard curve range of the BCA protein (0 – 
2mg/ml). Homogenates were then mixed 1:1 with cell lysis buffer. Protein standards were made 
92 
 
using ddH2O and mixed 1:1 with cell lysis buffer. BCA reagent was added to protein samples 
(standards or homogenates) in a 96 well plate (Thermos scientific) and incubated at 37OC for 
30 minutes. After incubation, a purple/blue colour forms due to the reaction of BCA with the 
cuprous cation which was subsequently read at 562nm. 
2.5.7 Sample preparation for Gel Loading 
 
Tissue homogenates (containing between 15 - 40μg of protein) were prepared in (4x) NuPAGE 
LDS ® Sample Buffer (Invitrogen) (pH 8.4). A standard laemmli buffer usually contains 
106mM Tris HCl, 141mM Tris base, 4% SDS, 20% Glycerol, 0.51mM EDTA, 0.2mM Serva 
Blue G250, 0.175mM Phenol Red.  
SDS is a detergent that solubilises all the protein but also makes proteins negatively charged 
meaning that proteins will run towards the positive end on the gel. As all the proteins are 
negatively charged, the only factor that affects the rate of travel through the gel is molecular 
weight. Glycerol increases the density of the protein sample and thereby ensures that the sample 
stays in the well. EDTA is present as it is a strong chelator of metal (e.g. Mg2+) necessary for 
enzymatic activity. This therefore helps inhibit protease and phosphatase enzymes found in the 
samples. Serva Blue and Phenol Red act as tracking dyes.  
An appropriate volume of 1x cell lysis buffer was added to each sample, ensuring the same 
volume and protein concentration remained the same in each sample. The samples were then 
boiled at 95oC for 5 minutes, denaturing of proteins. The samples were immediately placed on 
ice followed by centrifugation for ~30s using a top table centrifuge prior to being loaded into a 
gel. A molecular marker (Precision Plus Protein All Blue Standard, Bio-Rad) is also added into 
an adjacent well to the samples. The molecular marker or ladder is a mixture of protein of 
known molecular weight/size. This is used to determine the relative size of proteins which are 
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subject to gel electrophoresis. Proteins of interest can matched to know weights found in the 
protein marker.  
2.5.8 Polyacrylamide gel electrophoresis and protein blotting 
Gel electrophoresis is routinely used to analyse protein mixtures quantitatively and 
qualitatively. It enables high resolution of proteins, some of which may on vary in size by a few 
hundred Daltons. As the proteins carry the same negative charge, their migration can be initiated 
by an electric field and their mobility will dependent on their size. The most commonly used 
system is sodium dodecyl sulfate polyacrylamide gel electrophoresis or SDS-PAGE for short.  
Proteins of a molecular size between 15 – 125kDa were separated using gel electrophoresis in 
the presence of 1x MOPS running buffer (Invitrogen). The running buffer contains 25mM Tris 
base, 190mM glycine and 0.1% SDS. Protein samples were pre-loaded onto a 4-12% precast 
Tris-Glycine polyacrylamide (PAGE) gel (Invitrogen) and resolved at 180v for 90minutes using 
the Xcell Surelock Mini-Cell Electrophoresis system (Invitrogen). A 4-12% gradient gel was 
used as we were separating a mixture of proteins with different molecular weights. 
Once the proteins have been separated by electrophoresis, they must be transferred onto an 
appropriate membrane. The most common method is electroblotting, first described by Towbin 
et al 1979 377. An electric field is applied perpendicular to the plane of the gel for 1 hour at 40V 
using a wet electro blotting system XCell II Blot Module (Invitrogen), this causes the proteins 
to migrate to a charged protein binding membrane, nitrocellulose membrane (Amersham). The 
membrane is in direct contact with the PAGE gel and a ‘sandwich’ is created between the 
electrodes with the addition of filter paper and sponges. This is submerged in 1x transfer buffer/ 
conducting solution (25mM Tris, 192mM glycine, 20% methanol) to allow the protein to move 
readily from the Page gel to the membrane. Transfer of proteins can be visualised by staining 




   
Prior to antibody treatment, the membrane is blocked for 1 hour at room temperature using 5% 
non-fat milk solution (Marvel) in Tris Buffered Saline with Tween (TBST) (Sigma). This is 
crucial as it helps prevent non-specific binding of antibodies (primary and secondary) to the 
nitrocellulose membrane. 
Bovine Serum albumin (BSA) is another commonly used blocking solution that can be used 
instead of milk. It is believed to work better especially when probing using phospho antibodies 
as albumin is a secreted protein and tends not to be phosphorylated. Milk also contains a protein 
called phospho casein. This phosphoprotein can lead to higher background due to non-specific 
recognition of the phospho motifs. However studies carried out previously in our laboratory 
have found that milk provides less background than BSA. 
2.5.10 Detection of Protein of Interest  
 
In order to detect our proteins of interest, the membranes have to be probed using a primary 
antibody that recognises the specific epitope found on our protein. The primary antibody is not 
detectible, instead a secondary antibody which is raised against the IgG of the same species of 
primary antibody will be used. The following table (Table 2.1) demonstrates primary and 
secondary antibody protein targets, dilutions factors and expected molecular weight of protein 











Secondary Antibody (Species and 
Dilution) 
P-MYPT1 (thr 850) 125 1 in 3000 Goat               Anti Rabbit (1 in 3000) 
    
MYPT1 125 1 in 1000 Goat               Anti Rabbit (1 in 3000) 
    
P-MLC (ser 19) 20 1 in 1000 Goat               Anti Mouse (1 in 3000) 
    
MLC 20 1 in 1000 Goat               Anti Rabbit (1 in 3000) 
    
P-Src (tyr 416) 60 1 in 500 Goat               Anti Rabbit (1 in 3000) 
    
Src 60 1 in 1000 Goat               Anti Rabbit (1 in 3000) 
    
Phospho Tyrosine  1 in 1000 Goat               Anti Rabbit (1 in 3000) 
    
ARHGEF1 115 1 in 1000 Goat               Anti Rabbit (1 in 3000) 
    
GAPDH 37 1 in 4000 Goat               Anti Mouse (1 in 2000)               
 
Table 2.1: Primary and Secondary antibodies and dilutions  
Shows the dilutions of primary and secondary antibodies for all target proteins detected using 
western blot. The species of the secondary antibody is also mentioned.  
 
The secondary antibody is linked to an enzyme called horseradish peroxidase (HRP). When 
mixed with an appropriate chemiluminescent substrate, the resulting reaction emits light which 
can be detected by light sensitive film or camera. HRP is commonly used as it is able to amplify 
a weak signal and allow the detection of low levels of target proteins.  
Antibody dilutions are prepared using a wash buffer containing a low percentage of blocking 
reagent. This helps prevent background and non-specific staining. The wash buffer used is Tris 
Buffered Saline with Tween (TBST) (SIGMA). It contains Trizma base, NaCl (0138M), 
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distilled water and Tween-20 (0.05%) which acts as a detergent. Washing the membrane also 
helps remove and minimise nonspecific binding. 
All antibodies were made up in TBST and 5% non-fat milk. The majority of the antibodies have 
been used previously within the group7,41,83,88. Furthermore, p115 RhoGEF antibody has also 
been used by other groups 230,308, therefore I was confident in the dilutions and specificity of 
the antibodies used.  
Nitrocellulose membranes were incubated with primary antibody overnight at 4oC with constant 
agitation. Membranes were then washed 3 times in TBST, 10 minutes per wash. The appropriate 
HRP-secondary antibody was applied for 1.5 hours at room temperature with constant agitation. 
Following incubation with the secondary antibody, the nitrocellulose membranes were 
subsequently washed a further 3 times in TBST, 10 minutes per wash. In order to detect our 
protein of interest, membranes were exposed to an appropriate enhanced chemiluminescent 
(ECL) substrate.  
Phospho-proteins have a much weaker signal and require a much stronger ECL. Therefore all 
3 of our phospho proteins were detected using SuperSignal West Femto chemiluminescent 
substrate (Thermo scientific). This substrate, as described by Thermo scientific, is ultra-
sensitive an able to detect low-femtogram levels of protein by Western blot analysis with 
horseradish peroxidase (HRP) enzyme.  
Membranes were initially probed 1st for phospho-proteins due to their weak signal. Following 
detecting of phospho-protein, membranes were rinsed with TBS to remove any excess ECL. 
The same membrane was then stripped of antibody using 10ml of Restore Western Blot 
stripping buffer (Thermo scientific) for 1 hour at room temperature under constant agitation. 
The membrane were then rinsed using TBS and blocked again in 5% non-fat milk solution for 
1 hour at room temperature and then re-probed with an appropriate total antibody in 5% non-
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fat milk overnight at 4oC again under constant agitation. This protocol was performed for each 
membrane. 
The total antibody detects the total amount of non-phosphorylated and phosphorylated forms 
of its protein. This is used as an internal control and allows the ratio of phosphorylated: non-
phosphorylated protein to be determined. GAPDH was used during IP/CO-IP studies as a 
loading control because it is stable and constitutively expressed and considered a housekeeping 
gene.  
Membranes were then incubated with an appropriate secondary antibody for 2 hours at room 
temperature. As total proteins have a stronger signal a weaker ECL was used e.g. ECL plus or 
ECL prime (Amersham, GE healthcare). This also helped limit any bleed through by any 
phosho signal that has not been removed during the stripping process.  
Detection of proteins was carried out using Biorad ChemiDoc XRS+ gel imaging system. Bands 
were detected using a high resolution protocol suitable for the distinction of bands that are close 
together.  
On each gel there were at least 3 controls. The average of these controls was calculated and an 
average of their phospho-protein: total protein ratio was used as the control values. The effects 




2.6 Pulmonary artery smooth muscle cell (PASMC) Studies 
 
2.6.1 Pulmonary artery Smooth Muscle Cell Line Generation 
 
PASMCs were isolated by digestion of the pulmonary arterial tree. The digestion process targets 
the connective tissue and not the cells. Arterial trees were dissected as previously described (in 
section 2.1.1), then cut into small pieces and added to a glass tube containing (~2mL) of filtered 
PSS solution (Gibco). The pieces of tissue were cleaned using filtered PSS (3X) and then added 
to the enzymatic solution. 
The enzymatic solution contained HEPES buffer (pH7.4) which was composed of (mM): 120 
NaCL, 4 KCL, 1 MgCl2, 10 HEPES (no Ca2+, no EGTA and 1gl/L glucose) and an enzymatic 
composition of 4mg of collagenase Type XI (0.2%w/v) (Sigma), 2mg of papain (0.1% w.v) 
(Sigma), 2mg of trypsin inhibitor (0.1%w/v)(Sigma) and 20μL of DL-Dithiothreitol 
(1mM)(Sigma). This solution was vortex mixed at room temperature for 2 minutes, filtered 
through a 0.2μM filter (Millex) and then incubated at 37oC for 30 mins (inverting the tube 
several times to ensure a thorough mixing).  
The cell suspension created was centrifuged at 200g for 1 minute at room temperature, the 
supernatant was aspirated and ~2mL of warm filtered HEPES solution was added. The tube 
was inverted (3x) before being centrifuged at 200g for 1 minute. This stage was repeated 2 more 
times with HEPES buffer. The washing stage was continued using warm media a further 3 
times.  
The media was aspirated and 5mL of fresh media was added. The solution was dispersed into 
individual cells by vigorously pipetting up and down (~30x) using a glass pipette and rubber 




2.6.2 Cell Culture medium  
 
Primary smooth muscle cells lines were cultured using, Dulbecco’s Modified Eagle Medium 
(DMEM) (500ml) containing Foetal Bovine Serum (FBS heat inactivated) (50ml), Sodium 
Pyruvate (100mM) (5ml), Non-essential amino acids (MEM NEAA 100x) 5ml, PSG (100x) 
5mL (penicillin 10,000 U/ml, streptomycin 10mg/ml, l-glutamine 200mM). A detailed 
composition of supplements and their function can be found in table 2.2 below: 
Table 2.2: 
Supplements added 
to DMEM: Normal 
Cell culture 
Function  
Fetal Bovine Serum Provides growth factors to support growth and satisfy metabolic 
needs of the cells during culture 
  
Glucose Acts as an energy source for cells in a reduced environment 
  
L-Glutamine Acts as an alternative energy source for cells that are not efficient at 
metabolising glucose. Supports Cellular growth where there are 
high energy demands and large levels of protein and nucleic acid 
synthesis 
  








Used to prevent bacterial contamination from gram positive and 
gram negative 
 
Table 2.2: Cell Culture media Supplements 
Details the supplements present in Dulbecco’s modified Eagle Medium (DMEM) used for 
PASMC culture.  
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2.6.3 Smooth Muscle Cell Line Culture 
 
Cells were initially seeded into 1xT25 (passage 1) however after reaching 80% confluency, the 
cells were then seeded at approximately 1 in 3 dilutions  e.g. 1xT25 into 1xT75 flask (passage 
2) and from 1xT75 flask into 3xT75 (passage 3). Cells were grown in appropriate size flasks 
until used for experimental procedures usually after passage 3. Each passage on average took 4 
days. 
In order to split the cells, media was aspirated and the cells washed with sterile 1XPBS thereby 
removing all the cell debris. Trypsin ethylenediaminetetraacetic acid (EDTA) (0.05%) was 
added to the flask containing cells and left to incubate at 37OC for 3 minutes. Trypsin is an 
enzyme that acts by severing peptide bonds which hold the cells together as well as keep them 
attached to the flask. EDTA is an important component which aids trypsin as this acts as a 
chelator of Ca2+ and Mg2+ which inhibits trypsin activity.  
The flask was tapped horizontally several times to ensure all of the cells had detached and 
separated from each other. The appropriate volume of warm media was then added and mixed 
with the cells (FBS in the media inhibits the activity of trypsin). The cells were then centrifuged 
for 5 minutes (200g) at room temperature. The supernatant was aspirated and the cells were re-
suspended in the appropriate volume of fresh media (DMEM).  
After enough cells were grown, these were required to undergo growth arrest or serum 
starvation for 24 hours. Serum starvation forces the cells (mostly) into G0 arrest 378 but also 
ensures that the cells return to a contractile phenotype as contractile protein levels are 
dramatically reduced during proliferation. PASMCs take ~12hours to divide in our hands, 
therefore 24 hours allows the cells to finish diving and all be at the same growth arrest point. 
Furthermore all other proliferative signals which may interfere with signalling events will have 
been silenced.  
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During serum starvation, the cells are still alive and functioning properly, they just lack the 
necessary proteins to undergo cell division. In order to growth arrest cells, cells were incubated 
in DMEM containing all the necessary supplements except FBS. The composition of 
supplements used can be found in table 2.2 but without FBS. 
2.6.4 Verification of PASMC as smooth Muscle (Detection of Smooth Muscle 
Markers) 
 
There are 2 key markers that are used for the detection of vascular smooth muscle; calponin 
and α-actin. Staining for these markers was carried out at a low and later passage number 
thereby ensuring no cell differentiation.  
Calponin binds to actin and myosin Ca2+ binding proteins and inhibits actomyosin ATPase as 
well as the movement of actin filaments over myosin. α-actin is a cytoskeletal actin-binding 
protein localized in dense bodies which stabilizes the muscle contractile apparatus. Therefore 
both proteins are considering to be an integral in smooth muscle function 379,380 and good 
markers of smooth muscle. This is demonstrated in Figure 2.4, where staining for both proteins 
can be clearly seen and is evidence that the cells are indeed smooth muscle cells. 
Figure 2.4 
(A)                                                  (B)                                                        
               
 
Figure 2.4: Staining for VSMC markers  
Staining for (A) α-actin and (B) calponin staining, confirming that these cells are smooth muscle 
cells. Hoechst, which stain for DNA show the presence of the nucleus.    
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2.6.5 Reactive Oxygen Species (ROS) measurement in PASMC and tissue   
 
Reactive oxygen species (ROS) measurement was investigated in both PASMCs and IPAs. As 
discussed in the introduction section, ROS are believed to act as signal moieties at physiological 
levels but dysregulation is associated with numerous diseases.  
2.6.6 Choice of 96 well plate for ROS measurements 
 
White or black solid bottom and white or black clear bottom plates are available in which to 
perform these experiments. Clear bottom plates provide and an advantage of being able to 
examine cells by microscope during the course of an experiment. However, there is an essential 
difference between white and black plates and that is their reflective properties. White plates 
reflect light and maximise light output signal whereas black plates absorb light and reduce 
background and crosstalk. For these reasons, white plates are used when measuring 
luminescence while black plates are used for fluorescence.  
2.6.7 Luminescent and fluorescent probes used 
 
Luminescence  
Luminescence is a general term used to describe the emission of light by a substance that is not 
due to heat (Incandescence is light from heat energy). Luminescence is "cold light" that can be 
emitted at room or lower temperatures and involves the release of an electron from its lowest 
energy "ground" state into a higher energy "excited" state. The electron then returns the excess 
energy in the form of light so it can return back to its "ground" state. With few exceptions, the 
excitation energy is always greater than the energy (wavelength, colour) of the emitted light.  
Luminescent studies were performed primarily using the dye L-012 (8-amino-5-chloro-7-
phenylpyrido [3,4-d]pyridazine-1,4-(2H,3H) dione) (Wako Pure Chemical Industries). L-012, 
a modified form of luminol, has been described as a specific probe for O2•- 381-384 producing a 
much stronger signal than other CL probes. There are a number of reasons I chose to use  
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L-012, the first being is that it is not subject to redox cycling and has been described as being 
reliable for detecting NOX-derived O2•− using high throughput screening (HTS) assays384,385. 
L-012 is much more sensitive than other probes such as luminol and lucigenin and produces a 
signal at least 100 times stronger. The procedure is inexpensive, easy to perform, quick and 
unlike luminol is not pH dependent. Furthermore when performing control experiments, L-012 
produced much higher and consistent results when compared to other luminescent dyes. The 
main drawback is that L-012 primarily detects superoxide but may also detect ONOO− and 
probably other ROS 383,385-387.  
 
Lucigenin (bis-N-methylacridinium nitrate) was also use briefly when determining which probe 
to use throughout my studies. It is the most widely used chemiluminescent probe used 
extensively to detect superoxide102,388-392 in enzymatic and cellular systems. For example, 
lucigenin has been used to detect superoxide production from NADPH-oxidase in phagocytic 
cells, NADH-dehydrogenase in mitochondria, NADPH-cytochrome P450 reductase in 
microsomes, and from xanthine oxidase and NAD(P)H oxidases in endothelial and vascular 
smooth muscle cells 84,389,393-396. Lucigenin’s main strengths are that it is specific for superoxide 
(O2•-), cell permeable and inexpensive. I did not use lucigenin due to it being involved in redox 
cycling and able to generate superoxide (O2•-). Furthermore, in control experiments I found that 
the lucigenin signal is only slightly above background meaning normal chemiluminescence 
plate readers or luminometers that we use within the laboratory are not sensitive enough to 
detect a strong enough signal that I would be confident with. I would have also had to of run 
substantially more plates than L-012 to obtain significant results.    
 
Luminol was also briefly used during preliminary experiments. Luminol is one of the oldest 
used chemiluminescent probes397. It can be oxidized by a variety of ROS, including H2O2398, 
hydroxyl radical 399, hypochlorous acid400, and peroxynitrite 401,402. The main advantage to using 
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luminol is that it can detect intracellular and extracellular ROS, is not involved in redox cycling 
and inexpensive to perform. Luminol in not specific for a certain ROS species, require the 
presence of peroxidases and is also pH dependent with optimal pH being 9-10. Furthermore as 
with lucigenin, I found luminol to produce a very weak signal and found the signal to only be 
above background. 
Fluorescence  
Fluorescence is the emission of light by a substance that has absorbed light. The emitted light 
has a longer wavelength, and therefore lower energy, than the absorbed light. Therefore 
allowing for an accurate reading of results. 
The main fluorescent probe used throughout this investigation is Amplex Red (N-acetyl-3, 7-
dihydroxphenoxazine) which has been used in the detection of extracellular hydrogen peroxide 
(H2O2)403,404. Amplex Red involves the measurement of H2O2 by horseradish peroxidase-
catalysed oxidation of the Amplex Red to resorufin which when excited at 530nM emits 
strongly emits light at 590nM.  
 
Amplex Red has a number of advantages, it has low background fluorescence, high specificity 
for H2O2, resorufin is also stable with the excitation and emission maximum wavelengths that 
are far enough apart to stop autofluorescence also Amplex Red can also be used in a wide range 
of different cell types 403,404.  
 
Amplex Red assay does have a number of drawbacks, the first being that resorufin is a substrate 
of HRP and can be further oxidised resulting in fluorescence 405. Furthermore the stability of 
Amplex Red may be an issue at high pH values (>8.3)405. Also like other HRP methodologies, 
it is susceptible from interference with substances which that oxidize this enzyme.
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2.6.8 ROS measurement in cell free system 
 
As discussed above, each probe has their own advantages and disadvantages. Therefore a 
control experiment was performed for each probe in a cell free system to determine which probe 
gave an accurate, readable (far greater than baseline) and a more stable signal.  
Lucigenin (10μM) and NADPH (100μM), luminol (10μM), L-012 (50μM), Amplex Red 
(50μM) and 0.1U/ml horseradish peroxidase (HRP) were aliquoted individually into 20ml of 
PBS (GIBCO). Amplex Red solution was prepared in dim light. Xanthine oxidase (Sigma) (0.5- 
2mU/ml) and its substrate hypoxanthine (Sigma) (250μM) were added to each mixture at room 
temperature or to PBS alone. 150μL of the resulting mixtures were added to the corresponding 
96 well plate. Changes in luminescence was measured at 5 minute intervals with 5 readings 
taken, while fluorescent readings was measured every minute for 10 minutes. This was 
performed using Promega GloMax Discover: Multimode detection system at 37OC. 
Xanthine oxidase caused no marked increase in luminescence in the presence of lucigenin + 
NADPH (Fig 2.5A) or luminol (Fig 2.5B). Lucigenin is shown to produce a low luminescent 
reading with virtually no difference between blanks and samples containing xanthine oxidase 
at any time point. In the presence of luminol, samples containing xanthine oxidase actually 
reduced luminescence levels below the blank readings at each time point. In the presence of L-
012, 2mU/ml of xanthine oxidase did cause a marked increase in luminescence at 5 minutes 
(Fig 2.6A). This signal did decrease over time to plateau ~25minutes, however the signal 
produced was still much greater than what was obtained from blank readings. Finally, xanthine 
oxidase at the concentrations used, produced a large increase in fluorescence in the presence of 
Amplex Red (Fig 2.6B). The fluorescent signal increased over time and did not appear to 
plateau with the exception of 1mU/ml of xanthine oxidase.   
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Xanthine oxidase is an enzyme known to produce ROS, therefore changes in 
luminescence/Fluorescence correspond to changes in ROS production. Lucigenin produced a 
very weak signal which would require an extremely large n number to be able to gain statistical 
significance. Luminol signal actually decreased in the presence of xanthine oxidase when it 
should have increased. For these reasons I decided not to use these probes for future 
experiments.           
L-012 and Amplex Red produced measurable results much greater than blank values at all time 
points. Furthermore, both probes are structurally different and each offer a different method of 
measuring ROS (L-012 = luminescence, Amplex Red = fluorescence). Therefore, these probes 
were chosen to measure ROS in future experiments in cells and/or tissue. Previous work within 
my group using Amplex Red found no measurable responses in cells when stimulated, therefore 









Figure 2.5: Effect of xanthine oxidase on ROS production in the presence of lucigenin 
and luminol  
Luminescent results from (A) Lucigenin (10μM) and NADPH (100μM) (upper panel) and (B) 
Luminol (10μM) (lower panel) in the presence and absence of 0.5 – 2mU/ml xanthine oxidase 
and its substrate hypoxanthine (250μM). Line graphs represent reads at every 5 minutes (n = 1) 





   
(B) 
 
Figure 2.6: Effect of xanthine oxidase on ROS production in the presence of L-012 and 
Amplex Red  
Shows luminescent results from (A) L-012 (50μM) (upper panel) and fluorescent results for (B) 
Amplex Red (50μM) (lower panel) in the presence and absence of 0.5 – 2mU/ml xanthine 
oxidase and its substrate hypoxanthine (250μM). Line graphs represent reads at every 5 minutes 
(n = 1) for L-012 and reads at every minute for Amplex Red. 
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2.6.9 Buffers used during studies 
 
While investigating ROS production in cells and tissue, it was important to choose the right 
buffer in which to perform my experiments. Phosphate Buffered Saline (PBS) and Hanks 
Balanced Salt Solution (HBSS) were deemed to be suitable buffers as they are stable at room 
temperature and at 37OC, maintain cell osmolarity and maintain a neutral pH in order not to 
destroy the cell or tissue sample. Furthermore, bubbling with CO2 is not required as this is not 
a bicarbonate buffer and would be extremely difficult to perform using Promega GloMax 
Discover: Multimode detection system. 
I therefore performed a control experiment to determine which buffer would be used along with 
L-012. 
L-012 (50µM), xanthine oxidase (2U/ml) and its substrate hypoxanthine (Sigma) (250μM) were 
added to each buffer at room temperature. 150μL of the resulting mixtures were added to the 
corresponding 96 well plate. ROS production was then measured at 5 minute intervals at 37OC 
using Promega GloMax Discover: Multimode detection system (Figure 2.7).   
Results indicate that L-012 and PBS give the highest signal over the shorter time point. 







Figure 2.7: Effect of PBS and HBSS on xanthine oxidase ROS production in the presence 
of L-012   
Shows luminescent results from L-012 and xanthine oxidase in PBS (upper panel) and HBSS 
(lower panel). Line graphs represent reads at every 5 minutes (n = 1) for each condition
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2.6.10 ROS measurement in PASMCs 
 
Following initial growth of PASMCs cell lines, PASMCs were seeded into a 96 well white solid 
bottom plate at a density of between 5.0 – 10.0x104 cells per well. Cells were allowed to attach 
overnight at 37oC in DMEM + 10% FBS (as described in 2.6.1). Following ~24 hour incubation, 
media was subsequently aspirated and fresh media added. Cells were then left to incubate until 
they were 90% confluent. The media was then aspirated and replaced with serum free media 
(as described in 2.6.3), cells were then incubated for ~24 hours. Following serum starvation, 
media was aspirated and replaced with PBS containing luminescent dyes: L-012 (50µM). 
150μM of solution was added to the appropriate wells as a control or in the presence of U46 
(100nM), U46 and tempol (3mM), U46 and ebselen (10μM), tempol (3mM) or ebselen (10μM). 
As a positive control, this was also carried out in the presence of our superoxide generator 
LY83583 (1 or 10μM). LY83583 (1μM) ROS was also measured in the presence of antioxidants 
tempol (3mM), ebselen (10μM). ROS production was then measured at 5 minute intervals from 
0 – 30 mins at 37OC using Promega GloMax Discover: Multimode detection system.   
2.6.11 ROS measurement in Tissue 
 
L-012 Measurement 
Rat Intra-pulmonary artery were cut into 2 pieces, added to a well in a 96 well plate and 
incubated for 30 minutes. Initially 150μM of solution containing solely L-012 (50μM) was 
added to each well for 10 minutes followed by the addition of U46619 (0.1 or 1 µM) for 10 
minutes finally with the addition of superoxide dismutase (SOD) (200U/ml) or tempol (3mM) 
for the final 10 minutes. Chemiluminescence was then measured at 1 minute intervals from 0 – 
30 mins at 37OC.  
U46619 (0.1 or 1µM) did not enhance chemiluminescence as measured by L-012 (Fig 2.8) in 
IPA with control and treated samples appearing to follow a similar pattern of luminescence. 
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Furthermore, SOD and tempol were able to marginally reduce chemiluminescence suggesting 
they are inhibiting basal ROS production in control and treated samples. However, as there was 
no difference between U46619 treated and control samples, I therefore did not use L-012 to 
measure ROS production in tissue.       
Figure 2.8 
 
Figure 2.8: Effect of U46619 and antioxidants on ROS productions in the presence of L-
012 in IPA    
Shows luminescent results from ROS production in tissue. Line graphs represent reads at every 
1 minutes (n = 1) for each condition. There was no significant increase in ROS production with 
U46619 or compared to control. 
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Amplex Red Measurement 
Rat Intra-pulmonary artery were cut into 2 pieces and incubated at 37OC in the dark for 3 hours 
in 1.5ml eppendorf tubes containing 1ml PBS, Amplex Red (10μM), 0.1U/ml HRP and U46619 
(0.1 or 1 µM) with or without SOD (200U/ml) or ebselen (10µM), Phospho 12-13-dibutyrate 
(PDBU) (0.1 or 1µM) (Sigma), SOD (200U/ml) and ebselen (10µM).  Following 3 hour 
incubation, 150µl of supernatant from each condition was pipetted into a solid clear bottom 
black plate, and read using Promega GloMax Discover: Multimode detection system at room 
temperature.  
PDBU was used as a positive control during this set of experiments. PDBU is a known activator 
of PKC 406 which activate NOX production via phosphorylation of the p47phox subunit thus 
enhance ROS production125. 
U46619 and PDBU were unable to increase fluorescence using Amplex Red, rather both stimuli 
were shown to decrease the fluorescent signal. U46619 in the presence of ebselen and SOD 
showed similar results to U46619 alone whereas ebselen had no effect vs control however SOD 
marginally increase luminescence. The variety of results obtained along with the knowledge 
that U46619 and PDBU were unable to increase fluorescence, I therefore did not use Amplex 





Figure 2.9: Effect of U46619 and antioxidants on ROS productions in the presence of 
Amplex Red in IPA    
Shows fluorescent results from ROS production in tissue. Bar chart represent the mean (n = 2) 
per condition. There was no significant increase in ROS production with U46619 or PDBU 
compared to control.  
 
2.7 Transfection of PASMC’s for visualising Protein 
Translocation 
 
PASMC’s were transfected in order to visualize protein movement within the cell in response 
to stimuli and/ or inhibitors. As discussed in the introduction section, RhoA and ARHGEF1 are 
located in the cytosol in an inactive form however upon stimulation, translocate to the cell 
periphery where they are believed to be activated.   
Green Fluorescent protein (GFP) 
GFP has been used extensively during fluorescent microscopy. GFP is composed of 238 amino 
acids that exhibits bright green fluorescence with a major peak at 395 nm and a minor peak at 
475 nm when exposed to light in the blue wavelength 407-409. GFP can be tagged along with 
other proteins such as RhoA or ARHGEF1. This creates a fusion protein which are proteins 
created through the joining of two or more genes that originally coded for separate proteins but 
115 
 
code for both proteins from 1 promoter site. Creating a fusion protein such as eGFP-tagged 
RhoA or eGFP-tagged ARHGEF1, allows us to combine the functionality of both proteins. Due 
to the fluorescent properties of GFP, this allows us to visualise protein movement throughout 
the cell. GFP was therefore excited at 395nm and emission was captured at 509nm during my 
experiments.      
2.7.1 Cloning of rat RhoA and ARHGEF1 into a C-terminal GFP vector 
 
Plasmid design and generation was carried out by Dr Yasin Shaifta prior to the initiation of my 
research and the full protocol can be found in the appendix. However the whole process can be 
broken down into several important steps. 
Initially our genes of interest to be isolated, cloned and over-expressed are RhoA and 
ARHGEF1. RhoA cDNA product was made and purified “in house” while ARHGEF1 was 
obtained and verified from Source Bioscience (Source BioScience UK Limited) cDNA library. 
RhoA mRNA was obtained from rat PASMCs. This was then reverse-transcribed to produced 
complimentary DNA (cDNA). RhoA forward (start) and reverse (finish) primers were then 
designed using the known RhoA DNA sequence to serve as start and finish points for 
transcription, thus ensuring accuracy and limiting non-specific transcription. 
Polymerase chain reaction (PCR) was then performed to amplify the DNA product to generate 
millions of copies of our DNA sequence. The PCR samples were then run on a 1% agarose gel, 
with enough sample left to perform the following cloning procedure. GeneRulerTM 1kb DNA 
Ladder or λ DNA/ EcoRI+HindIII Marker were run alongside the samples to determine the size 
of the PCR product to determine semi-quantitatively that we have the correct product.   
The band at the correct molecular weight was cut from the gel, and cloned into PCR®2.1-TOPO 
vector using DNA ligase. This vector was initially used as it was a cheaper alternative to using 
pcDNA™6.2/C-EmGFP/TOPO® which will be used when we have obtained a purified product. 
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The reaction mixture was then chilled on ice before proceeding to One Shot® Chemical 
Transformation of competent E .coli cells (Invitrogen Life Technologies, UK). The reaction 
mixture and E .coli cells were incubated to allow the plasmid to enter the cells. The resulting 
mixture of bacterial cells were spread onto pre-warmed LB-agar-ampicillin (100 μg/ml) 
selection plates and left to incubate. Cells have not been transfected with the plasmid will be 
unable to grow as they do not have the antibiotic resistance gene found on the plasmid. The 
clones that had grown were then lysed, protein was precipitated, DNA was captured in a 
column, eluted, precipitated and then re-dissolved. This stage was performed to purify the DNA 
product.  
Once we have the correct product, this process was again carried out for both RhoA and 
ARHGEF1 except the DNA product was cloned into pcDNA™6.2/C-EmGFP/TOPO®. 
TOPO® TA cloning allows cloning of the PCR insert in the forward and reverse orientation, 
due to identical overhangs in the insert and in the vector. The occurrence of both orientations 
should theoretically be of equal chance. Therefore, to identify the clones which have the RhoA 
PCR insert ligated in the forward orientation, clone was assessed for their restriction 
endonuclease sites. 
2.7.2 Cell Transfection 
 
PASMCs were grown until confluency and then detached as previously described. Transfection 
was carried out using Amaxa™ Basic Nucleofector™ Kit for Primary Smooth Muscle Cells 
(LONZA). For each transfection, 1.3x106 cells was used.  
Initially a transfection mix was prepared at room temperature, consisting of 19μL supplement 
and 85.5μl nucleofector (protects cells). Cells were then centrifuged at room temperature for 5 
minutes at 200g, the media was then aspirated. 4µg of eGFP tagged-RhoA or eGFP-tagged 
ARHGEF1 plasmid was then added into a transfection tube. The nucleofector and supplement 
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mixture was added to the cell pellet and thoroughly mixed. This cell mixture was then added to 
the plasmid and thoroughly mixed. This was subsequently added to a nucleofector corvette 
(Lonza). Transfection was then performed by electroporation using a Nucleofector™ 2b 
Device (Lonza).  
Electroporation was used due to the higher transfection rate and cell survival when compared 
to lipofection. This works by shocking the cells with an electrical pulse which disrupts the 
phospholipid bilayer of the membrane, creating temporary pores. This also raises the electrical 
potential across the membrane allowing charged molecules such as DNA to pass through the 
pores 410. 
Immediately after transfection, cells were added to warm media. 1ml of media containing the 
transfected cells were added to round 19mm glass coverslips (VWR international) and left to 
incubate until the following day were the media was aspirated and fresh media was added. Cells 
were left to grow until ~50% confluent. This allowed imaging of a single cell to be carried out 
with relative ease, furthermore if there was a greater confluency, then cells would be grown on 
top of each other making imaging difficult. It also allowed cells to grow and spread out again 
making it easier to see translocation from the perinuclear region to the cell periphery.   
When cells reached ~50% confluent, media was aspirated and replaced with serum free media 
and left to incubate at 37OC for 24 hours and then imaged.   
2.7.3 Live Cell Imaging      
 
Live cell imaging was performed using a Zeiss Axiovert 200 Microscope and visualized using 
BD™ CARV II Confocal Imager. The light source used was a 120W Metal Halide light source 
which allows a full-spectrum (360nm–700nm) imaging through filter sets which are matched 
to the excitation and emission requirements of our fluorescent sample.  
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Therefore in order to image proteins tagged with eGFP, light emitted from our light source 
passes through our excitation filters which is matched to the UV wavelength. This is then 
focussed onto our sample which emits a green fluorescence which is filtered through the 
emission filters matched to green fluorescence and enables visualisation of our protein as 




Figure 2.10: Overview of the excitation light path from the light source to the sample 
and the emission light emitted from the sample toward towards the camera.   
Shows the excitation light path from the light source, where it is filtered by the excitation filter, 
and reflected towards the sample via a dichroic mirror. The emitted light from the sample passes 
through the dichroic mirror where it is filtered by an emission filter, finally reaching the camera.     
 
Images were taking using a digital camera built into the imaging system. The images itself were 
constructed by binning of pixel intensities. Each pixel has a specific number and this number 
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relates to what colour the pixel is. Binning allows the combination of adjacent pixel to create 
one single pixel in the recorded image. In this experiment, I used a 3 x 3 binning factor 
optimised previously by others within the laboratory. This allowed me to gather information 
from 9 pixels (in a square), thereby increasing the pixel intensity by 9. This does increase the 
signal to noise ratio but reduces resolution. Each image was exposed to light for 65.0ms. I varied 
the frame rate during the experiment to reduce photo-bleaching of eGFP. This occurs when the 
fluorophore, in this case eGFP permanently loses its ability to fluoresce due to photo induced 
chemical damage and covalent modification.  
Media was aspirated and replaced with PSS which is continuously bubbled with 5%CO2/95% 
air. Coverslips were mounted onto the microscope and visualised at X40 magnification at 37OC.  
Initially 5-10 frames were taken of the coverslip every 5 seconds were no treatment was applied 
as a control run. U46619 (100nM) or LY83583 (1µM) was then applied and frames were taken 
every 2 seconds for 30 seconds. The coverslip was then washed with PSS and left to incubate 
for 10 minutes during which time 5 frames were taken over 10 minutes, 1 frame every 2 
minutes. Following incubation period, U46619 (100nM) or LY83583 (1µM) was then reapplied 
to control cells and frames were taken every 2 seconds for 30 seconds. In non-control cells, 
inhibitors ebselen (1µM),  tempol (3mM), or PP2 (1µM) was added to the coverslip and left to 
incubate for 10 minutes with 5 frames being taken, 1 frame every 2 minutes. U46619 (100nM) 
or LY83583 (1µM) was then reapplied to control cells and frames were taken every 2 seconds 
for 30 seconds. The software used for image building was Metafluor and Metamorph 
(Molecular Devices) (7.8.12.0).  
Translocation image Analysis 
Image J software was used to measure puncta formation or changes in background intensity in 
the presences of our stimuli and inhibitors. The image was loaded into image J and a line scan 
was performed. This was carried out by drawing a line through 3 separate points in the image 
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at opposite ends of the cell where puncta appeared or background region. The line was drawn 
from the inside of the cell to the outside. The profile of the line was plotted and the greyscale 
value of intensity is shown. This process is demonstrated below in Figure 2.11. The values 




















      
Figure 2.11: Analysis of a transfected PASMC picture while stimulated using Image J 
software.  
Shows Measurement of puncta Using Image J. The top panel shows the line scan function that 
was used for measurements. The second panel shows how the line scan function was applied to 
our image. The bottom panel shows the greyscale profile that was generated from the analysis. 
As illustrated in the bottom panel, the initial grayscale readings corresponds to cytosol grayscale 
value, the subsequent increase in grayscale value corresponds to the appearance of 
spots/patches and the final grayscale values correspond to outside grayscale value. The 
grayscale values obtained from the readings inside the cell periphery next to their corresponding 
spots were used as background measurements. The average of 3 points was obtained and 
subsequently subtracted from the measurements of spots/patches. The reversible appearance of 
peripheral spots or patches was associated with a reversible darkening of adjacent background 
level cellular fluorescence. This change was also measured by performing a lines scan function 
adjacent to where the spots/patches appeared.   
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2.8 Statistical Analysis 
 
Data were statistically analysed using Sigmastat (version 3.5; Systat Software Inc., USA). All 
values were expressed as means +- SEM, n = number of arteries / cells, N = number of 
animals/cell lines which will be detailed for each experiment. Results were considered 
significant if p < 0.05, actual levels of significance are detailed for each experiment. 
Simple paired comparisons of ‘before and after treatment’ in the same tissue sample and 
unpaired comparisons of independent or unpaired samples were performed using a 
paired/unpaired Student’s t test. Multiple comparisons were performed using analysis of 
variance (ANOVA).  One-way ANOVA with a Holms Sidak post-hoc test was used where there 
was a single independent variable, for example differences in mean phosphorylation in IPAs 
for control, agonist/hypoxia, agonist/hypoxia + inhibitor conditions and SrcFK, MYPT-1 and 
MLC20 time controls.  
Two-way ANOVA with a Holms Sidak post-hoc test was used to compare results with multiple 
independent variables and/or time series where multiple measurements were made from each 
preparation, for example to investigate interactions between ‘time’ and ‘treatment’ factors on 
ROS measurements. 
The power of each test of the overall ANOVA will be detailed within the figure legends for 
each experiment.     
Variation of n Numbers 
 
Throughout my studies, there is some variability in n numbers particularly with regards to 
phosphorylation data such as figure 3.12. In this figure, the n number for LY1µM treatment at 
30 seconds is higher than treatment at 30 minutes. This variation was due to data that had 




Other examples where n numbers varied include figures 3.13, 3.17 and 3.18. The variation 
between control and treated samples in these figures arose due to how the data was originally 
going to be presented. Initially, the data was going to be presented as untreated, U46 treated, 
U46+ebselen/tempol or PP2 with ebselen/tempol or PP2 vs basal levels. Thus presenting the 
data as 3 graphs/blots for each protein.  
I then decided that the data should be presented as untreated, U46 treated, U46 +ebselen, U46 
+tempol and U46 +PP2 with a separate set blot for ebselen, tempol, PP2 vs basal. I was therefore 
able to combine all untreated and U46 data from each set of data but not for U46 + inhibitor. I 
subsequently had ~3 times the amount of controls and U46 treated samples vs U46 + inhibitor. 
This consequently gave rise to the variation in n numbers but allowed me to present the data as 
two graphs/blots per protein.           
Variation of n numbers within other figures was due to variance between samples. Therefore 
by repeating the experiment, I was trying to distinguish whether the variance was due to the 
treatment or from random variance caused by underlying differences between rats or vessels 
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SrcFKs act as ROS sensitive intermediates in 






ROS are generated through incomplete reduction of molecular oxygen by oxido-reductase 
enzymes, such as NADPH-oxidase (NOX) 98,205,411 or the mitochondrial electron transport chain 
412,413. Oxidant stress has long been associated with cardiovascular diseases such as ischemic 
reperfusion injury 205, atherosclerosis 414 and pulmonary hypertension 117,411,415. It is only 
relatively recently that reactive oxygen species (ROS) have been implicated as physiological 
signalling moieties that modulate cellular functions including vascular tone in health. ROS are 
produced in healthy tissue in response to a wide variety of vasoconstrictor agonists including 
thromboxane416, angiotensin 116, endothelin 117,118 and thrombin 119 leading to increased [Ca2+]i 
concentration and Rho-Kinase mediated vasoconstriction. ROS are also believed to be 
increased by acute hypoxia and are implicated in hypoxic pulmonary vasoconstriction 301,412,413.  
Protein function can be altered by oxidative modification of key amino acid residues, especially 
cysteine. Therefore, physiological levels of ROS may modify specific cysteine residues of key 
proteins involved in cellular signal transduction altering their functions and interaction with 
other proteins87. An example being protein kinases92. Amongst these, SrcFK may be directly 
activated by oxidative modification 92,213 while opposing tyrosine phosphatases are inhibited, 
leading to a net increase in tyrosine phosphorylation199,417. The eponymous member of the 
SrcFK, c-Src is of particular interest because it is a signalling molecule involved in smooth 
muscle proliferation and migration in response to various stimuli 205,213,418, and as discussed 
previously, in contractile responses.  
In addition to evidence for ROS-mediated activation of Src in oxidative stress-associated with 
hyper-contractile states 204,205, as discussed, many vasoconstrictors generate ROS under 
physiological conditions and activate tyrosine kinases. Previous results within my group have 
shown that prostaglandin – F2α and hypoxia enhance total tyrosine phosphorylation, activate 
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Src and cause SrcFK-dependent constriction 7,41. Similar relationships have been seen in other 
vascular beds 82,419,420. Combining these observations with the proposed ROS-sensitivity of Src 
leads me to propose that the interaction between SrcFK and ROS makes a central contribution 
to vascular smooth muscle function.   3.2 Hypothesis 
 
I hypothesise that SrcFK will act as a ROS sensitive intermediate acting as an upstream 
signalling moiety involved in vasoconstriction and activation of the RhoA/Rho-Kinase 
pathway. SrcFK will act as a link between agonist induced ROS production and 
vasoconstriction via activation of Rho-Kinase. SrcFK is therefore a requirement in agonist 
induced ROS mediated vasoconstriction. 
 
3.3 Experimental Design 
 
The following methods were adopted in order to help address my chapter hypothesis.  
ROS Measurement  
ROS measurements were performed in PASMC’s using the luminescent dye L-012 (50μM). 
PASMCs were grown until 80-90% confluent, followed by 24 hour serum starvation. Following 
24 hours, media was aspirated and L-012 or L-012 + U46619 / LY8383 or L-012 + U46619 / 
LY83583 + inhibitor was added to all wells in a row. The cells were immediately read on a 
Promega GloMax Discover: Multimode detection system with a reading being taken every 5 
minutes with a 5 minute incubation in-between reads. An average of eight wells in a row was 
calculated, and changes were expressed as a % change from control at each time point. Data 
was expressed as means +- SEM and statistical analysis was carried out using 2 way ANOVA 
in sigma stat (version 3.5). As time was found not to be a factor for ROS production, rather 
whether the presence of stimulus plus inhibitor, representative graphs plotted were at 15 




Functional studies were performed in Intra Pulmonary arteries (IPA’s) to investigate whether: 
(1) ROS-induced contraction is SrcFK dependent and to investigate the ROS dependency of 
U46619 in tissue on the myograph, (2) U46619 induced contraction is SrcFK and ROS 
dependent, (3) LY83583 enhanced, U46619 contraction is not due to the removal of NO instead 
of increased ROS production, finally, (4) the concentrations of ebselen, tempol and PP2 used 
have any non-specific contractile effects (using KPSS contractile responses).   
Although inhibitors of ROS and SrcFK have previously been used within our laboratory, it was 
essential to carry out an inhibitor cumulative dose responses to KPSS contractile responses. As 
discussed in the introduction, recent data has shown that Rho-Kinase signalling can be induced 
by membrane depolarisation. Therefore, to ensure that the inhibitor concentration used is not 
acting as a Ca2+ channel antagonist or MLCK inhibitors, these inhibitors were tested against 
KPSS contractile function believed to be predominant Ca2+ mediated contraction. This will 
clarify that the effects seen using these inhibitors will be predominantly via Rho-Kinase 
signalling and not Ca2+ signalling. 
 
In addition, ROS and SrcFK inhibitors are poorly water soluble and are therefore diluted in our 
vehicle DMSO. I therefore investigated whether DMSO had any effect on contractile responses. 
Dose responses were carried out in the presence of (A) inhibitor plus vehicle and (B) vehicle 
control only. IPA’s were dissected from the same vascular tree, mounted onto a wire myograph 
so that for each experiment, there was at least 1 vessel from the same arterial tree which was 
treated with inhibitors and DMSO or DMSO only.  
IPA were pre-constricted with KPSS or U46619 (100nM) to achieve ~70% of KPSS. This was 
allowed to plateau. Subsequently, a cumulative concentration response was performed using 
either ebselen (0.1µM - 10µM), tempol 0.1mM – 3mM), PP2 (1µM – 30µM) or DMSO (0.5 - 
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6µL which is the same volume present in the solution of inhibitor plus DMSO). Each 
concentration was allowed to incubate for 10 minutes. Following the final concentration, IPA 
were washed at least 3 times in PSS and contractile force was allowed to return to baseline. 
When investigating the effect of NOS inhibition of U46629 induced contraction, L-NAME 
(300nM) was added to the chamber and allowed to incubate for 15 minutes before the addition 
of U46619 and cumulative concentration response with inhibitors.               
The effect of DMSO, ebselen (10µM), tempol (3mM) and PP2 (30µM) was investigated in 
response to U46619 induced, LY83583 enhanced contractile responses. An initial control 
response was performed whereby U46619 (2nM) was initially added to IPAs for 10 minutes to 
achieve ~10% of KPSS. This was immediately followed by the addition of LY83583 (1µM) 
and incubated for a further 10 minutes. IPA’s were subsequently washed three times in PSS and 
allowed to rest until a steady baseline was achieved. Inhibitors of either ROS: ebselen (10µM), 
tempol (3mM), SrcFK: PP2 (30µM), NOS: L-NAME (300nM) and DMSO were then added to 
the chamber and allowed to incubate for ~15 minutes before conducting a second response in 
their presence. IPA were then washed at least 3 times in PSS following treatment and contractile 
force was allowed to return to baseline.  
Phosphorylation studies  
Phosphorylation studies were performed to determine, if SrcFK does act as ROS sensitive 
intermediate upstream of Rho-Kinase. If so, inhibition of ROS should decrease SrcFK activity 
and inhibition of both ROS and/or SrcFK should decrease the activity of Rho-Kinase. SrcFK 
activity will be measured by SrcFK autophosphorylation (Tyr416), Rho-Kinase via 
phosphorylation of MYPT-1 (Thr850) and MLCK activity via MLC20 phosphorylation (ser19).  
Secondly, SrcFK autophosphorylation (Tyr416) was investigated in the presence of LY83583 
(1µM) as LY is a verifiable source of ROS therefore confirming the ROS sensitivity of SrcFK. 
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As the largest peak responses from U46 time control occurred at 0.5 min and 30 min (for SrcFK 
autophosphorylation) these time points were investigated using LY83583 (1µM) treatment. The 
effect of LY83583 (1µM) on MYPT-1 (Thr850) or MLC20 phosphorylation was not 
investigated in this study as previous studies from our group have explored this 88,89.  
Finally, phosphotyrosine was also investigated in the presence of LY83583 and PP2. 
Phosphotyrosine shows a rage of proteins of various molecular weights which are tyrosine 
phosphorylated. If there is an increase in band intensity in response to LY83583 and this is 
inhibited by PP2, I can infer that the protein is tyrosine phosphorylated in response to SrcFK 
activation either directly or indirectly via a SrcFK sensitive intermediate.  
The ratio of phosphorylated SrcFK, MYPT-1 and MLC20 was calculated by dividing phospho 
levels by total level of protein thus giving an indication of protein activity. 
Initially, time control experiments for SrcFK autophosphorylation, MYPT-1 and MLC20 
phosphorylation was investigated in the presence of U46619 (100nM). IPA’s were dissected 
and treated with U46619 for 0.5, 2, 5 and 30 minutes or left untreated. The highest 
phosphorylation responses and therefore activation for all 3 proteins was 30 minutes. This time 
point was therefore used in future investigations with inhibitors.  
IPA were dissected and initially incubated with our inhibitors for 15 minutes, U46619 (100nM) 
was then added for 30 minutes. Simultaneously untreated samples were prepared. The lysate 
was then prepared and analysed as previously discussed (see chapter 2, section 2.6.5).  
Strength of experimental design (Chapter 3)  
During this chapter, one of the main strengths was that during each experiment a control 
vascular was always included amongst a set of rings isolated from a single rat, each would 
then receive a specific treatment e.g. U46, ebselen, tempol, PP2 etc. Therefore, an effects seen 
can be compared to its control preparation.  
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Although the n numbers are variable, for most experiments throughout my thesis the n 
numbers are high. This helps ensure that the results I am obtaining are a genuine. It also helps 
reduce the risks or type 1 or 2 errors while performing statistical analysis.  
The samples are from multiple sets of rats, again this ensures that the effects seen are not due 
to a homogenous group but rather across a population. Making any results obtained more 
















3.4 Results Section 
3.4.1 ROS and SrcFK are Key intermediates contributing to U46619-induced 
contraction 
 
Initially, I examined whether the selective TP receptor agonist U46619 stimulated endogenous 
ROS production and whether the glutathione peroxidase mimetic ebselen (10µM) or the SOD-
mimetic 4-hydroxy-TEMPO (tempol) (3mM) were acting as antioxidants in PASMCs using the 
luminol-derived ROS-sensitive chemiluminescent probe L-012 385. U46619 enhanced 
chemiluminescence which was abolished by prior incubation with ebselen or tempol (Fig 3.1). 
Basal chemiluminescence was significantly reduced by ebselen, however, tempol abolished 
basal chemiluminescence, suggesting tempol to be a better basal ROS scavenger in this system 
(Fig 3.1). The data presented in this figure was at one time point (15 minutes as this was deemed 
to present the most stable and accurate data), whereas measurements were made at multiple 
time points and all of those data were entered into the statistical analysis (Fig 3.1). 
I next wanted to determine the influence endogenous ROS production has on agonist-induced 
contraction. Contractile responses were measured using rat intra-pulmonary arteries. Sub-
maximal contraction induced by U46619 (100nM) was inhibited by ebselen (10µM) (Fig 3.3) 
and tempol (3mM) (Fig 3.4) in a dose dependent manner, whilst, our vehicle showed no 
significant changes indicating U46619 induced contraction is partially ROS dependent (Fig 
3.2). U46619-induced contraction was also shown to be is partially dependent on SrcFK as the 
SrcFK antagonist, PP2, induced a concentration-dependent relaxation (Fig 3.5). 
Representative traces show that treatment with our vehicle DMSO caused no significant 
changes in contractile force elicited by U46619 (Figure 3.2), this data taken together with data 
from KPSS contraction data (shown later) indicates that DMSO is a suitable solvent for use in 
my studies and that any inhibitory effect observed will be due to the presence of inhibitor and 
not DMSO.  
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A concentration of 30μM PP2, 10μM ebselen and 3mM tempol was used for future 
experiments. The PP2 concentration is approximately 15 times that of the IC50 (previous 
laboratory studies). This concentration is required as PP2 dose responses carried out previously 
in pulmonary artery homogenates demonstrate that a concentration of 30μM PP2 is required to 
fully inhibit SrcFK activity (measured by Tyr-416 phosphorylation). 30μM PP2 was shown to 
inhibit KPSS contractile responses by a small but significant amount (shown later) but as 
discussed in future sections, SrcFK play a role in regulating membrane potential and therefore 
I concluded that this concentration was suitable for subsequent experiments 70,421,422. 
Figure 3.1    
 
Figure 3.1: Effects of U46619, antioxidants on ROS production  
Effects of ebselen (10µM) or tempol (3mM) on U46619-induced ROS production (15min, 
100nM) or on basal ROS production in PASMC, measured by L-012 chemiluminescence. 
##P<0.001 vs. control; #P<0.05 vs. control; **P<0.001 vs. U46619 alone (2-way ANOVA, 
factors: time and drug treatment), n=10 separate smooth muscle cell cultures passage 3, isolated 




Figure 3.2  
 
Figure 3.2: Effects of DMSO on U46619 induced contraction  
Concentration-dependent relaxation responses to DMSO (n=5 arteries, isolated from 5 different 




















Figure 3.3: Effects of U46619 and ebselen on U46619 induced contraction 
Concentration-dependent relaxation responses to ebselen (n=8 arteries, isolated from 7 different 
rats) in IPA pre-constricted with 100nM U46619. Upper panel: representative traces with 
arrows highlighting where each dose was added. Bottom panel: mean effects of inhibitors 
plotted against DMSO vehicle control (n=5 arteries, isolated from 5 different rats). **P<0.001 










Figure 3.4: Effects of U46619 and tempol on U46619 induced contraction 
Concentration-dependent relaxation responses to tempol (D, n=8 arteries, isolated from 7 
different rats) in IPA pre-constricted with 100nM U46619. Upper panel: representative traces 
with arrows highlighting where each dose was added. Bottom panel: mean effects of inhibitors 
plotted against DMSO vehicle control (n=5 arteries, isolated from 5 different rats). **P<0.001 









Figure 3.5: Effects of U46619 and PP2 on U46619 induced contraction 
Concentration-dependent relaxation responses to PP2 (E, n=6  arteries, isolated from 6 different 
rats) in IPA pre-constricted with 100nM U46619. Upper panel: representative traces with 
arrows highlighting where each dose was added. Bottom panel: mean effects of inhibitors 
plotted against DMSO vehicle control (n=5 arteries, isolated from 5 different rats). **P<0.001 
vs. DMSO control, *P<0.05 vs. DMSO control (2-way ANOVA, Factors: DMSO and drug 






3.4.2 LY83583-induced-ROS production augments U46619-induced 
contraction in a SrcFK and ROS dependent manner  
 
Having established that U46619 enhances PASMC ROS production and IPA contractile 
responses in a ROS and SrcFK dependent manner, I next wanted to repeat these experiments 
using a well-known exogenous ROS source. This would allow us to confirm ROS production 
in my system but also show that ROS induced contraction is SrcFK dependent.   
Using the membrane permeable quinolinequinone LY83583, a known generator of intracellular 
superoxide 423, LY83583 (1µM and 10 µM) increased L-012 chemiluminescence with 1µM 
showing a similar increase as 100nM U46619 (Fig 3.6A). Similarly, the effect of 1µM LY85683 
was abolished by ebselen and tempol confirming that both drugs are acting as antioxidants (Fig 
3.6B). Again, the data data presented in this figure was at one time point (15 minutes), whereas 
measurements were made at multiple time points and all of those data were entered into the 
statistical analysis (Fig 3.6A and B).  
Previous work carried out within our laboratory has shown that 1µM LY85683 does not in itself 
promote constriction in IPA 88, however it can enhance the response to 2nM U46619 pretone 
which is ~10% of KPSS. Repeating this response but pre-incubating IPA with ebselen (Fig 3.8), 
tempol (Fig 3.9) or PP2 (Fig 3.10) along with increasing U46619 concentration to 8-10nM to 
match initial pretone levels, LY83583 contractile responses were significantly reduced, while 
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Figure 3.6: Effects of exogenous superoxide, ebselen and tempol on ROS production in 
PASMCs  
A: LY83583 (LY, 1 and 10 µM, 15min, n=12 separate smooth muscle cell cultures passage 3, 
isolated from 9 different rats.) generates superoxide, in PASMC, as measured by L-012 
chemiluminescence, ##P<0.001 vs. control, (2-way ANOVA, Factors: Time and Drug 
treatment, Power of performed test 0.653), which was B: subsequently inhibited by ebselen 
(ebs, 10µM, n=10 separate smooth muscle cell cultures passage 3, isolated from 7 different 
rats.) or tempol (temp, 3mM, n=10 separate smooth muscle cell cultures passage 3, isolated 
from 9 different rats.). **P<0.001 vs. LY alone, ##P<0.001 vs. control (2-way ANOVA, 










Figure 3.7: Effects of LY83583 and DMSO on U46619-induced contraction  
U46619 concentration was adjusted to achieve ~10% of KPSS (U46). 1µM LY83583 was then 
added for 10min (U46+LY). This response was then repeated in the presence of DMSO vehicle 
(n=6 arteries, isolated from 5 different rats) Upper panel: representative traces. Bottom panel: 
mean ± SEM measurements of peak LY83583-induced contraction, expressed as a percentage 
increase of U46619 pre-constriction. **P<0.01 vs. U46, (2-way ANOVA, Factors: U46, 







Figure 3.8: Effects of LY83583 and ebselen on U46619-induced contraction  
U46619 concentration was adjusted to achieve ~10% of KPSS (U46). 1µM LY83583 was then 
added for 10min (U46+LY). This response was then repeated in the presence of ebselen (10µM, 
n=7 arteries isolated from 7 different rats). Upper panel: representative traces. Bottom panel: 
mean ± SEM measurements of peak LY83583-induced contraction, expressed as a percentage 
increase of U46619 pre-constriction. **P<0.001 vs. U46, *P<0.05 vs. U46; ##P<0.001 vs. 
control U46+LY (2-way ANOVA, Factors: U46, U46+LY +- inhibitor drug treatment. Power 







Figure 3.9: Effects of LY83583 and tempol on U46619-induced contraction 
U46619 concentration was adjusted to achieve ~10% of KPSS (U46). 1µM LY83583 was then 
added for 10min (U46+LY). This response was then repeated in the presence of tempol (3mM, 
n=11 arteries isolated from 8 different rats) Upper panel: representative traces. Bottom panel: 
mean ± SEM measurements of peak LY83583-induced contraction, expressed as a percentage 
increase of U46619 pre-constriction. **P<0.001 vs. U46, *P<0.05 vs. U46; ##P<0.001 vs. 
control U46+LY (2-way ANOVA, Factors: U46, U46+LY +- inhibitor drug treatment. Power 






Figure 3.10: Effects of LY83583 and PP2 on U46619-induced contraction  
U46619 concentration was adjusted to achieve ~10% of KPSS (U46). 1µM LY83583 was then 
added for 10min (U46+LY). This response was then repeated in the presence of PP2 (30µM, 
n=11 arteries isolated from 8 different rats) Upper panel: representative traces. Bottom panel: 
mean ± SEM measurements of peak LY83583-induced contraction, expressed as a percentage 
increase of U46619 pre-constriction. **P<0.001 vs. U46; *P<0.05 vs. U46; ##P<0.001 vs. 
control U46+LY (2-way ANOVA, Factors: U46, U46+LY +- inhibitor drug treatment. Power 
of performed test: 0.976). 
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3.4.3 U46619 and LY83583 promote SrcFK autophosphorylation in a time 
dependent, ROS dependent and SrcFK dependent manner 
 
The data produced so far has shown that both U46619 and LY83583 increased ROS production 
and enhanced contractile responses which is sensitive to antioxidants and PP2. The next step is 
to investigate whether SrcFK activity is increased following U46619 treatment and blocked by 
antioxidants and SrcFK inhibitor PP2. This will help verify that SrcFKs are indeed ROS 
sensitive and also confirm I am indeed measuring Src-autophosphorylation. LY83583 
stimulation will also be investigated as a control to confirm that SrcFK is indeed ROS sensitive. 
Src-FK activity can be measured by measuring its autophosphorylation site at Tyr-416 in 
response to stimulation.  
U46619 enhanced SrcFK autophosphorylation in a biphasic time-dependent manner peaking at 
0.5min and 30min (Fig 3.11). LY83583 (1µM) also enhanced SrcFK auto-phosphorylation 
without the presence of U46619, suggesting that SrcFK activity is ROS sensitive (Fig 3.12). 
SrcFK are indeed shown to be ROS sensitive, as prior incubation with antioxidants ebselen, 
tempol or PP2 inhibited U46619-induced increase in SrcFK autophosphorylation (Fig 3.13A). 
Basal SrcFK phosphorylation was unaffected by ebselen and somewhat reduced by tempol (Fig 
3.13B) whilst PP2 significantly inhibited basal SrcFK phosphorylation (Fig 3.13B), which is 
explored further in the discussion. 
When blots were further probed with anti-phospho-tyrosine (P-Y). LY83583 enhanced P-Y 
immunoreactivity at multiple bands, particularly bands at 80, 90 and 115 kDa. These bands 
along with another at approximately 140 kDa were sensitive to PP2, suggesting SrcFK-




Figure 3.11  
 
 
Figure 3.11: Effects of U46619 on SrcFK auto-phosphorylation in IPA  
U46619 (U46, 100nM) enhances SrcFK auto-phosphorylation (Tyr-416) in IPA in a time-
dependently manner (n=9 arterial samples isolated from 5 different rats, #P<0.05 vs. control, 





Figure 3.12: Effects of exogenous superoxide on SrcFK auto-phosphorylation in IPA  
LY83583 (1µM) enhanced SrcFK auto-phosphorylation at 0.5min (n=16) and 30min (n=7 
arterial samples isolated from 4 different rats), #P<0.05 vs. control (1-way ANOVA, Factor: 










Figure 3.13: Effects of U46619 and antioxidants on SrcFK auto-phosphorylation in IPA  
A: At 30 min, U46619-induced SrcFK auto-phosphorylation is inhibited by ebselen (ebs, 
10µM, n=14 arterial samples isolated from 10 rats), tempol (temp, 3mM, n=11 arterial samples 
isolated from 9 rats) or PP2 (30µM, n=10 arterial samples isolated from 9 rats), ##P<0.001 vs. 
control, **P<0.001 vs. U46 alone, while in the absence of U46 (B), Basal SrcFK auto-
phosphorylation is unaffected by ebselen (n=10 arterial samples isolated from 9 rats) or tempol 
(n=10 arterial samples isolated from 9 rats) but significantly inhibited by PP2 (n=8 arterial 
samples isolated from 6 rats), #P<0.05 vs. control, (2-way ANOVA, Factors: U46+inhibitor 





Figure 3.14:  Effects of U46619, antioxidants and exogenous superoxide on SrcFK auto-
phosphorylation in IPA  
LY83583 (1µM) enhanced tyrosine phosphorylation of multiple proteins, including bands of 
approximately 80, 90, 115 and 140 kDa. These bands were sensitive to SrcFK inhibition with 
PP2 (30µM, n=4 Arterial samples isolated from 3 rats). ##P<0.01 vs. control, *P<0.05, 
**P<0.001 vs. LY alone (2-way ANOVA, Factors: control, LY +- inhibitor, Power of 


















3.4.4 U46619 promotes MYPT-1 and MLC20 phosphorylation in a time 
dependent, ROS dependent and SrcFK dependent manner 
 
Previous work has shown that SrcFKs play a role in pulmonary contraction via activation of 
Rho-Kinase7,41,82,83  and that exogenous ROS can activate Rho-Kinase 88. Therefore, I 
investigated whether SrcFKs is a ROS sensitive intermediate acting upstream of Rho-Kinase. 
I therefore investigated Rho-Kinase activity by measuring the phosphorylation of the Rho-
kinase target myosin phosphatase targeting subunit-1 (MYPT-1) and of the MLCK target, the 
20 KDa regulatory subunit of myosin (MLC20). U46619 enhanced phosphorylation responses 
in a time-dependent manner of both MYPT-1 (Fig 3.15) and MLC20 (Fig 3.16). Prior incubation 
with either ebselen, tempol or PP2 inhibited the U46619-induced, 30 minute increase in 
phosphorylation responses (MYPT-1: Fig 3.17A, MLC20: Fig 3.18A). Basal phosphorylation 
















Figure 3.15: U46619-induced MYPT-1 phosphorylation is partly mediated via ROS and 
SrcFK in IPA 
U46619 (U46, 100nM) enhances phosphorylation of MYPT-1(T850) (n=8 arterial samples 
isolated from 5 rats) in a time-dependent manner in IPA, #P<0.05 vs. control, ##P<0.001 vs. 





Figure 3.16: U46619-induced MLC20 phosphorylation is partly mediated via ROS and 
SrcFK in IPA 
U46619 (U46, 100nM) enhances phosphorylation of MLC20 (S19) (n=10 arterial samples from 
6 different rats) in a time-dependent manner in IPA, #P<0.05 vs. control, ##P<0.001 vs. control, 
1-way ANOVA. Factor: time. Power of performed test: 0.966). 
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Figure 3.17: U46619-induced MYPT-1 and MLC20 phosphorylation is partly mediated via 
ROS and SrcFK in IPA 
A: At 30 min, U46619-induced MYPT-1 phosphorylation is inhibited by ebselen (ebs, 10µM, 
n=8 arterial samples isolated from 8 rats), tempol (temp, 3mM, n=12 arterial samples isolated 
from 10 rats) and PP2 (30µM, n=18 arterial samples isolated from 13 rats) ##P<0.001 vs. 
control (n=27 arterial samples isolated from 16 rats), **P<0.001 vs. U46 alone, while, B: basal 
levels of  MYPT-1 phosphorylation was unaffected by ebselen (n=11 arterial samples isolated 
from 11 rats), tempol (n=12 arterial samples isolated from 11 rats) or PP2 (n=18 arterial samples 
isolated from 13 rats) (2-way ANOVA, Factors: U46+inhibitor and inhibitor alone. Power of 









Figure 3.18: U46619-induced Rho-kinase activity and MLC20 phosphorylation is partly 
mediated via ROS and SrcFK in IPA. 
A: At 30 min, U46619-induced MLC20 phosphorylation is also inhibited by ebselen (n=14 
arterial samples from 12 rats), tempol (n=12 arterial samples from 11 rats) and PP2 (n=17 
arterial samples from 14 rats) ##P<0.001 vs. control (n=27 arterial samples isolated from 16 
rats), **P<0.001 vs. U46 alone, while, B: basal levels of MLC20 phosphorylation is unaffected 
by ebselen (n=13 arterial samples from 12 rats), tempol (n=12 arterial samples from 11 rats) or 
PP2 (n=18 arterial samples from 14 rats) (2-way ANOVA, Factors: U46+inhibitor and inhibitor 




3.4.5 KPSS contraction is unaffected by ebselen, tempol, and marginally 
affected by PP2 
  
This is a set of control experiments in order to show that ebselen, tempol or PP2 are not 
inhibiting contractile function via inhibition of VDCC or MLCK. Therefore, I performed a 
cumulative dose response of these inhibitors to investigate these drugs on a pure Ca2+ influx 
pathway such as KPSS induced contraction. As KPSS contraction involves the opening of 
voltage gated calcium channels, therefore allowing the influx of calcium and subsequent MLCK 
activation, significant inhibition of these contractile responses makes it difficult to interpret any 
results using that concentration of drug as the drug could simply be inhibiting the opening of 
calcium channels or MLCK activation. 
Treatment with DMSO (Figure 3.19), ebselen (0.1μM - 10μM) (Figure 3.20), tempol (0.1 – 
3mM) (Figure 3.21) had no effect on KPSS induced contraction whilst PP2 (30μM) (Figure 
3.22) reduced KPSS contraction but only by 15-20%.  
Figure 3.19  
 
Figure 3.19: Effects of antioxidants and SrcFK inhibition on KPSS induced contraction in 
IPA  
Effect of DMSO (0.5 – 6.0μL) on KPSS induced contraction in IPA. Panel: representative trace 
with arrows indicating where each dose was added (2-way ANOVA, Factors; DMSO and 







Figure 3.20: Effects of ebselen on KPSS induced contraction in IPA 
Effect of ebselen (0.1μM - 10μM) on KPSS induced contraction in IPA. Upper panel: 
representative traces with arrows indicating where each dose was added. Bottom panel: mean 
relaxation ± SEM measurements. (2-way ANOVA, DMSO and inhibitors, Power of performed 







Figure 3.21: Effects of tempol on KPSS induced contraction in IPA 
Effect of tempol (0.1mM – 3mM) on KPSS induced contraction in IPA. Upper panel: 
representative traces with arrows indicating where each dose was added. Bottom panel: mean 
relaxation ± SEM measurements. (2-way ANOVA, Factors: DMSO and inhibitors, Power of 








Figure 3.22: Effects of PP2 on KPSS induced contraction in IPA 
Concentration-dependent relaxation responses to PP2 in IPA pre-constricted with KPSS. Effect 
of PP2 (1µM– 30µM) on KPSS induced contraction. Upper panel: representative traces with 
arrows indicating where each dose was added. Bottom panel: mean relaxation ± SEM 
measurements (*P<0.05 vs. KPSS, n=8 arteries isolated from 8 rats) (2-way ANOVA: Factors: 
DMSO and inhibitors, Power of performed test 0.970). 
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3.4.6: LY83583-induced enhancement of U46619-induced contraction is not 
nitric oxide dependent 
 
Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) is an analogue of arginine (cell 
permeable) that is known to inhibit the production of endothelial NO. NO has an essential role 
in vasodilation via activation of Protein Kinase G (PKG) and also suppresses contractile 
responses to GPCR agonists 424-426. I therefore investigated whether pre-incubation with L-
NAME (300nM), a nitric oxide scavenging, enhanced contraction, also, to test whether the 
effect of LY83583 was via NO scavenging. 
As shown previously, 1µM LY85683 enhanced contractile responses to 2nM U46619. When 
this response was repeated, but in the presence of L-NAME (300nM), U46619 concentration 
was lowered to 1nM to match pre-constriction amplitude, the LY83583-induced enhancement 
of the U46619-induced contraction was similar to what was seen without L-NAME (Fig 3.23). 
Therefore, the observed enhancing effect of LY on U46-induced contraction is not via 
scavenging of NO by LY-generated superoxide.  
 
I also investigated whether prior removal of NO by L-NAME influenced inhibition of U46-
induced contraction by antioxidants or PP2. Therefore, these experiments were repeated in the 
presence of L-NAME (300nM). U46619 concentration was lowered to 50nM to maintain sub 
maximal contraction. Under these conditions, relaxation responses to DMSO (Fig 3.24), 
ebselen (Fig 3.25), tempol (Fig 3.26) and PP2 (Fig 3.27) were essentially the same as without 
L-NAME (section 3.4.1). To further augment these results, the differences between L-NAME 
plus inhibitor and its paired DMSO control were also compared to the difference between 
inhibitor alone and its paired DMSO control. Relaxation responses were the same under both 
conditions, thus providing further evidence that ebselen, tempol and PP2 are not promoting 
relaxation via NO scavenging. This data can be found in the appendix section (Fig A.1). As 
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contractile function is significantly affected primarily by the highest 2 doses of each inhibitor, 





Figure 3.23: Effects of L-NAME on LY83583 enhanced U46619-induced contraction in IPA  
U46619 concentration was adjusted to achieve ~10% of KPSS (U46). 1µM LY83583 was then 
added for 10min (U46+LY). This response was then repeated in the presence of L-NAME 
(300nM, n=8 arteries isolated from 4 rats). Upper panel: representative traces. Bottom panel: 
mean ± SEM measurements of peak LY83583-induced contraction, expressed as a percentage 
increase of U46619 pre-constriction. ##P<0.001 vs. U46 (2-way ANOVA, Factors: U46, 





Figure 3.24: Effects of L-NAME and DMSO on U46619 contraction 
Concentration-dependent relaxation responses to DMSO (B, n=8 arteries isolated from 8 rats) 
in IPA pre-constricted with 100nM U46619 in the presence of L-NAME (300nM). Panel: 
representative traces with arrows highlighting where each dose was added (2- Way ANOVA, 



















Figure 3.25: Effects of L-NAME and ebselen on U46619 contraction 
Concentration-dependent relaxation responses to ebselen (C, n=7 arteries isolated from 7 rats) 
in IPA pre-constricted with 100nM U46619 in the presence of L-NAME (300nM). Upper panel: 
representative traces with arrows highlighting where each dose was added. Bottom panel: mean 
± SEM measurements of peak LY83583-induced contraction, expressed as a percentage 
increase of U46619 pre-constriction. **P<0.01 vs. DMSO control (2-way ANOVA Factors: 







Figure 3.26: Effects of L-NAME and tempol on U46619 contraction 
Concentration-dependent relaxation responses to tempol (B, n=6 arteries isolated from 6 rats) 
in IPA pre-constricted with 100nM U46619 in the presence of L-NAME (300nM). Upper panel: 
representative traces with arrows highlighting where each dose was added. Bottom panel: mean 
± SEM measurements of peak LY83583-induced contraction, expressed as a percentage 
increase of U46619 pre-constriction. **P<0.001 vs. DMSO control (2-way ANOVA Factors: 








Figure 3.27: Effects of L-NAME on U46619 and PP2 contraction 
Concentration-dependent relaxation responses to PP2 (E, n=8 arteries isolated from 8 rats) in 
IPA pre-constricted with 100nM U46619 in the presence of L-NAME (300nM). Upper panel: 
representative traces with arrows highlighting where each dose was added. Bottom panel: mean 
± SEM measurements of peak LY83583-induced contraction, expressed as a percentage 
increase of U46619 pre-constriction. *P<0.05, **P<0.01 vs. DMSO control (2-way ANOVA 





3.5 Summary of findings 
 
The purpose of this chapter was to investigate the stated hypothesis of: 
“ROS are key secondary messenger molecules mediating vascular smooth muscle contraction 
in response to multiple stimuli and Src-family kinases have a critical role as ROS-sensitive 
intermediaries in these signalling pathways”. 
 
The findings of this chapter are: 
- U46619 and LY83583 induce ROS production in PASMCs which along with basal ROS 
production is sensitive to antioxidants ebselen and tempol.  
- U46619 and LY83583 both directly constrict pulmonary arteries independently of nitric 
oxide and that these constrictions are sensitive to SrcFK inhibition with PP2 or 
antioxidants ebselen and tempol. 
- U46619 and LY83583 enhance SrcFK autophosphorylation in a time dependent 
manner. In the case of U46619 responses, this is also ROS and SrcFK dependent. 
- LY83583 enhance tyrosine phosphorylation of multiple protein targets in pulmonary 
arteries and this phosphorylation is sensitive to PP2. 
- U46619 enhance MYPT-1 and MLC20 phosphorylation and that this is sensitive to 









It is well established that RhoA and its effector Rho-Kinase play an essential role in regulating 
smooth muscle contraction and Ca2+ sensitization. Agonist induced Ca2+ sensitization involves 
Rho-Kinase mediated phosphorylation of myosin light chain phosphatase (MLCP) thereby 
inhibiting MLCP activity 29,427, however the link between agonist and RhoA/Rho-Kinase 
activation in response to upstream mediation needs further investigation. 
Many vasoconstrictors generate ROS under physiological conditions and also activate tyrosine 
kinases. Previous work within our group has shown that prostaglandin-F2α and hypoxia enhance 
total cellular tyrosine phosphorylation, activate Src and cause Src-FK-dependent constriction 
7,88. Similar relations have been identified within other vascular beds 82,419. These observations 
combined with the noted ROS-sensitivity of Src213 suggest that interactions between SrcFK and 
ROS make a central contribution to vascular smooth muscle function.   
This study was therefore designed to investigate the relationship between vascular ROS 
production, SrcFK activity and Rho-kinase activity in normal vasoconstrictor responses in IPA 
and to investigate whether SrcFK act as ROS sensitive intermediates acting upstream of 
RhoA/Rho-kinase. 
3.6.1 U46 & LY induce antioxidant-sensitive ROS production   
 
Key studies within my group have shown a role for SrcFK in HPV 7, interactions between 
SrcFK and Rho-Kinase in agonist induced Ca2+ sensitization41 and the role of superoxide in 
pulmonary and systemic signalling pathways 89. A key element missing was how agonists, 
hypoxia, exogenous ROS, SrcFK and Rho-Kinase activation are all linked together. I therefore 
investigated how ROS, SrcFK and Rho-Kinase are linked together to promote contraction in 
pulmonary arteries.   
165 
 
Firstly, I investigated ROS production in PASMCs. ROS are considered bona fide secondary 
messenger molecules which are produced within the cell in response to physiological and 
pathophysiological stimuli. The two main sources of ROS in VSM being NADPH oxidase 
(NOX) 98,428 and mitochondrial electron transport 94,413,429. A number of studies have shown 
that vascular NOX activity is enhanced by a number of G-protein-coupled receptor (GPCR) 
such as angiotensin II, endothelin-1, thrombin, ATP, thromboxane and U46619 134,430-433. 
Indeed within this study I also show in our system, the TP receptor selective agonist U46619 is 
able to stimulate production of ROS in PASMCs and that this is inhibited by antioxidants 
ebselen and tempol.  
Throughout the study, the membrane permeable quinolinequinone LY83583 was used as it is a 
verifiable source of ROS, that our group has previously used to compare the genuine effects of 
GPCR on endogenous ROS production88. This therefore helped validate methods and drugs 
used i.e. by acting as a positive control for measuring ROS production along with confirming 
that ebselen and tempol were indeed acting as anti-oxidants. The LY83583 results also mirrored 
results obtained from U46619. This helped support the conclusions that ROS are key secondary 
messenger molecules mediating vascular smooth muscle contraction and that SrcFK have a 
critical role as ROS-sensitive intermediaries in vascular smooth muscle contraction.     
U46619 acts through thromboxane receptor, also known as the prostanoid TP receptor coupled 
to Gq 434 356. Activation of receptors coupled to Gq/11-proteins activates phospholipase C (PLC) 
leading to the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) and generation of 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). This results in activation of PKC 
and Ca2+ release from intracellular stores 435. The PKC family are well known too 
phosphorylate the p47phox subunit of NOX thereby promoting its activity and ROS production 
125,436. On the other hand, LY83583 promotes ROS production by acting as a substrate for 
NADPH:quinone oxidoreductase diaphorase (see methods section) 89.   
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In the presence of ebselen or tempol, ROS production was inhibited with tempol more effective 
than ebselen. L-012 is known to measure O2•- 381-384, however may also detect ONOO− and 
probably other ROS383,385-387. Since tempol has been described as a SOD mimetic131,437 and 
ebselen being a glutathione peroxidase mimetic 438, it makes perfect sense for tempol to be a 
more effective antioxidant in this system particularly if the primary ROS species being 
measured is superoxide.   
The ROS that is being produced is believed to be from NOXs as previously described in this 
tissue 99, and coupled with the wealth of data already published which shows agonist-induced 
ROS production is via NOX activation by constrictor stimuli.  The possible role of 
mitochondrial ROS will be addressed in chapter 4. 
What is not made clear throughout this study is which NOX is involved in ROS production. 
However, the aim of the study was not to determine which NOX is being activated rather what 
the ROS being produced are acting on.  
The use of specific inhibitors, knockout models or co-localisation studies could be used to 
determine which NOX is being activated. Published data has shown that the vasculature 
expresses NOX1, NOX2, NOX4 and NOX5 439-442, which can be regulated by a number of 
factors including physical factors (stretch), contractile agonists such as angiotensin II (Ang II) 
and endothelin-1 (Et-1) as well as growth factors (e.g. EGF, PDGF)443-446. Furthermore, Shaifta 
et al99  have recently shown that Sphingosylphosphorylcholine (SPC) mediates vasoreactivity 
via PLC and NOX1-mediated increase in ROS 99.  
NOX1 has been shown to be responsible for O2•− production and redox signalling following 
agonist stimulation 99 and associated with pathological conditions, such as atherosclerosis, 
diabetes, and hypertension447. NOX1 regulation has also been accredited to phosphorylation 448. 
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Taken together, the activation of NOX is complex and that more than one NOX family member, 
alone or in association, may be involved in NAD(P)H oxidase–mediated ROS production.  
3.6.2 Activation of SrcFK by endogenous and exogenous ROS 
 
Contractile and phosphorylation studies were performed to investigate whether SrcFKs perform 
a critical role acting as ROS-sensitive intermediaries in smooth muscle contraction and whether 
this interaction leads to the activation of Rho-Kinase.   
Previous studies carried out by Oda et al 449 and Sakai et al 200 demonstrated that SrcFK is  
highly expressed in vascular and airway smooth muscle. Previous work, investigating the role 
of tyrosine kinases in smooth muscle have used broad spectrum TKI’s, tyrphostins and genistein 
which promoted relaxation 71,72. However, these TKIs do not distinguish between receptor and 
non-receptor tyrosine kinases. Following the development of selective SrcFK inhibitors, PP2 
186 and SU6656 450, the role of SrcFK has been studied in more detail particularly within our 
laboratory 7,41,83 along with other groups 82.  
In this study, I demonstrate that U46619 -induced contraction and LY83583 enhanced U46619-
induced pre-constriction is SrcFK and ROS dependent. In both cases, contraction is inhibited 
by the unrelated antioxidants ebselen and tempol and SrcFK inhibitor PP2.  
U46619 and LY83583-induced SrcFK auto-phosphorylation on Y416, a recognised indicator 
of SrcFK activity, peaking at both 30 seconds and 30 minutes.  
The biphasic response seen in these experiments was also noted by Knock et al in response to 
PGF2α41 and as explained in Chapter 1 and discussed below, can be explained by direct and 
indirect redox regulation of SrcFK.   
SrcFK is retained in an inactive state by binding of its SH2 domain to its own phosphorylated 
C-terminal regulatory domain at Tyr-527, this folding may be disrupted and lead to the 
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autophosphorylation of Tyr-416. The cysteine residue within the SH2 domain of Src (cys-245) 
may be directly oxidised by ROS, leading to the activation of Src 211. Src may also be oxidised 
at both cys-245 and cys-487 213. This also causes unfolding of the Src protein and 
autophosphorylation of the tyr-416 residue 451. ROS may also promote the activation of Src 
through oxidative modulation of the proteins involved in normal Src regulation. These ‘indirect 
redox regulation mechanisms’ involve the oxidation and pre-dominantly inhibition of both 
PTPs and C-terminal Src kinases (Csks) – an important kinase group involved with the 
phosphorylation, and inactivation, of Src at tyr-527 92,452. 
The disparity of activation levels between the two time points may suggest that ROS in this 
case may be activating SrcFK via different pathways. As mentioned, ‘direct’ oxidation 
mechanisms of SrcFK activation would be, faster and more instantaneous than those of the 
indirect pathways. Therefore, at 30 seconds, ROS may preferentially modulate SrcFK via these 
direct mechanisms, leading to faster, but more unstable active forms of Src, which may be 
quickly dephosphorylated. Alternatively, the activation of SrcFK by indirect redox regulation 
may be more predominant at 30 minutes particular PTPs that are oxidatively inactivated by  
ROS 92,213,418,451,453. 
The U46619 (at 30 minute) increase in SrcFK phosphorylation is blocked by ebselen and tempol 
and SrcFK inhibitor PP2 but basal levels are not blocked by ebselen or tempol but are by PP2. 
This indicates that basal SrcFK autophosphorylation is not regulated by ROS but also confirms 
PP2 to be a SrcFK inhibitor. This also suggests interacts between ROS and SrcFK only during 
stimulation of G-protein-coupled-receptor. A possible explanation could be that GPCR 
stimulation, enhances interactions between ROS and SrcFK within the same microdomain. 
Without stimulation, it is likely that SrcFK and ROS will not significantly interact and are 
located within different microdomains therefore unable to interact. This perhaps explains why 
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tempol and ebselen inhibit basal ROS production but do not significantly affect basal 
phosphorylation in the absence of U46 or LY. 
LY (1 and 10µM) enhanced ROS production in PASMCs however LY (10µM) enhanced ROS 
production to a greater level than LY (1µM) however there was no significant difference 
between each concentration. LY (1µM) was able to induced activation of SrcFK (at 30s and 
30min) but is unable to alter tension without combining with another stimuli such as U46. 
Previous work within my group has shown that LY (at > 1 μmol/L), causes a sustained, 
reproducible, SOD- and Y27632-inhibitable constriction in small pulmonary arteries 
88,89. Similar to my results, Knock et al 88,89 also determined that LY at lower concentrations 
(<1 μmol/L) can enhance ROS production but is unable to alter tension but can do so when 
applied in combination with other stimuli such as PGF2α. It is believed that although both 
concentrations of LY can enhance ROS (albeit not significantly different from each other), LY 
(10µM) does enhance ROS to a greater level which reaches a threshold whereby the need for a 
secondary stimuli is not required to generate tension. Furthermore, LY (at > 1 μmol/L), is able 
to enhance rho-kinase activity but also increase intracellular Ca2+ concentration whereas LY at 
(<1 μmol/L) can only enhance rho-Kinase activity. As calcium is essential for contraction (see 
introduction) this will be why LY (at > 1 μmol/L) is able to generate tension. Finally, as LY (at 
> 1 μmol/L) can enhance Ca2+ whereas LY at (<1 μmol/L) is unable to can perhaps be explained 
by bursts of ROS generated in response to LY. Although as mentioned, there is no significant 
difference between 1 or 10μm LY, 10μm LY is still able to produce a higher concentration of 
ROS which could overwhelm the redox buffer systems within the microdomain. This could 
allow ROS to “escape” which may activate Ca2+ channels in the membrane or promote release 
from stores.  
Furthermore, LY83583 enhanced SrcFK-dependent tyrosine phosphorylation of multiple 
proteins bands in IPA which are sensitive to SrcFK inhibition. One can therefore postulate that 
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the increased phosphorylation of these bands may be direct targets for SrcFK or regulated via 
another tyrosine kinases which in turn is mediated by SrcFK. What is of interest is the band 
~115kDa. This which as discussed in chapter 5, could be ARHGEF1. These findings are not 
direct evidence for the tyrosine phosphorylation of ARHGEF1 by SrcFK, but phosphorylation 
has been shown to be a requirement for ARHGEF1 activation, albeit by JAK2 325. Furthermore, 
FAK, PYK2 and JAK2 have been shown to phosphorylate RhoGEFs which may be partly 
mediated via SrcFK interactions. The band located ~120kDa could be FAK, which Shaifta et 
al have recently shown to interact with SrcFK in airway smooth muscle 83.  
My results demonstrate that SrcFK, act as ROS sensitive intermediates in IPA contractile 
responses. This correlates with previous published data by Knock et al 41 where the SrcFK 
selective inhibitors, SU6656 and PP2, both selectively inhibit PGF2α but not Ca2+ induced 
contraction in α-permeabilized rat pulmonary artery,  also O2.•- constricts rat pulmonary arteries 
via Rho-Kinase-mediated Ca2+ sensitization88. Furthermore, functional data by liu et al453 
demonstrated that genistein had a profound effect on U46619 induced contraction in pulmonary 
artery, showing similar results to what I have seen using the SrcFK specific inhibitor PP2. The 
effects of SrcFK inhibition was also shown by Sakai et al 200, whereby in angiotensin-II (ANG-
II)-induced hyper-responsiveness to carbachol which was blocked using the SrcFK specific 
inhibitor SU6656 in rat bronchi. 
The general constrictor role for ROS has been explored using exogenously applied superoxide 
using xanthine/xanthine oxidase or quinones including LY83583 and menadione 88,151,423. 
Furthermore, the internal stimuli for hypoxic pulmonary vasoconstriction (HPV) is believed to 
be an initial rise in mitochondrial ROS 94,140,176,412,413. Importantly, physiological responses too 
many of the stimuli and changes in protein kinase activity described have been inhibited by 
antioxidants 117,119,290,454 and SOD 454,455 , correlating with the effects seen here using ebselen 
and tempol.  
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My data further contributes to the wealth of data that vasoconstrictor stimuli increase ROS 
levels and enhance tyrosine phosphorylation 41,88,456,457 subsequently promoting 
vasoconstriction. More specifically, that SrcFK act as ROS sensitive intermediates during this 
process. 
It is important to note that vascular beds react differently to externally applied ROS. ROS 
promote constriction in a number of vascular beds including aorta 192, pulmonary artery 
88,193,196,458, coronary artery 195 and mesenteric artery 192 and is associated with associated with 
numerous cardiovascular diseases, including systemic and pulmonary hypertension. However, 
ROS have complex constricting and relaxing actions on the systemic vasculature, depending 
on the size of the artery, nature of pre-constriction, amount and type of ROS present, and where 
the ROS is being generated 89,198,459. The two principal ROS species, O2•- and H2O2 have unique 
actions on the vasculature. O2•- promotes contraction in both pulmonary and systemic arteries 
via nitric oxide scavenging 460,461 but also through activation of redox sensitive kinases 88. 
Whereas, systemically, hydrogen peroxide mediates vasodilation and may act as an 
endothelium-derived hyperpolarizing factor (EDHF) via opening of K+ channels 462 89. In 
pulmonary arteries, hydrogen peroxide is more likely to be pro-contractile 194 and EDHF  not 
as important than it is systemically 463. 
O2•- and H2O2 also contribute to endothelium-independent constriction through activation of 
multiple protein kinase pathways 196. Previously, we showed that  O2•- acts predominantly 
through Rho-kinase88 whilst H2O2 mediates its actions via activation of PKC directly constricted 
rat PA194. Furthermore, hydrogen peroxide also causes Ca2+ release from ryanodine-sensitive 
stores194. However, a greater understanding is required to elucidate the differences exhibited by 
O2•- and H2O2 in different vascular beds. 
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3.6.3 Endogenous ROS production mediates activation of Rho-kinase via 
interactions with SrcFK  
 
After establishing that SrcFK are ROS sensitive intermediates involved in mediating U46619 
and LY83583 contraction in rat IPA, I extended my investigation to determine whether this 
occurred upstream of RhoA/Rho-Kinase.   
If ROS and SrcFK are indeed upstream mediators of the RhoA/Rho-Kinase and form a 
signalling axis, then inhibition of either ROS or SrcFK should decrease Rho-Kinase activity. 
Previous work has shown that Rho-Kinase inhibits MLCP activity via phosphorylation of 
MYPT-1, the regulatory subunit of myosin phosphatase, primarily at the thr-855 site 41 which 
is independent of changes in intracellular calcium 33. Subsequently, leading to increased MLC20 
phosphorylation via MLCP inhibition.  
MYPT-1 and MLC20 phosphorylation responses follow a parallel time course in response to 
U46619 stimulation. This can be attributed to the activation of RhoA/Rho-Kinase pathway 
which as discussed, inhibits myosin light chain phosphatase thereby enhancing MLC20 
phosphorylation. This is in line with a number of studies that have shown, measuring MYPT-1 
phosphorylation, that agonists activate Rho-Kinase 7,41,43,89,281,464.  
U46619 induced MYPT1 and MLC20 phosphorylation is inhibited in the presence of ebselen, 
tempol and PP2, however basal levels remain unaffected confirming that agonist-induced ROS, 
not basal ROS, is contributing to SrcFK and Rho-kinase activation (section 3.4.4).   
The question arises as to whether ROS and SrcFK in response to U46619 is upstream of 
RhoA/Rho-kinase or enhances Ca2+-sensitivity through a separate pathway. Previously, Knock 
et al 41 demonstrated that the SrcFK inhibitor SU6656 and the Rho-Kinase inhibitor Y27632 
were not additive with respect to both inhibition of PGF2α-induced MYPT-1 and 
MLC20 phosphorylation and inhibition of the associated PGF2α-induced contraction, suggesting 
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that SrcFK and Rho-kinase may be part of the same pathway. Furthermore, Rho-kinase 
translocation was blocked by prior treated with SU6656, suggesting that SrcFK mediated rho-
kinase translocation.  
My data adds to these findings as both U46619 and LY enhance SrcFK (Tyr-416) and Rho-
kinase (MYPT-1and MLC20) phosphorylation responses which are sensitive to ebselen, tempol 
and PP2 whilst basal levels remain unaffected. As SrcFK activity is sensitive to antioxidants, 
whilst Rho-Kinase activity is sensitive to antioxidants and PP2, this suggests a signalling axis 
whereby in response to constrictor stimuli such as U46619 and LY, there is an increase in ROS 
production which enhances SrcFK activity subsequently activating Rho-Kinase.  
Basal levels remain unaffected by antioxidants and PP2, suggesting there is little interactions 
between these molecules at the basal level and that prior stimulation is required for this 
signalling axis to occur. This further suggests that these molecules may be in different signalling 
microdomains under basal conditions but are then brought together to create this signalling axis 
following stimulation.           
A further consideration is that this was not performed in calcium clamped conditions. 
Therefore, Ca2+ will play a role in MLC20 phosphorylation responses. Agonists cause 
contraction through a combination of Ca2+ responses such as DAG mediated activation of non-
selective cation channels thereby promoting calcium influx and IP3 mediated Ca2+ release from 
stores but also through Rho-Kinase activation. SrcFK has been implicated in both responses. 
Previous studies from our group confirmed a role for Src upstream of Rho-Kinase by clamping 
Ca2+ therefore I did not need to perform these experiments myself in calcium free condition41,88.  
There is no evidence that Rho-Kinase is directly redox sensitive. Therefore activation of 
RhoA/Rho-kinase may be mediated further upstream by tyrosine kinases 88. Since the SrcFK 
inhibitor PP2 is also shown to inhibit MYPT-1 and MLC20 phosphorylation, it is reasonable to 
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suggest that SrcFK are involved as ROS sensitive intermediates involved in the activation of 
RhoA/Rho-kinase in response to constrictor stimuli.  
Taken together, inhibition of ROS and SrcFK or indeed enhancement can affect contractile 
responses via multiple pathways.    
3.6.4 Control Experiments 
  
Dose responses for ebselen, tempol and PP2 were initially conducted to KPSS in order to find 
the correct concentration of drug where there where minimal off target contractile effects. To 
investigate such effects, high K+ was used to induce contraction.  High K-induced contractions 
in healthy smooth muscle promotes depolarization of smooth muscle cell membrane and opens 
voltage dependent Ca2+ channels, resulting in an influx of extracellular Ca2+ and an activation 
of contractile machinery. As discussed in the introduction, membrane depolarisation can 
activate parallel contractile signalling pathways such as Rho-Kinase. However, this is believed 
to be a secondary response and the primary function of depolarisation is Ca2+ signalling.  As 
ebselen and tempol were shown to have no affect at the concentrations used, this suggest at the 
concentrations used will have no non-specific effect on contractile machinery. PP2 at the 
highest concentration has a slight effect on high K+ however previous data within our laboratory 
has shown PP2 to have no effect in human ASM high K responses. Lack of effect of PP2 on 
80mM K+ (where Ca2+ channels are fully opened by depolarisation, suggests that PP2 is not a 
Ca2+ channel antagonist independently of its actions on Src. U46 induces ROS production via 
NOX, however there is little evidence to suggest that depolarisation can also activate NOX. 
Therefore, it is expected that U46 induced contraction will be more sensitive to antioxidants 
and PP2 vs high K+ contraction.  
In order to determine the role of nitic oxide in U46619 and LY83583 contractile responses, 
dose responses were repeated in the presence of L-NAME (a NO synthase inhibitor). What I 
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see from the results is that L-NAME enhances tissue sensitivity to U46619 which is why a 
lower concentration of U46619 was used to match contraction amplitudes In the presence of L-
NAME. However, L-NAME did not alter the enhancing effect of LY83583 on U46619-induced 
contractile response. Therefore LY83583 is not enhancing contraction by removing NO.  
In conclusion, the data in this chapter strongly suggests ROS are key secondary messenger 
molecules mediating vascular smooth muscle contraction in response to multiple stimuli and 
Src-family kinases have a critical role as ROS-sensitive intermediaries in these signalling 
pathways. The ability of ebselen and tempol inhibit SrcFK autophosphorylation and PP2 to 
inhibit both SrcFK and MYPT1 and MLC20 phosphorylation is strong evidence that ROS 
activates SrcFK which subsequently activates Rho-Kinase, as summarised in figure 3.28. The 















    
 
Figure 3.28: Shows the upstream regulation of the Rho-kinase pathway by ROS and 
SrcFK.  
The data demonstrate that SrcFK are ROS sensitive intermediate in response to stimulation. 













Chapter 4  
 
Hypoxia enhances SrcFK, MYPT-1 and 






Hypoxic pulmonary vasoconstriction (HPV) is a is a rapid and reversible contractile response 
to hypoxia, whereby blood flow is directed away from poorly ventilated areas of the lung to 
areas with higher oxygen content thereby maximising ventilation perfusion matching. HPV is 
typically bi-phasic in isolated pulmonary arteries, with a large transient first phase followed by 
a gradually developing second phase 372,465. The first phase is associated with a large transient 
rise in intracellular calcium ([Ca2+]i) however phase 2 develops gradually with a stable but small 
and rapid increase in [Ca2+]i 465, which is enhanced in a Rho-Kinase dependent Ca2+ 
sensitization manner 370 and is endothelium dependent 466,467.  
As discussed in the introduction chapter, SrcFK’s are a family of closely related non-receptor 
tyrosine kinases including Src, Fyn and Yes which are highly expressed in pulmonary arteries 
41. Tyrosine kinases are involved in cell growth but are also important in smooth muscle 
contraction 76,235. Studies by this group and others have shown that SrcFKs play a critical role 
in agonist induced Rho-Kinase mediated Ca2+ sensitization 41,82. Furthermore, Knock et al 7 
have also implicated that SrcFK play a central role in HPV. Previously, SrcFK have been shown 
to play a direct role in contractile responses to hypoxia and that SrcFK inhibitors block hypoxia-
mediated Rho-Kinase dependent MYPT-1 phosphorylation 7. This along with evidence that 
hypoxia triggers an increase in ROS production94,140,413 suggests that SrcFK act as ROS 
sensitive intermediate involved in hypoxia mediated Ca2+ sensitization.  
A widely accepted view is that HPV is initiated via increased ROS production from complex 
three of the electron transport chain412,468. Due to the oxidative sensitivity of SrcFK and the 
perception that hypoxia increases ROS production, it is reasonable to assume that increased 
ROS production from the mitochondria can activate SrcFK to promote Rho-Kinase mediated 





I hypothesise, that hypoxia will enhances SrcFK, MYPT-1 and MLC20 phosphorylation in a 
mitochondrial ETC-dependent manner. Furthermore, if SrcFK do act as ETC-dependent 
intermediates in Rho-Kinase mediated vasoconstriction, inhibition of the ETC should decrease 
the activity of SrcFK, as well as Rho-Kinase, of which the latter will be apparent by inhibition 
of MYPT-1 and MLC20 phosphorylation responses.  
 
4.3 Experimental Design 
 
The following methods were adopted in order to help address my hypothesis that hypoxia will 
enhance SrcFK, MYPT-1 and MLC20 phosphorylation in a mitochondrial ETC-dependent 
manner.  
Phosphorylation Responses 
In order to determine whether hypoxia-induced SrcFK and Rho-kinase activity in IPA is 
dependent on mitochondrial ETC ROS production, I investigated the effects of rotenone 
(100nM) and myxothiazol (100nM) (complex I and III inhibitors, respectively) on peak 
hypoxia-induced SrcFK (1min), MYPT-1 (5min) and MLC20 (5min) phosphorylation responses 
in IPA. 
To achieve measurable responses to hypoxia, pre-tone is required. Therefore, ~2nM U46 was 
pre incubated for 15 minutes (achieves 10% of KPSS contraction) before making the sample 
hypoxic. Samples were then gassed in 1% O2 for 1 minute (SrcFK) or 5 minutes (MYPT-1 or 
MLC20) and protein extracted as previously described (see methods chapter, section 2.6.5). 
These time points were chosen as a previous study from out group7 determined that SrcFK 
autophosphorylation was increased following 1 minute hypoxia while MYPT-1 and MLC20 was 
increased following 5 minutes of hypoxia 7. To investigate the inhibitor effect, pre-incubating 
with either myxothiazol (100nM), rotenone (100nM) or DMSO (5µL) was performed for 15 
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minutes prior to exposing the samples to U46 (~2nM) for 1 or 5 minutes of hypoxia. Bands 
were then analysed by measuring the ratio of phosphorylated SrcFK, MYPT-1 and MLC20 total 
SrcFK, MYPT-1 and MLC20. The data was expressed as a % mean change from control +- 
SEM. 
Functional Studies 
In order to ensure that complex I and III blockers rotenone (100nM) and myxothiazol (100nM) 
were primary targeting signalling events downstream of the ETC and not through enhanced 
activation of NOX signalling and to ensure that DMSO vehicle was have no effect on 
contraction, the effect of DMSO and inhibitors rotenone (100nM) and myxothiazol (100nM) 
was investigated on U46619 (100nM) induced contraction. An initial control response was 
performed whereby U46619 (100nM) was initially added to IPAs and allowed to incubate for 
10 minutes. IPA’s were subsequently washed three times in PSS and allowed to rest until a 
steady baseline was achieved. DMSO or Inhibitors rotenone (100nM) or myxothiazol (100nM) 
were then added to the chamber and allowed to incubate for 15 minutes before conducting a 
second response with U46619. IPA were then washed at least 3 times in PSS following 
treatment and contractile force was allowed to return to baseline. Data was expressed as mean 
% change from control +- SEM. 
4.4 Results Section 
 
4.4.1 Hypoxia enhances SrcFK, MYPT-1 and MLC20 phosphorylation in a 
mitochondrial ETC-dependent manner 
 
Previous work within our laboratory has shown that hypoxia activates SrcFKs and triggers 
protein tyrosine phosphorylation in IPA. Furthermore, hypoxia-mediated Rho-kinase 
activation, Ca2+ sensitization, and Ca2+ responses are dependent on SrcFKs, suggesting that 
SrcFKs play a central role in HPV 7. I therefore wanted to determine whether hypoxia-induced 
SrcFK and Rho-Kinase activity in IPAs is dependent on mitochondrial ETC ROS production. I 
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investigated the effects of rotenone (complex I inhibitor) or myxothiazol (complex III inhibitor) 
on hypoxia-induced SrcFK (1min), MYPT-1 (5min) and MLC20 (5min) phosphorylation 
responses. A small degree of pre-tone is required in order to achieve a full hypoxic response372 
similar to what was witnessed during contractile studies using LY83583 (chapter 3). Following 
15 minutes pre-incubation with 2nM U46619, phosphorylation responses of all three proteins 
were investigated under hypoxic conditions. Hypoxia enhanced phosphorylation responses of 
all three proteins, which was subsequently abolished by either rotenone or myxothiazol (SrcFK: 
Fig 4.1A, MYT1: Fig 4.2A and MLC20 Fig: 4.3A). U46619-induced and basal phosphorylation 
responses were not significantly affected by either inhibitor (SrcFK: Fig 4.1B, MYT1: Fig 4.2B 



























Figure 4.1: Effects of hypoxia and mitochondrial ETC inhibitors on SrcFK phosphorylation 
in IPA  
A: Hypoxia (1% O2, 1min) enhanced SrcFK auto-phosphorylation following U46619 (U46, 
2nM, 15min) pre-tone, which was inhibited by myxothiazol (myx, 100nM) or rotenone (rot, 
100nM). #P<0.05 vs. U46 alone, *P<0.05 vs. U46/1% O2 (2-way ANOVA, Factors: Normoxia 
and hypoxia + inhibitors, Power of performed test: 0.540, n=9-10 arterial samples isolated from 
7 rats). B: Myxothiazol or rotenone alone has no significant effect on basal SrcFK auto-
phosphorylation (1-way ANOVA, Factor: Inhibitor alone, Power of performed test: 0.640 n=8-








Figure 4.2: Effects of hypoxia and mitochondrial ETC inhibitors on MYPT1 
phosphorylation in IPA  
A: Hypoxia (1% O2, 5min) enhances MYPT-1 phosphorylation following U46619 (U46, 2nM, 
15min) pre-tone, and this enhancement is blocked by myxothiazol (myx, 100nM) or rotenone 
(rot, 100nM). ##P<0.01 vs. U46 alone, **P<0.01 vs. U46/1% O2 (2-way ANOVA, Factors: 
Normoxia and hypoxia + inhibitors, Power of performed test: 0.756, n=9-10 arterial samples 
isolated from 7 rats). B: Myxothiazol or rotenone alone has no significant effect on basal 
MYPT-1 phosphorylation (1-way ANOVA, n=9-11, Factor: Inhibitor alone, Power of 








Figure 4.3: Effects of hypoxia and mitochondrial ETC inhibitors on MLC20 
phosphorylation in IPA  
A: Hypoxia (1% O2, 5min) enhances MLC20 phosphorylation following U46619 (U46, 1nM, 
15min) pre-tone, which was inhibited by myxothiazol (myx, 100nM) or rotenone (rot, 100nM) 
#P<0.05 vs. U46 alone, *P<0.05 vs. U46/1% O2 (2-way ANOVA, Factors: Normoxia and 
hypoxia + inhibitors, Power of performed test: 0.595, n=9-10 arterial samples isolated from 7 
rats n=9-10). B: Myxothiazol or rotenone alone has no significant effect on MLC20 basal 
phosphorylation (1-way ANOVA, Factor: Inhibitor alone, Power of performed test: 0.502, n=9-
10 arterial samples from 5 rats). 
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4.4.2 U46619 induced contractile response is not mitochondrial ETC-
dependent 
 
ROS, as previously discussed, can be derived from a number of sources such as NOX and 
mitochondria (see introduction, section 1.3). Previous studies, have suggested that ROS induced 
via NOX promotes increased ROS production from the mitochondria which is subsequently 
involved in signalling, so called ROS induced ROS release and vive vesa 102,144,469.  
ROS induced ROS release (RIRR) overview  
As discussed, a number of investigations have indicated that ROS participate in regulating 
vascular function in both normal vessels or as part of an adaptive response during disease 
470,471. The concentration and localisation of oxidant-generating and quenching enzymes 
indicate a high compartmentalization within the cell. As ROS are ubiquitous and are known to 
be involved in signal transduction and cell injury, their accumulation must be controlled. 
RIRR is an example of this control. 
Lee et al 472 demonstrated that complete serum withdrawal in human 293T cells increased 
mitochondrial ROS production. Mitochondria ROS then stimulated phosphoinositide 3-kinase 
followed by translocation of Rac1, allowing its interaction with NOX1. ROS generation in 
this model is such that initial ROS production from mitochondria is relatively transient, but 
the evoked activation of NOX1 is more prolonged 472. This study therefore demonstrated 1) 
How a transient ROS signal (from mitochondria) can be converted into a more sustained ROS 
release (from NADPH oxidase), and 2) it also describes a pathway by which ROS generated 
at one subcellular site triggers ROS production in a different site through signal transduction. 
Conversely, ROS generation from mitochondria can be triggered from ROS produced by 
NADPH oxidase. Hawkins et al 473  demonstrated in pulmonary microvascular endothelial 
cells that the activation of NADPH oxidase produces extracellular O2•-. The O2•- produced can 
then be transported intracellularly through a chloride channel-3, where it triggers rapid 
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Ca2+ mobilization followed by mitochondrial O2•- production. These findings not only 
demonstrate a link between two enzymatic sources of ROS but also establish a role for O2•-as 
a signalling molecule involved in RIRR where extracellular ROS stimulate intracellular ROS 
production, resulting in endothelial dysfunction and cellular apoptosis.  
Furthermore, Kimura et al 474 identified a novel signalling pathway where ANG-II stimulation 
of ANG-I receptors activates NADPH oxidase in the heart by a protein kinase C-mediated 
mechanism. The NOX derived ROS are essential for the activation of mitochondrial ATP-
sensitive K+(KATP) channels, which elicit preconditioning through an increase in 
mitochondrial ROS release474 . The findings of this study reveal how ROS generated in one 
region of the cell (membrane) coordinates ROS production in a separate compartment 
(mitochondria) to effect a physiological response. This mechanism was more recently 
demonstrated by Dikalov et al 102,142 in endothelial cells, whereby, angiotensin II activates 
NOX2 via PKCɛ which phosphorylates and activates the mitochondrial ATP-sensitive 
potassium channels leading to an increase in ROS production from the mitochondria which 
subsequently activates SrcFK. This increased SrcFK activity further activates NOX leading to 
a potential feed forward mechanism (Fig 4.4). 
Stimuli that elevate ROS production may therefore cause tandem activation of PKC and 
SrcFK. It has been suggested that a reciprocal relationship between Src and PKC appears to 
exist at least in the context of ROS signalling92. Activation of Src may be enhanced by PKC-
mediated phosphorylation of Src in the SH2 domain203,475 whereas H2O2 promotes 
colocalization of several PKC isozymes with Src, followed by src-dependent phosphorylation 







Figure 4.4: Schematic showing the potential signalling mechanisms involved during ROS 
induced ROS release. 
Agonists acting via GPCRs can induce ROS production via NADPH Oxidase (NOX). The 
increase in ROS production can subsequently Activate PKC and SrcFK which either (1) 
Phosphorylate each other leading to tandem activation or (II) phosphorylate NOX leading to a 
further increase in ROS. PKC can enhance ROS production from the mitochondria via 
phosphorylation of mitoK+ATP Channels. This increase in ROS may also (I) Further activate 
SrcFK and PKC which may lead to increased phosphorylation of NOX or (II) Activate NOX 
directly. This suggests a number of positive feedback loops which may be generated 
following NOX or mitochondrial activation leading to increased ROS production. 
 
Due to the potential influence of RIRR in this system, I wanted to determine whether using 
rotenone (complex I inhibitor) and myxothiazol (complex III inhibitor) which primarily targets 
the mitochondria, affects signalling via mitochondria inhibition and not through enhanced 
activation of NOX signalling.  
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In order to investigate this question, I assessed the effects of rotenone (complex I inhibitor) or 
myxothiazol (complex III inhibitor) on U46619 induced contraction. An initial control response 
was performed whereby U46619 (100nM) was incubated with IPA for 15 minutes followed by 
3 washes in PSS to achieve a stable baseline. Subsequently, IPA’s were pre-incubation with 
DMSO (Figure 4.5), rotenone (100nM) (Figure 4.6) or myxothiazol (100nM) (Figure 4.7) for 
10 minutes followed by a secondary dose of U46619 (100nM). Representative traces show that 
treatment pre-incubation with DMSO and rotenone had no effect on contraction whereas 





















Figure 4.5: Effects of DMSO on U46619 induced contractile responses in IPAs 
U46619 (U46, 100nM, 15min) was initially incubated with IPAs. This response was then 
repeated in the presence of DMSO. Upper panel: representative traces. Bottom panel: mean ± 










Figure 4.6: Effects of rotenone on U46619 induced contractile responses in IPA 
U46619 (U46, 100nM, 15min) was initially incubated with IPAs. This response was then 
repeated in the presence of rotenone. Upper panel: representative traces. Bottom panel: mean ± 








Figure 4.7: Effects of myxothiazol on U46619 induced contractile responses in IPA 
U46619 (U46, 100nM, 15min) was initially incubated with IPAs. This response was then 
repeated in the presence of myxothiazol. Upper panel: representative traces. Bottom panel: 





4.5 Summary of findings 
 
The purpose of this chapter was to investigate the stated hypothesis of: 
“SrcFK will act as a link between hypoxic induced ROS production and Rho-Kinase 
activation”. 
 
The findings of this chapter are:  
- Hypoxia enhances SrcFK, MYPT-1 and MLC20 phosphorylation in a mitochondrial 
ETC-dependent manner. 
- Rotenone and myxothiazol act primarily by target the mitochondrial ETC.  
 



















This study provides complimentary evidence for a role of SrcFKs as a ROS sensitive 
intermediate in HPV and supportive evidence that SrcFKs act as upstream regulators of the 
Rho-Kinase pathway. Previous work performed within the laboratory7 was used to help 
determine peak hypoxic phosphorylation responses.  
Activation of the Src-Family Kinases is thought to occur through redox modification leading to 
autophosphorylation. Direct redox modification has been demonstrated whereby ROS 
generated from lipoxygenase, modulates SrcFK activity directly through oxidative modulation 
of cysteine residues; cys-245 in the SH2 domain and cys-487 in the kinase domain92 at focal 
adhesions, contributing to cell movement and attachment to the extracellular matrix 213. ROS 
may also promote the activation of Src through oxidative modulation of the proteins involved 
in normal Src regulation. These ‘indirect redox regulation mechanisms’ involve the oxidation 
and inhibition of both PTPs and C-terminal Src kinases (Csks) – an important kinase group 
involved with the phosphorylation, and inactivation, of Src at tyr-52792. Alternatively, SrcFK 
may also be activated without prior de-phosphorylation of tyr-527 through oxidation of as yet 
unidentified cysteine residues by either H2O2 or NO 211. 
SrcFK and Rho-kinase have previously been shown to be activated by hypoxia in PA and act 
as major contributors to HPV 7. Our findings demonstrate that hypoxia (in the presence of U46), 
activates SrcFK at 1 minute in IPA which compliments previous work by Knock et al 7 who 
also demonstrates that SrcFKs are activated in IPA in response to hypoxia. Furthermore,  Seko 
et al 480 also show that hypoxia induced Fyn activation, a SrcFK member. Hypoxia (in the 
presence of U46) is also shown to enhance MYPT-1 and MLC20 phosphorylation at 5 minutes. 
This time point was chosen as it is primarily associated with Ca2+ sensitization pathway 370,465 
(sustained phase).  
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U46619 is a prostanoid and promotes contraction via Rho-Kinase mediated phosphorylation 42. 
It has been shown by Knock et al 41 that SrcFK are involved in PGF2α mediated Ca2+ 
sensitization. Here, MYPT-1 phosphorylation was inhibited by the SrcFK inhibitor SU6656 
and hypoxia induced translocation was inhibited by siRNA knockdown of Src and Fyn, 
providing strong evidence for SrcFK acting upstream of Rho-Kinase.  
I cannot confirm the synergistic effect of U46619 and hypoxia on phosphorylation since I never 
looked at hypoxia alone on phosphorylation responses. However, since PGF2α and hypoxia have 
been shown to have a synergistic effect 7 it is reasonable to assume that U46619 as a prostanoid 
(similar to PGF2α) and hypoxia will have a similar effect. Similarly, I did not look at calcium 
responses, therefore I cannot confirm any increases in intracellular calcium. Again, PGF2α and 
hypoxia have been shown to increase intracellular calcium 7, there is no reason to think that 
U46619 and hypoxia will not accomplish the same. Since hypoxia (as discussed) has previously 
been shown to activate SrcFK and that U46619 (chapter 3) activates SrcFKs, which enhances 
MYPT-1 and MLC20 phosphorylation, the actions of hypoxia on phosphorylation or blockers 
of mitochondria are independent of pre-constriction events.  
Hypoxia promotes increased leakage of electrons primarily from complex III of the electron 
transport chain (ETC), producing ROS, which enters the cytosol to cause contraction.  This is 
supported by work performed by Leach et al 93 who concluded that complex III of the 
mitochondrial ETC acts as the hypoxic sensor in HPV. Furthermore, recent work performed by 
Waypa and colleagues demonstrated that in PASMC and lungs from adult mice with smooth 
muscle specific deletion of the Rieske iron-sulfur protein (RISP), which is required for 
superoxide generation at Complex III, attenuates hypoxia induced ROS signalling 94. Here, I 
compliment these previous findings by showing that hypoxia-induced SrcFK auto-
phosphorylation and hypoxia-induced MYPT-1 and MLC20 phosphorylation are inhibited by 
mitochondrial inhibitors rotenone and myxothiazol.  
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Pharmacological inhibitors such as rotenone and myxothiazol can block electron transfer at a 
specific site which can impact ROS generation (figure 4.8). As most of the ROS generated at 
the mitochondria comes from complex III, inhibition of complex III by myxothiazol will inhibit 
hypoxic signalling. Rotenone acts as a downstream inhibitor of complex 1, suppressing electron 
transfer to complex III subsequently inhibiting hypoxic signalling481. ROS can still be produced 
from complex 1481,482, II 138 however unlike complex III where the ROS enters the 
intermembrane space and is rapidly ejected from the mitochondria483,  ROS produced in 
complex I and II is released primarily into the matrix compartments where it is rapidly broken 

















Figure 4.8: Inhibition of mitochondrial ETC complexes by rotenone and myxothiazol  
Rotenone and myxothiazol work by interfering with the electron transport chain in the 
mitochondria. Rotenone acts by blocking electrons being transfered from complex I while 
myxothiazol also acts by blocking electron transfer from complex III. This creates a backup of 
electrons within the mitochondria. This will also lead to a decrease in ATP generation at ATP 
production is driven by the proton gradient which is itself set up by the transfer of electrons. 
 
Furthermore, SrcFKs act as ROS sensitive intermediates that contribute to Rho-Kinase 
activation during hypoxic challenge. Rotenone and myxothiazol do not significantly inhibit the 
underlying basal phosphorylation of these proteins indicating that these inhibitors only 
influence protein activity during states of hypoxia.   
I next investigated whether rotenone and myxothiazol act by primarily targeting the 
mitochondrial ETC and not through enhanced activation of NOX signalling. Since NOX and 
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mitochondria may interact via a phenomenon known as ROS induced ROS release (RIRR) (as 
discussed earlier in this section) 484, whereby ROS produced through activation of NOX (via 
GPCR activation) enhances ROS production from the mitochondria. Conversely, ROS 
produced from the mitochondria can initiate ROS production from NOX 472 thereby promoting 
a feed-forward amplification of ROS 144,473,474,485 and subsequently activating signalling events.  
This mechanism was demonstrated by Dikalov et al 102,142 in endothelial cells, whereby, 
angiotensin II activates NOX2 thereby enhancing ROS production which subsequently activate 
PKCɛ. PKCɛ phosphorylates and activates the mitochondrial ATP-sensitive potassium channels 
(mitoKATP) which increased the production of mitochondrial ROS 143,144. The enhanced ROS 
production from the mitochondria activates SrcFK. This increased SrcFK activity further 
activates NOX and leads to a potential feed forward mechanism involving Src, PKC, NOX and 
mitochondria leading to increased ROS production. 
Here, I demonstrate that myxothiazol marginally but not significantly inhibited U46619-
induced contraction whereas rotenone had no effect, indicating that myxothiazol and rotenone 
primary target signalling events downstream of the ETC, and that U46619-induced contraction 
occurs independently of this. Although myxothiazol does not significantly reduce U46 induced 
contraction, it still has a marginal effect. This could be due to a reduction in ATP by oxidative 
phosphorylation, which is required for cross bridge cycling. Roteneone does not have the same 
effect as electrons can still flow from complex 2.     
There is still controversy that exists between whether hypoxia does indeed increase ROS 
generation, known as the ROS hypothesis, and whether hypoxia decreases ROS production, 
known as the Redox hypothesis.  
Numerous studies exists which demonstrate that HPV involves an increase in ROS production 
from the mitochondria, either directly or indirectly 94,301,413. Several reports indicate that 
198 
 
hypoxia increases mitochondrial ROS production in both freshly isolated and cultured rat 
PASMCs 176,486. Further evidence for hypoxia-induced increases in ROS generation in the 
pulmonary circulation came from studies by Waypa et al who demonstrated that HPV required 
electron flux through complex III and that an increase in ROS were responsible for inducing a 
hypoxic contractile response 94,140,412.  Using the thiol redox sensor, roGFP (which does not 
have the serious limitations of commonly-used probes), targeted to the cytosol,  intermembrane 
space (IMS) or the mitochondrial matrix, Waypa et al were able to compare basal and hypoxic 
changes PASMC412. The roGFP sensor is a mutant of GFP which contains outer surface 
cysteine residues 487. Oxidation of these residues alters the fluorescent properties allowing for 
it to act as a thiol redox sensor furthermore as this is reversible, this can be used as an absolute 
measure of percentage oxidation 488. Waypa et al demonstrated in PASMCs a 20% increase in 
cytosol and IMS oxidation while a decrease in matrix oxidation during hypoxia and similar 
changes in isolated systemic arterial smooth muscle cells 412. Suggesting, that hypoxia elicits 
an oxidative signalling response. More recently, Waypa et al extended these finding by PASMC 
and lungs from adult mice with smooth muscle specific deletion of the RISP gene 94. They 
observed a loss of hypoxia-induced changes in thiol redox state implicating mitochondrial 
complex III and ROS signalling in the oxygen sensing response underlying the acute HPV 
response.  
Indirect evidence for the increased ROS hypothesis is also provided by observations that low 
concentrations of peroxide induce a sustained constriction of PA 194, and elevation of PASMC 
[Ca2+]i via release from ryanodine sensitive stores176,194,486. Furthermore, ROS scavengers in 
cultured PAMSCs during hypoxia abolish the [Ca2+]i increase induced by hypoxia in the 
cytosol, indicating that ROS signals are required for signal transduction linking hypoxia to 
contractile responses in these cells 140,413,489. Finally, antioxidants or overexpression of 
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antioxidant mechanisms suppress HPV in perfused lungs 490 and hypoxia-induced elevation of 
[Ca2+]i in PASMC 486. 
Many proteins including SrcFK 7,204, PKC194, mitogen-activated protein kinase (MAPKs) 192, 
FAK, PYK2 and JAK 299,325,348 are indeed activated by hypoxia or have at least been shown to 
be involved in ROS mediated vasoconstriction. 
PKC is a family of cytosolic serine/threonine kinases family known to be activated by H2O2 or 
peroxynitrite in pulmonary artery smooth muscle and endothelium 491. H2O2 has also been 
shown to trigger subcellular translocation of various PKC isozymes in PASMCs 492. Both PKC 
and ROS have been implicated in HPV493.  
 
Acute HPV in rat IPA has been found to be biphasic 465. In this study, the first phase is 
associated with a sharp transient rise in Ca2+ through intracellular stores from the SR (and some 
influx through membrane channels), with a PKC-dependent component and the subsequent 
prolonged phase which involves a smaller and more regulated increases in Ca2+, and enhanced 
contraction through Ca2+ sensitisation 370. PKC-mediated activation of SrcFK may also be 
involved in this process. Stimuli that elevate ROS production may cause a tandem activation of 
PKC and SrcFK. ROS signalling may also involve a reciprocal relationship between Src and 
PKC. Activation of Src may be enhanced by PKC mediated phosphorylation of Src in the SH2 
domain, whereas H2O2 promotes colocalization of several PKC isozymes with Src, followed by 
Src-dependent phosphorylation and activation of PKC. In addition, both SrcFK and PKC may 
act upstream of the MAPKs 203,475-478. 
However, a study by Robertson et al 465 investigating the effect of hypoxia on intracellular Ca2+ 
([Ca2+]i) and tension in small rat intrapulmonary arteries (IPA), demonstrated that the first 
phase of the hypoxic constriction is associated with a transient rise in [Ca2+]i via either Ca2+ 
influx and/or release, and may be associated with PKC-dependent component. Whereas, the 
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second phase involves a PKC-independent sensitization of the contractile machinery to Ca2+. 
This suggests that PKC could be involved initially in the activation of hypoxic signalling events 
but is of less importance during more sustained hypoxic events 494.  
MAPKs are key kinases involved in a number of signalling pathways triggered by G-protein-
coupled receptors and receptor tyrosine kinases. MAPKs have been implicated in control of 
vascular function in response to cellular stresses such as hypoxia, oxidative stress, 
inflammation, vasoconstrictor hormones, integrins, and cytokines177,495. MAPKs are not 
directly redox-sensitive but instead rely on ROS-mediated activation of upstream pathways 
such as SrcFK and PKC. Phosphorylation of MAPKs is enhanced by peroxide and occurs 
through trans-activation of growth-factor receptors or SrcFK in tandem with PKC496. Reports 
vary over the importance of MAPKs to ROS-mediated smooth muscle constriction, however 
Ang II-mediated NADPH-dependent ROS production is required for p38 MAPK and MAPK 
activation 497. 
A recent study by Morrell et al 498  investigating whether p38 MAP kinase mediates acute 
hypoxic pulmonary vasoconstriction in isolated rat pulmonary artery demonstrate that: (1) p38 
MAP kinase inhibitor SB-203580 attenuates the delayed hypoxic contraction, (2) p38 MAP 
kinase inhibition does not have a significant effect on rat pulmonary artery under normoxic 
conditions, (3) p38 MAP kinase activation significantly affected vasodilation. The authors 
conclude that p38 MAPK is an important mediator of sustained hypoxia-induced 
vasoconstriction of the pulmonary artery and also plays a major role in phase I vasodilation. 
Furthermore, the authors suggest a signalling axis whereby hypoxia activates Rho-Kinase 
which phosphorylates p38 MAP kinase which subsequently phosphorylates heat shock protein 





Finally, FAK, PYK2 and JAK2 have been shown to phosphorylate and activate 
RhoGEFs299,325,348. These kinases are not known to be directly ROS sensitive, however they are 
activated by GPCR in a NOX dependent manner and by exogenous ROS349-351. This appear to 
occur through SrcFK mediated phosphorylation which will be explored further in chapter 5 
352,353. 
The Redox hypothesis developed by Weir, Archer and colleagues describes hypoxia decreasing 
ROS generation in PASMCs 499,500. This attenuation in ROS production would alter the redox 
state within the cell and chemically reduce Kv channels thereby closing these channels, resulting 
in membrane depolarisation and entry of extracellular Ca2+ leading to contraction501. This 
concept was supported by studies where they measured reciprocal changes in PA pressure and 
ROS levels during hypoxia and normoxia in perfused lungs using lucigenin or luminol 
chemiluminescence to detect ROS 502. Furthermore, Reeve et al503, reported that rotenone 
decreased chemiluminescence and increased vascular tone in isolated perfused lungs. 
A recent study by Nagaraj et al 70 determined that the two-pore-acid-sensitive K+ channel 
TASK-1, is phosphorylated and activated by SrcFKs at resting membrane potential. However 
during hypoxia, SrcFKs are inhibited thereby inhibiting TASK channel activity, promoting 
depolarisation and enhancing contraction. This is at odds with a report by Knock and co-
workers who report that hypoxia increased SrcFK activity504. A potential explanation for this 
discrepancy relies on the importance of tyrosine kinases in the pathophysiology of Pulmonary 
Arterial Hypertension (PAH). It has recently been shown that treatment with dasatinib, a dual 
Bcr/abl and SrcFK inhibitor, for chronic myeloid leukaemia causes PAH which is resolved 
following discontinuation of dasatinib treatment 505-507. Suggesting, that it may not due to 
marked cellular proliferation, but to chronic vasoconstriction. Furthermore, imatinib which is 
the first-line therapy for CML 508 and an effective inhibitor of the platelet-derived growth factor 
receptor, may improve haemodynamics in some PAH patients 509. Nagaraj et al 70 suggest that 
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dasatinib initiated pulmonary hypertension may relate to their findings that SrcFK inhibition 
reduces potassium channel current and causes depolarisation of hPASMCs in response to 
hypoxia. However this is only consistent with the knowledge that SrcFKs are ROS sensitive if 
hypoxia inhibits ROS production therefore contradicting the work by Waypa et al 2007. In 
order to resolve the discrepancy, the relationship between ROS and K+ in pulmonary VSM and 
the importance of K+ channels in vascular tone would be required.  
The discrepancy between the ROS hypothesis and the Redox hypothesis arises most likely due 
to the methods used to assess ROS generation. The studies by Archer and co-workers relied 
heavily on lucigenin- a chemiluminescent probe which interacts with superoxide 510 to detect 
primarily extracellular ROS. In contrast, intracellular generation of ROS during hypoxia, and 
chemical or genetic sensors of intracellular ROS detect small but significant reversible changes. 
It is therefore reasonable to conclude that at least some of the controversy regarding whether 
ROS is increased or decreased during hypoxia is due to probes or measurement systems used. 
Furthermore, a number of studies have shown that ROS generation within cells is regulated 
differently amongst subcellular compartments, therefore measurements in one compartment 
can be markedly different from another. Finally, on balance, recent reports strongly favour the 
ROS hypothesis.    
My results show that although hypoxia does activate SrcFK upstream of Rho-Kinase, this has 
no effect on U46619 induced contractions. This also coincides with contractile and 
phosphorylation data (chapter 3) which clearly demonstrate that U46619 promotes contraction 
in a ROS and SrcFK dependent manner. My results also agree that hypoxia increases ROS 
production to activate hypoxic mediated cell signalling. The mechanism by which hypoxia 
enhances SrcFK activation and subsequent activation of Rho-Kinase are still not fully 
understood. However Rho-Kinase-mediated Ca2+ sensitisation of PA contraction is critical for 
sustained HPV and contributes to increased resistance in chronic hypoxic PH 511. The 
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mechanism by which hypoxia activates Rho-Kinase was until recently unknown. Knock et al. 
have now shown in rat distal PA that Src-family kinases are involved in the activation of Rho-
Kinase by both agonists41 and hypoxia7 and indeed also by superoxide (but not 
peroxide)88,consistent with the ROS hypothesis of HPV. The link between ROS, SrcFK and 
RhoA/Rho-Kinase is still unknown but will be discussed further in chapter 5.   
In Summary, my results in this chapter demonstrate that ROS production in response to hypoxia 
activate SrcFK upstream of Rho-kinase and acts as a key ROS sensitive intermediary. I also 
confirm that U46619 induced contractile responses are not dependent on mitochondrial ROS 
production (as illustrated in Fig 4.9). 
Figure 4.9 
 
Figure 4.9: Shows the upstream regulation of the Rho-kinase pathway by ROS and SrcFK  
The data demonstrate that SrcFK are ROS sensitive intermediate in response to hypoxia. The 
mechanism by which RhoA/Rho-Kinase is activated will be discussed in chapter 5.   
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Chapter 5:  
 
Interaction between ROS, SrcFK, AHRGEF1 





Ca2+ sensitization occurs in response to constrictor stimuli, whereby there is increased 
contractile force without an increase in [Ca2+]i 29. This process is mediated primarily through 
the activation of the small monomeric G protein RhoA and its principle effector, the serine-
threonine kinase Rho-Kinase 29,504. Rho-Kinase enhanced constriction occurs primarily through 
phosphorylating the myosin phosphatase binding subunit (MYPT-1), thereby inhibiting myosin 
light chain phosphatase, subsequently enhancing myosin light chain phosphorylation 29,41,42.  
Rho-kinase is activated by the monomeric G-protein RhoA, which tends to ‘translocate’ from 
the cytosol to the plasma membrane 512,513. RhoA is a molecular switch that cycles between an 
inactive, GDP-bound form and an active, GTP-bound form306,514. The active, GTP-bound form 
triggers activation of its effector Rho-kinase.  
Key proteins involved in RhoA/Rho-Kinase activation are unknown however logical targets are 
guanine nucleotide exchange factors (RhoGEFs). These are a highly diverse group of proteins, 
some of which include ARHGEF11 (PDZ-RhoGEF), ARHGEF12 (LARG) and ARHGEF1 
(p115-RhoGEF) which are known to be tyrosine phosphorylated 324,325,345.  However, 
phosphorylation of GEFs is not an absolute requirement for the activation of RhoA, as GEFs 
can be activated through direct interactions with Gα12/13. The exception is the VAV family which 
does require phosphorylation to be activated. ARHGEFs, translocate in response to GPCR 
stimulation308, subsequently exchanging GDP for GTP on RhoA, thereby activating RhoA.   
I chose to examine ARHGEF1 because it has previously been implicated in AngII-induced 
hypertension, and shown to be tyrosine phosphorylated by JAK2 in mesenteric artery, an 
essential step in its activation by AngII325.   
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We and others have also shown that constriction induced by agonists or hypoxia in PA and 
other vascular preparations involves activation of Rho-Kinase 41,235 and RhoA46,117,504. A 
number of studies have also suggested that SrcFK contribute to constriction via activation of 
RhoA/Rho-Kinase 7,41,82,515. 
Previous studies have already shown that superoxide activates Rho-Kinase and causes Rho-
Kinase dependent constriction in PA 88,89, SrcFK may also activate the RhoA/Rho-Kinase 
pathway in response to ROS via interaction with a RhoGEF such as ARHGEF1.   
5.2 Hypotheses   
 
Having established that Rho-kinase was a mediator of endogenous ROS-dependent and SrcFK-
dependent U46619-induced phosphorylation responses, I further explored what SrcFKs are 
acting upon in order to activate Rho-Kinase.  
I therefore hypothesised, that ROS and SrcFK may mediate eGFP- tagged RhoA and eGFP-
tagged ARHGEF1 translocation. If SrcFK and ROS do mediate eGFP- tagged RhoA and eGFP-
tagged ARHGEF1 translocation, inhibition of either SrcFK or ROS should inhibit translocation 
of these protein.   
To further clarify the relationship between SrcFK and ARHGEF1, I also examined their co-
localisation in IPA by immunoprecipitation, to test the hypothesis that prior treatment with 
U46619 will enhance co-immunoprecipitation between c-Src and ARHGEF1.
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5.3 Experimental Design 
 
The following methods were adopted in order to help address my hypotheses that “ROS and 
SrcFK may be mediating RhoA and ARHGEF1 translocation in PASMCs. Furthermore, 
U46619 will enhance co-immunoprecipitation between c-Src and ARHGEF1 in IPA”.  
Translocation studies  
PASMCs generated from Pulmonary arteries (as described in the methods chapter) were 
transfected with either eGFP-tagged RhoA or eGFP-tagged ARHGEF1 and grown until 
confluent. Cells were subsequently serum starved for 24 hours in serum free media. Following 
24 hour serum starvation, coverslips were mounted onto a zeiss axiovert 200 inverted 
fluorescent microscope and cells were imaged at x40 magnification. Cells were imaged by 
taking 5 frames every 5 seconds as a control run, U46619 (100nM) / LY83583 (1µM) was then 
added to the chamber and images were taken every 2 seconds for 2 minutes. The frequency and 
time of images taken was increased due to the quick initiation and quick nature of translocation. 
Cells were subsequently washed in PSS and allowed to rest for 10 minutes with an image being 
taken every 2 minutes. This process was then repeated in control cells otherwise cells were pre-
treated for 10 minutes with inhibitor (ebselen 1µM, tempol 3mM and PP2 3µM) with an image 
being taken every 2 minutes for 10 minutes. U46619 (100nM) / LY83583 (1µM) was then 
added and images were taken every 2 seconds for 2 minutes.  Data was expressed as % change 
from control means +- SEM.  
Co-immunoprecipitation 
CO-immunoprecipitation studies were performed in protein extracted from pulmonary arteries, 
untreated / treated with U46619. CO-immunoprecipitation was performed by 
immunoprecipitating c-Src and probing for the co-immunoprecipitated ARHGEF1. Protein 
levels of Src and ARHGEF1 are unaffected by U46619 treatment, therefore the levels of Src in 
treated and untreated samples will be similar, as this protein is being pulled down however, the 
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level of co-immunoprecipitated ARHGEF1 found in the bound fraction, should be enhanced by 
U46619 treatment. 
For each sample condition, a full arterial tree was used. Arteries were gassed for 15 minutes 
prior to treatment to allow samples to equilibrate. Following 15 minutes gassing, control 
samples were immediately snap frozen, alternatively U46619 (100nM) was incubated for 15 
minutes with the tissue after which the tissue was immediately snap frozen. The 15 minute time 
point was used as MYPT-1 phosphorylation was significantly increased at 5 and 30 minutes 
therefore a compromised time would offer the best chance of observing SrcFK and ARHGEF1 
interactions particularly if this is acting upstream of RhoA/Rho-Kinase activation. Protein was 
extract from Pulmonary arteries using a 1% Triton based buffer. CO-IP was then performed as 
described in the methods chapter, section 2.6.5. 
Strength of experimental design        
During this chapter, the main strength was that multiple cell lines generated from different rat 
tissue, was used to investigate translocation responses. As multiple cell lines were used this 
ensures that the effects seen were genuine rather than seeing a response from 1 particular cell 
line which matched my hypothesis. Also each set of translocation data had at least 1 control to 









5.4 Results Section 
 
5.4.1 U46619 and LY83583 promote reversible eGFP-tagged RhoA 
translocation which is SrcFK and ROS dependent. 
 
Data from previous chapters established that SrcFK contributes to ROS-mediated Rho-kinase 
activation in response to GPCR stimulation, exogenous ROS and hypoxia. I therefore further 
investigated the link between SrcFK and Rho-kinase. 
Rho-kinase is activated by the monomeric G-protein RhoA. RhoA activation involves 
translocation from the cytosol to the plasma membrane. Therefore, using eGFP-tagged RhoA 
in live PASMC, I visualised and quantified translocation in response to U46619 and LY83583 
as a corollary of activation 512,513. In unstimulated PASMC, eGFP-tagged RhoA fluorescence 
was primarily located in the nucleus/perinuclear region. Exposure to U46619 (100nM) or 
LY83583 (1µM) brought about a rapid and reversible translocation (enhanced concentration of 
eGFP fluorescence into spots/patches) at the cell periphery or at cellular attachment points 
which was visible for several seconds (Fig 5.1- 5.7).   
Following a successful response to the initial stimuli, cells were washed (10min) and then 
incubated either with ebselen (1µM, 10min), tempol (3mM, 10min) or PP2 (3µM, 10min) 
before being re-exposed to either U46619 or LY83583 (Fig 5.3-5.7). The second translocation 
responses were abolished by all three inhibitors (enhanced concentration of eGFP fluorescence 
into spots/patches was absent in the presence of inhibitor) i.e. ebselen and tempol inhibit ROS 
whilst PP2 is blocking SrcFK activity (Fig 5.3- 5.7), while in control cells, following washout, 
re-application of stimuli promoted a similar pattern and intensity as the first exposure, 
confirming that the responses are reproducible (Fig 5.1- 5.2). It was also noted that the addition 
of U46619 or LY83583, promoted a reversible redistribution of low level diffuse background 
fluorescence that surrounds the region where the spots (patches) appear, confirming a re-
distribution of RhoA (Fig 5.1- 5.7). In the presence of inhibitor, this redistribution did not occur 
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(Fig 5.3 – 5.7). These changes were confirmed by quantification, further supporting the 






     U46 (1st exposure)  
U46 (2nd exposure)  
 
      
Figure 5.1: Effects of U46619 on eGFP-tagged RhoA translocation in PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged RhoA, 
unstimulated (top left panel), or in the presence of U46619 (top left, right and middle left panels) 
(U46619, U46, 100nM). Background measurements were made from readings inside the cell 
periphery next to the corresponding spots (top left, right and middle left panels). Quantification 
of spot/patch fluorescence intensity expressed as % change of control levels during U46619 
stimulation (Bottom left and right panels).  ##P<0.001 vs. baseline, 2-way ANOVA, Factors: 
U46 alone, U46+ DMSO, Power of performed test: 0.735, n=9 cells from a total of seven 






     LY (1st Exposure)     
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Figure 5.2: Effects of LY83583 on eGFP-tagged RhoA translocation in PASMC. 
Representative fluorescent images of PASMCs transfected eGFP-tagged RhoA, unstimulated 
(top left panel), or in the presence of LY83583 (top right and middle left panels) (LY83583, 
LY, 1µM) Background measurements were made from readings inside the cell periphery next 
to the corresponding spots/patches (top left, right and middle left panels). Quantification of 
spot/patch fluorescence intensity expressed as % change of control levels during LY83583 
stimulation (bottom left and right panels)  ##P<0.001 vs. baseline, 2-way ANOVA, Factors: 
LY alone, LY+ DMSO, Power of performed test: 0.946, n=8 cells from a total of seven different 
cell lines. Each measurement is combined from at least 3 spots/patches from each cell. 
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Figure 5.3  
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Figure 5.3: Effects of U46619 and ebselen on eGFP-tagged RhoA translocation in PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged RhoA, 
unstimulated (top left panel), in the presence of U46619 (top right panel) and in the presence 
of U46619 plus ebselen (middle left panel) (U46619, U46, 100nM, ebselen, Ebs, 1µM). 
Background measurements were made from readings inside the cell periphery next to the 
corresponding spots/patches (top left, right and middle left panels). Quantification of spot/patch 
fluorescence intensity expressed as % change of control levels during U46619 stimulation and 
in the presence of U46619 plus ebselen (bottom left and right panels)  ##P<0.001 vs. baseline, 
**P<0.001 vs. U46619 alone, *P<0.05 vs. U46619 alone, 2-way ANOVA, Factors: U46 alone, 
U46+ inhibitor, Power of performed test: 0.993, n=9 cells from a total of seven different cell 






    U46  
U46 + Tempol  
 
        
Figure 5.4: Effects of U46619 and tempol on eGFP-tagged RhoA translocation in PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged RhoA, 
unstimulated (top left panel), in the presence of U46619 (top right panel) and in the presence 
of U46619 plus tempol (middle left panel) (U46619, U46, 100nM, tempol, Temp, 3mM). 
Background measurements were made from readings inside the cell periphery next to the 
corresponding spots/patches (top left, right and middle left panel). Quantification of spot/patch 
fluorescence intensity expressed as % change of control levels during U46619 stimulation and 
in the presence of U46619 plus tempol (bottom left and right panels)  ##P<0.001 vs. baseline, 
**P<0.001 vs. U46619 alone, #P<0.05 vs. baseline, *P<0.05 vs. U46619 alone,  2-way 
ANOVA, Factors: U46 alone, U46+ inhibitor, Power of performed test: 0.912, n=9 cells from 
a total of seven different cell lines. Each measurement is combined from at least 3 spots/patches 






     U46         
U46 + PP2  
        
Figure 5.5: Effects of U46619 and PP2 on eGFP-tagged RhoA translocation in PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged RhoA, 
unstimulated (top left panel), in the presence of U46619 (top right panel) and in the presence 
of U46619 plus PP2 (middle left panel) (E: U46619, U46, 100nM, PP2, 3µM). Background 
measurements were made from readings inside the cell periphery next to the corresponding 
spots/patches (top left, right and middle left panel).  Quantification of spot/patch fluorescence 
intensity expressed as % change of control levels during U46619 stimulation and in the presence 
of U46619 plus PP2 (bottom left and right panels). ##P<0.001 vs. baseline, **P<0.001 vs. 
U46619 alone, #P<0.05 vs. baseline, *P<0.05 vs. U46619 alone, 2-way ANOVA, Factors: U46 
alone, U46+ inhibitor, Power of performed test: 0.977, n=8 cells from a total of seven different 
cell lines. Each measurement is combined from at least 3 spots/patches from each cell. 
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Figure 5.6  
      
 
 
     
Figure 5.6: Effects of LY83583 and ebselen on eGFP-tagged RhoA translocation in 
PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged RhoA, 
unstimulated (top left panel), in the presence of LY83583 (top left panel) and in the presence 
of LY83583 plus ebselen (middle left panel) (LY8383, LY, 1µM, ebselen, Ebs, 1µM). 
Background measurements were made from readings inside the cell periphery next to the 
corresponding spots/patches (top left, right and middle left panels). Quantification of spot/patch 
fluorescence intensity expressed as % change of control levels during LY83583 stimulation and 
in the presence of LY83583 plus ebselen (bottom left and right panel)  ##P<0.001 vs. baseline, 
**P<0.001 vs. LY83583 alone, *P<0.05 vs. LY83583 alone, 2-way ANOVA, Factors: LY 
alone, U46+ inhibitor, Power of performed test: 0.895, n=9 cells from a total of seven different 
cell lines. Each measurement is combined from at least 3 spots/patches from each cell. 
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Figure 5.7  
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Figure 5.7: Effects of LY83583 and PP2 on eGFP-tagged RhoA translocation in PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged RhoA, 
unstimulated (top left panel), in the presence of LY83585 (top right panel) and in the presence 
of LY83585 plus PP2 (middle left panel) (LY8383, LY, 1µM, pp2, 3µM). Background 
measurements were made from readings inside the cell periphery next to the corresponding 
spots/patches (top left, right and middle left panels). Quantification of spot/patch fluorescence 
intensity expressed as % change of control levels during LY83583 stimulation and in the 
presence of LY83585 plus PP2 (bottom left and right panels).  ##P<0.001 vs. baseline, 
**P<0.001 vs. LY83583 alone, 2-way ANOVA, Factors: LY alone, LY+ inhibitor, Power of 
performed test: 0.592 n=8 cells from a total of seven different cell lines. Each measurement is 
combined from at least 3 spots/patches from each cell. 
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5.4.2: eGFP-tagged ARHGEF1 translocates in response to U46619 and 
LY83583 in a ROS and SrcFK dependent manner in PASMC  
 
Having established that ROS and SrcFK mediate RhoA translocation, I next investigated 
whether ROS and SrcFK may be mediating RhoA translocation via interaction with one or more 
RhoGEFs. I therefore examined translocation responses of eGFP-tagged ARHGEF1, a RhoA-
specific guanine nucleotide exchange factor, in live PASMC, in response to U46619 and 
LY83583 as described above for RhoA-GFP.  
eGFP-tagged ARHGEF1 responses were similar to those of eGFP-tagged RhoA. Basal eGFP-
tagged ARHGEF1 fluorescence was located primarily in the perinuclear region and clearly 
absent from the nuclei, as opposed to RhoA, which is present in the nuclei. Upon exposure to 
U46619 or LY83583, bright spots appeared at the cell periphery with a darkening of 
surrounding background fluorescence (Fig 5.8-5.14). Similarly, the appearance of spots and 
darkening of background fluorescence was abolished by ebselen, tempol or PP2, confirming a 
redistribution of eGFP-tagged ARHGEF1 (Fig 5.10- 5.14). Reapplication of either stimulus in 
control cells, produced a comparable response as the first exposure, confirming that the 
responses are reproducible (Fig 5.8– 5.9). 
5.4.3: U46619 enhanced co-immunoprecipitation between SrcFK and 
ARHGEF1 in IPA 
 
To further clarify the relationship between SrcFK and ARHGEF1, I also examined protein 
interactions in IPA by immunoprecipitating c-Src and probing for the co-immunoprecipitated 
ARHGEF1. U46619 treatment enhanced co-immunoprecipitation between c-Src and 






     U46 (1st Exposure)        
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Figure 5.8: Effects of U46619 on eGFP-tagged ARHGEF1 translocation in PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged ARHGEF1, 
unstimulated (top left panel), in the presence of U46619 (top right and middle left panel) 
(U46619, U46, 100nM). Background measurements were made from readings inside the cell 
periphery next to the corresponding spots (top left, right and middle left panels). Quantification 
of spot/patch fluorescence intensity expressed as % change of control levels during U46619 
stimulation (bottom left and right panels) ##P<0.001 vs. baseline, 2-way ANOVA, Factors: 
U46 alone, U46+ DMSO, Power of performed test: 0.767, n=8 cells from a total of seven 
different cell lines. Each measurement is combined from at least 3 spots/patches from each cell.
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Figure 5.9           
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Figure 5.9: Effects of LY83583 on eGFP-tagged ARHGEF1 translocation in PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged ARHGEF1, 
unstimulated (top left panel), in the presence of LY83583 (top right panel and middle left panel) 
(LY8383, LY, 1µM). Background measurements were made from readings inside the cell 
periphery next to the corresponding spots (top left, right and middle left panels). Quantification 
of spot/patch fluorescence intensity expressed as % change of control levels during LY83583 
stimulation  ##P<0.001 vs. baseline, #P<0.05 vs. baseline, 2-way ANOVA, Factors: LY alone, 
LY+ DMSO, Power of performed test: 0.937, n=7 cells from a total of seven different cell lines. 






     U46  
U46 + Ebselen  
    
Figure 5.10: Effects of U46619 and ebselen on eGFP-tagged ARHGEF1 translocation in 
PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged ARHGEF1, 
unstimulated (top left panel), in the presence of U46619 (top right panel) and in the presence 
of U46619 plus ebselen (middle left panel) (C: U46619, U46, 100nM, ebselen, Ebs, 1µM). 
Background measurements were made from readings inside the cell periphery next to the 
corresponding spots (top left, right and middle left panels). Quantification of spot/patch 
fluorescence intensity expressed as % change of control levels during U46619 stimulation and 
in the presence U46619 plus ebselen. ##P<0.001 vs. baseline, **P<0.001 vs. U46619 alone, 
*P<0.05 vs. U46619 alone. 2-way ANOVA, Factors: U46 alone, U46+ inhibitor, Power of 
performed test: 0.968, n=9 cells from a total of seven different cell lines. Each measurement is 
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Figure 5.11: Effects of U46619 and tempol on eGFP-tagged ARHGEF1 translocation in 
PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged ARHGEF1, 
unstimulated (top left panel), in the presence of U46619 (top right panel) and in the presence 
of U46619 plus tempol (middle left panel) (D: U46619, U46, 100nM, tempol, Temp, 3mM). 
Background measurements were made from readings inside the cell periphery next to the 
corresponding spots (top left, right and middle left panels). Quantification of spot/patch 
fluorescence intensity expressed as % change of control levels during U46619 stimulation and 
in the presence U46619 plus tempol  ##P<0.001 vs. baseline, **P<0.001 vs. U46619 alone, 
#P<0.05 vs. U46619 alone, 2-way ANOVA, Factors: U46 alone, U46+ inhibitor, Power of 
performed test: 0.684, n=8 cells from a total of seven different cell lines. Each measurement is 
combined from at least 3 spots/patches from each cell.
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Figure 5.12   
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Figure 5.12. Effects of U46619 and PP2 on eGFP-tagged ARHGEF1 translocation in 
PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged ARHGEF1, 
unstimulated (top left panel), in the presence of U46619 (top right panel) and in the presence 
of U46619 plus PP2 (middle left panel) (E: U46619, U46, 100nM, PP2, 3µM). Background 
measurements were made from readings inside the cell periphery next to the corresponding 
spots (top left, right and middle left panels). Quantification of spot/patch fluorescence intensity 
expressed as % change of control levels during U46619 stimulation and in the presence of 
U46619 plus PP2. ##P<0.001 vs. baseline, **P<0.001 vs. U46619 alone, *P<0.05 vs. U46619 
alone, 2-way ANOVA, Factors: U46 alone, U46+ inhibitor, Power of performed test: 0.837, 
n=9 cells from a total of seven different cell lines. Each measurement is combined from at least 
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Figure 5.13: Effects of LY83583 and ebselen on eGFP-tagged ARHGEF1 translocation in 
PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged ARHGEF1, 
unstimulated (top left panel), in the presence of LY83583 (top right panel) and in the presence 
of LY83583 plus ebselen (middle left panel) (F: LY83583, LY, 1µM, ebselen, Ebs, 1µM). 
Background measurements were made from readings inside the cell periphery next to the 
corresponding spots (top left, right and middle left panel). Quantification of spot/patch 
fluorescence intensity expressed as % change of control levels during LY83583 stimulation and 
in the presence LY83583 plus ebselen.  ##P<0.001 vs. baseline, **P<0.001 vs. LY83583 alone, 
*P<0.05 vs. LY83583 alone, 2-way ANOVA, Factors: LY alone, LY+ inhibitor, Power of 
performed test: 0.963, n=8 cells from a total of seven different cell lines. Each measurement is 
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Figure 5.14 Effects of LY83583 and PP2 on eGFP-tagged ARHGEF1 in PASMC. 
Representative fluorescent images of PASMCs transfected with eGFP-tagged ARHGEF1, 
unstimulated (top left panel), in the presence of LY83583 (top right panel) and in the presence 
of LY83583 plus PP2 (middle left panel) (LY83583, LY, 1µM, PP2, 3µM). Background 
measurements were made from readings inside the cell periphery next to the corresponding 
spots (top left, right and middle left panel). Quantification of spot/patch fluorescence intensity 
expressed as % change of control levels during LY83583 stimulation and in the presence of 
LY83583 plus PP2. ##P<0.001 vs. baseline, **P<0.001 vs. LY83583 alone, 2-way ANOVA, 
Factors: LY alone, LY+ inhibitor, Power of performed test: 0.989, n=9 cells from a total of 





      
 
Figure 5.15: U46619 enhances co-immunoprecipitation of c-Src and ARHGEF1.  
Representative blots show the effect of U46610 (100nM, 15mins) on ARHGEF1 (WB: GEF1) 
and c-Src (WB: c-Src) after c-Src immuno-precipitation (IP: c-Src). GAPDH in the u-bound 
fraction was used as a loading control (WB: GAPDH). Bar charts demonstrate that U46619 
increased co-immuno-precipitation of ARHGEF1 with c-Src proportionately to both c-Src IP 
content and GAPDH loading control, but does not change c-Src IP contents. ##P<0.001 vs. 
baseline, un-paired t-test, n=4.
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5.5 Summary of findings 
 
The purpose of this chapter was to investigate the stated hypotheses of: 
“ROS and SrcFK may be mediating RhoA and ARHGEF1 translocation in PASMCs. 
Furthermore, U46619 will enhance co-immunoprecipitation between c-Src and ARHGEF1 in 
IPA”. 
The findings of this chapter are: 
- U46619 and LY83583 promotes GFP tagged RhoA translocation in a SrcFK and ROS 
dependent manner.  
- U46619 and LY83583 promotes GFP tagged ARHGEF1 translocation in a SrcFK and 
ROS dependent manner. 
- U46619 promotes CO-IP between SrcFK and ARHGEF1. 
The discussion will set out to address how the experimental evidence in the results chapter met 
the aims and hypotheses.
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5.6 Discussion  
 
Results from this chapter describe a new signalling pathway within PASMC’s and IPA’s, where 
by, RhoA and ARHGEF1 translocate in response to contractile stimuli (U46 and LY). This 
translocation appears to be SrcFK and ROS dependent, and may be important in Ca2+ 
sensitization and contraction.  
As discussed in the introduction section (section 1.5.2), SrcFK can be activated directly by 
GPCR via their SH3 domains256,257 or via direct interactions with Gᾳ subunits such as Gαs and 
GᾳI 258. Gα12 has also been shown to activate Src via recruitment of HSP90 259. The Gβγ 
complex has also been shown to act as a key intermediate responsible for the activation of Src 
246,261. Finally, arrestins which inhibit GPCR signalling have also been shown to recruit and 
bind SrcFK leading to 'second wave' of GPCR signalling 262. There therefore exists a number 
of documented pathways whereby GPCR activate SrcFK. This study however provide 
evidence of a new novel pathway where GPCR induced ROS production may also activate 
SrcFK which potentially promotes contraction via interactions with ARHGEF1.  
Firstly, I demonstrate that translocation of eGFP-tagged RhoA and eGFP-tagged ARHGEF1 is 
stimulated by U46619 and exogenous ROS. Translocation responses were subsequently shown 
to be SrcFK and ROS dependent. Secondly and perhaps more importantly, I establish that 
U46619 enhanced co-immunoprecipitation of ARHGEF1 and c-Src in IPA, suggesting there is 
a close association between these two proteins. This association, coupled with the translocation 
data and phosphorylation data presented in chapter 3, may contribute to the activation of 
RhoA/Rho-kinase. I believe, this is the first study to show that SrcFK potentially interacting 
with ARHGEF1. This is also supported by phospho-tyrosine data, whereby, LY83583 enhances 
SrcFK-dependent tyrosine phosphorylation of multiple proteins in IPA, including one at 
approximately 115 kDa, the expected location of ARHGEF1. 
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Calcium sensitization occurs in response to constrictor stimuli via activation of RhoA and its 
principle effector Rho-Kinase 504,516. GPCR’s for various vasoconstrictor agonists such as 
angiotensin II, lysophosphatidic acid, thrombin, thromboxane (TXA2), sphingosine-1-
phosphoate (SIP) have been shown to be coupled to G12/13 342,517-519. Activation of G12/13, is 
known to activate the RhoA/Rho-Kinase pathway and induce RhoA and Rho-Kinase 
redistribution. RhoA translocates from the cytosol to the plasma membrane and Rho-Kinase 
translocates from the nucleus to the cytosol 514,520,521. This coincides with what I see during 
translocation of eGFP-tagged RhoA. In response to U46619 and LY83583, RhoA translocates 
to the cell periphery forming spots/patches at specific locations. This is also confirmed by 
changes in background intensity, which show a redistribution of low level diffuse background 
fluorescence that surrounds the region where the spots/patches appear, in response to stimuli. 
Translocation and background fluorescence changes were blocked by ebselen, tempol and PP2, 
demonstrating that translocation was SrcFK and ROS dependent. A study performed by Knock 
et al 88, demonstrated that LY83583 promotes Rock-2 translocation and increased MYPT-1 and 
MLC20 phosphorylation, which is subsequently inhibited by SOD. Suggesting, that ROS act as 
upstream mediators of Rho-Kinase.  
Rho-Kinase has not been reported to be directly ROS sensitive, however RhoA has been 
reported to be redox sensitive 311,312. This activation requires ROS to interact with two cysteine 
residues in the phosphoryl binding loop of RhoA, thereby bypassing the canonical GEF 
mediated RhoA activation 312. This system has been proposed in living cells where oxidation 
of these cysteine residues promotes guanine nucleotide dissociation, resulting in exchange of 
GDP to GTP, thus activating RhoA. A more widely studied view of ROS mediated activation 
of RhoA/Rho-Kinase is via upstream redox sensitive tyrosine kinases88, particularly by SrcFK. 
Previous studies, have demonstrated a role for SrcFK in PGF2α – mediated Ca2+ sensitization 
and contraction. Furthermore, SrcFKs have been implicated as upstream mediators of Rho-
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Kinase via increased translocation and enhanced MYPT-1 and MLC20 phosphorylation 
responses41,82. Similarly, hypoxia-induced MYPT-1 and MLC20 phosphorylation is inhibited 
by SU6656. Furthermore, translocation of Rho-Kinase from nucleus to the cytosol was 
prevented by Src siRNA 7.      
This conforms to my results as PP2 inhibits U46619 and LY83583 induced RhoA translocation 
and contraction (chapter 1). PP2 is also shown to inhibit SrcFK autophosphorylation and 
subsequently MYPT-1 and MLC20 phosphorylation in response to U46619. As SrcFK are redox 
sensitive, as detailed in chapter 1, and the fact that tempol and ebselen inhibit U46619 induced 
SrcFK autophosphorylation, MYPT-1 and MLC20 phosphorylation responses, this is highly 
suggestive that ROS are acting via SrcFK to activate RhoA/Rho-Kinase.          
The direct link between GPCR activation and RhoA/Rho-Kinase has been under investigation 
by numerous groups. The logical family involved upstream of RhoA/Rho-Kinase activation are 
RhoGEFs. RhoGEFs reduce the affinity of RhoA for GDP, thus allowing the more abundant 
GTP to displace it, thereby activating RhoA 306. RhoGEFs are a large family of proteins with  
~70 members in the human genome522 . Of these 70 members, there are a small family of RGS-
containing RhoGEFs which are regulated by G12/13 heterotrimeric G-protein 229,230,523. These are 
Rho Specific, and some of them such as ARHGEF11 (PDZ), ARHGEF12 (LARG) and 
ARHGEF1 (p115-RhoGEF) have been shown to be tyrosine phosphorylated 244,320,324,345,524, 
leading to increased levels of GTP-bound RhoA. This suggests that tyrosine phosphorylation 
may increase their exchange activity, or stabilize GEFs binding to GPCR, to allow for a longer 
period of GEF activity.  
A number of these RhoA-specific GEFs are expressed in the vasculature319. However, there are 
claims that VSM-RhoGEF is specific to vascular smooth muscle, hence the name 320. This 
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particular GEF was shown to be involved ephrin-A1-induced assembly of actin stress fibres in 
VSMCs and regulate VSMC contractility via the EphA4-Vsm-RhoGEF-RhoA pathway.  
A number of RhoGEFs are known to be phosphorylated and activated by three non-receptor 
tyrosine kinases, focal adhesion kinases (FAK), protein tyrosine kinase-2 (PYK2) and Janus 
Kinase (JAK2) 299,325,348. These kinases are not known to be directly ROS sensitive i.e. being 
oxidised themselves, but are activated by GPCR in a NOX dependent manner and by exogenous 
ROS349-351. This appears to occur through SrcFK mediated phosphorylation 352,353. This suggests 
that activation of FAK, PYK2 and JAK2 by ROS, may be indirect via the activation or 
inhibition of other proteins that are directly ROS sensitive, such as SrcFK. JAK activation also 
appears to require ROS-dependent activation of PYK2 354. To date, there are no studies showing 
that SrcFK are directly involved in the activation of RhoGEFs. However, SrcFKs have been 
shown to be directly ROS sensitive 211,213,418 and may act as ROS sensitive activators upstream 
of these kinases. Furthermore, RhoA has only been shown to be directly phosphorylated by 
PKG/PKA, which increased GDI interactions and cytosolic re-localisation, therefore inhibiting 
RhoA activity 525,526. I am not aware of any studies, which indicate that RhoA is directly 
phosphorylated by the mentioned kinases.  
In my study, I show that translocation of ARHGEF1 occurs in a SrcFK and ROS dependent 
manner. Furthermore, ARHGEF1 was shown to translocate to the cell periphery in response to 
U46619 and LY83583. Again, background intensity/fluorescent changes were investigated. 
Correspondingly, in response to stimulation, I see a clear movement of ARHGEF1 from the 
cytoplasm, where it is localized when unstimulated, to the cell periphery 336. This was then 
blocked in the presence of inhibitors.  
Work performed by Bhattacharyya et al 308 demonstrated that TP receptor activation, or indeed 
activation of Gα13 or Gα12 by an appropriate GPCR, induced translocation of endogenous 
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p115RhoGEF (ARHGEF1) from the cytosol to the plasma membrane. Using mutated forms of 
ARHGEF1, the authors discover that translocation occurs primarily due to the presence of two 
domains found within the ARHGEF1 structure, the regulator of G protein signalling (RGS) 
domain which acts as a binding site for Gα13 or Gα12 and a pleckstrin homology (PH) domain 
which is involved in membrane targeting. However, translocation alone may not be enough for 
GEF activation or indeed activation of RhoA/Rho-kinase signalling 308. Bhattacharyya et al 308 
also demonstrate, when using a novel PH domain mutation (leucine residue at position 677 was 
changed to proline), that PM recruitment is retained, although its signalling function is 
defective. This indicates a function beyond its role in membrane targeting 527,528. The authors 
postulate that further protein interactions may contribute to recruitment of ARHGEF1 and the 
initiation of Rho activation.   
Tyrosine phosphorylation is now believed to be involved in the enhancement of ARHGEF 
activity and stability, while at the plasma membrane. A study performed by Suzuki et al 345 
demonstrates, that LARG is phosphorylated by Tec tyrosine kinase. The authors show that non-
phosphorylated LARG is stimulated by Gα13 but not Gα12. Subsequently, phosphorylation by 
Tec tyrosine kinase allows Gα12 to effectively stimulate the RhoGEF activity of LARG. These 
results suggest a biochemical mechanism of Rho activation through Gα12, and that the regulation 
of RhoGEFs by heterotrimeric G proteins G12/13 is further modulated by tyrosine 
phosphorylation.  
Kato et al 529 provide evidence that the guanine exchange factor DBL, is tyrosine 
phosphorylated which augments its GEF activity, leading to an accumulation of GTP-bound 
form of Rho. These findings suggest, that the tyrosine kinase ACK1 may act as a regulator of 
DBL, which in turn activates Rho family proteins. Also, tyrosine phosphorylation of Vav or 
Vav-2 is also a requirement for their GEF activity530. Finally, the use of several tyrosine kinase 
inhibitors have been shown to block Gα12- or Gα13-mediated Rho activation in cells 531,532. 
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Taken together, these results suggest that, in response to G12/13 activation, ARHGEFs 
translocate to the membrane due to the RGS and PH/DH domains 308. However at the 
membrane, addition interactions are required for full activity and stability such as 
phosphorylation. 
Following on from the initial translocation experiments, co-immunoprecipitation experiments 
were performed. I show for the first time that SrcFK and ARHGEF1 co-immunoprecipitate with 
each other in response to U46619 stimulation. This taken together with the translocation data, 
is highly suggestive that SrcFK interacts with ARHGEF1 in response to U46619, which may 
be involved in Rho-Kinase activation. CO-IP experiments were not performed in response to 
LY83583. However, LY83583 did promote translocation, increased SrcFK 
autophosphorylation and enhanced phospho-tyrosine content at ~ 115kDa (size for ARHGEF1) 
amongst others, all of which is inhibited by PP2. Taken together with LY83583 induced 
translocation of Rho-Kinase88, I think it is fair to predict that LY83583 would have a similar 
effect to U46619.  
Translocation by both U46619 and LY83583 was inhibited by ebselen, tempol and PP2, as were 
any background intensity/fluorescence changes. In response to U46619, PP2 is shown to inhibit 
SrcFK autophosphorylation, MYPT-1 and MLC20 phosphorylation. Furthermore, ebselen and 
tempol inhibit SrcFK, MYPT-1 and MLC20 phosphorylation. These results indicate that ROS 
activate SrcFK, which interacts with ARHGEF1 either directly or indirectly, to mediate 
RhoA/Rho-kinase signalling. Furthermore, as hypoxia is shown to activate SrcFK, this could 
also activate ARHGEF1. However, as discussed below, this could involve another GEF. 
SrcFK can also regulate RhoA/Rho-Kinase signalling via interactions with RhoGDIs. RhoGDIs 
maintain Rho proteins in the cytoplasm by blocking the binding of RhoA into the cell membrane 
as well as inhibiting the binding of GTP303,533,534. Regulation of RhoGDIs is largely undefined. 
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However, DerMardirossian et al 318 show that that SrcFKs act as a RhoGDI kinases in vitro and 
in vivo. Furthermore, phosphorylation of RhoGDI by SrcFK inhibits RhoGDI function. This 
therefore provides another mechanism whereby SrcFK in response to ROS can regulate 
RhoA/Rho-kinase signalling.  
There are a large number of RhoGEFs (~70) in comparison to 20 Rho proteins, so it has been 
suggested that different upstream signals use different RhoGEFs to activate Rho proteins, as 
not all 70 GEFs activate RhoA522,535. Accordingly, depending on the upstream signals, different 
RhoGEFs might be similarly used to activate RhoA in VSMCs. Examples include this study, 
whereby I demonstrate that U46619 promotes translocation and presumably activation of 
ARHGEF1 in ROS and SrcFK dependent manner. AngII has also been show to activate 
ARHGEF1 in a Gαq and JAK dependent manner. Furthermore, p63RhoGEF may also be 
activated in response to Gαq stimulation by ET1. This therefore indicates a complex network 
involving a number of different or receptors and GEFs which can be activated depending on 
the physiological setting and local factors present.     
The data in this chapter demonstrates, a role for SrcFK as a ROS sensitive intermediate which 
interacts with ARHGEF1 and RhoA, potentially mediating the RhoA/Rho-Kinase pathway. 
This conclusion was reached due to the fact that inhibition of ROS with antioxidants (ebselen 
1µM, tempol 3mM) and SrcFK inhibitor (PP2 1µM) abolished eGFP-tagged RhoA/ARHGEF1 
translocation in PASMCs. Furthermore, treatment with U46619 enhanced CO-IP between 
SrcFK and ARHGEF1.  
The following schematic details what I believe to be occurring within this system (Figure 







Figure 5.16: Potential upstream regulation of the RhoA/Rho-kinase pathway by ROS and 
SrcFK.  
The data demonstrates that SrcFK act as ROS sensitive intermediates in response to endogenous 
and exogenous ROS. SrcFK interacts directly or indirectly with ARHGEF, which may activate 









6.1: Summary of Findings 
 
In this study, I demonstrated that U46619 and LY83583 induced ROS production in PASMCs, 
which is sensitive to antioxidants. Furthermore, U46619 and LY83583 enhance contractile 
responses in IPA are inhibited by antioxidants and SrcFK inhibition. U46619, hypoxia and 
LY83583 enhance SrcFK autophosphorylation, ROCK activity and MLC20 phosphorylation 
which are blocked by SrcFK inhibition (U46619 and LY83583), antioxidants (U46619 and 
LY83583) and mitochondrial inhibitors (hypoxia). U46619 and LY83583 also promote 
reversible translocation of eGFP-tagged RhoA and eGFP-tagged ARHGEF1 in a SrcFK and 
ROS dependent. Finally, U46619 enhanced co-immunoprecipitation of ARHGEF1 with SrcFK. 
Overall, these results suggest that, SrcFK act as ROS sensitive intermediates which enhance 
contractile responses potentially via interactions with ARHGEF1 and enhanced ROCK activity.  
6.2 Wider Ramifications of this work 
 
The signalling pathways involved in smooth muscle contraction are highly diverse and 
complex, and still not fully understood. Smooth muscle contraction involves crosstalk between 
a variety of cells and mediators including signalling, structural, contractile and inflammatory 
molecules. It is only now apparent that reactive oxygen species (ROS) are also important 
secondary messengers, which can modulate normal smooth muscle function at physiological 
levels, particularly contractility, however, when produced in excess (oxidative stress), 
contribute to endothelial dysfunction and cardiovascular diseases.  
A few studies, ours amongst them, have suggested that SrcFK and ROS act as upstream 
mediators which contributes to constriction via activation of the RhoA/Rho-kinase pathway41,88. 
Knock et al7 also demonstrate a role for SrcFKs in hypoxic pulmonary vasoconstriction. 
However, the role of SrcFKs as a ROS sensitive intermediate activating RhoA/Rho-kinase 
signalling has so far not been demonstrated. The results generated here are therefore the first 
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study to demonstrate that SrcFKs act a ROS sensitive mediator’s upstream mediator of 
RhoA/Rho-Kinase.  
In addition to contractility, ROS, SrcFK and RhoA/Rho-Kinase are also important regulators 
of cell migration and proliferation, which are key events in the pathogenesis of cardiovascular 
diseases such as pulmonary hypertension 267,298,536, atherosclerosis414 and ischemia-reperfusion 
injury205 and represents a signalling axis which could be a therapeutic target.        
How ROS and SrcFK or indeed other tyrosine kinases activate RhoA/Rho-kinase signalling is 
still largely unexplored. I therefore attempted to further clarify the link between SrcFK and 
Rho-kinase by identifying molecular targets/binding partners for SrcFK. The secondary focus 
of this research has explored the role of RhoGEFs, in particular the small subfamily of RGS-
containing RhoGEFs, which are themselves activated by upstream signals, such as G protein–
coupled receptors and tyrosine kinases, 427,537. This led me to the hypothesis that RGS-
containing RhoGEF, ARHGEF1, may be a molecular target/binding partner for SrcFK.  
Our observations suggest, ROS and SrcFK are likely to be stimulating Rho-kinase via prior 
activation of RhoA, which in turn is perhaps associated with altered ARHGEF1 activity 
downstream of ROS and SrcFK activity. Based on these findings, I suggest that in other 
contexts, other SrcFK members (Src, Yes, Fyn) might play a similar role in regulating 
ARHGEF1 and consequently RhoA activity. Finally, I cannot exclude the possibility that 
ARHGEF1 activation could also lead to activation of the close RhoA relatives RhoB and RhoC, 
the role of which in vascular tone regulation is unknown. 
This study describes a contractile signalling axis involving ROS, SrcFK, ARHGEF1, RhoA and 
Rho-kinase. In response to GPCR activation and hypoxia, SrcFKs act as ROS sensitive 
intermediates which may target ARHGEF1 as a potential upstream mediator of RhoA/Rho-
kinase in IPA contractile responses. Furthermore, investigations into this signalling axis, 
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particularly SrcFK and ARHGEF1 interactions, may lead to the discovery of novel therapeutic 
targets for the treatment of cardiovascular diseases such as pulmonary hypertension.  
6.3 Limitations of this work 
 
The primary limitation of this study is not being able to investigate SrcFK and ARHGEF1 
interactions further. At present, I show that SrcFK and ARHGEF1 interact in the presence of 
U46619 in IPA but not in response to LY83583 or in the presence of inhibitors ebselen, tempol 
or PP2. Therefore, I am unable to say that interactions between SrcFK and ARHGEF1 are 
SrcFK and ROS dependent or if this interaction is direct or indirect via another kinase. 
However, there is a precedent for direct interactions, albeit with another NRTK, JAK2325. I can 
hypothesis that LY83583 would enhance SrcFK and ARHGEF1 interactions as LY83583-
enhanced U46 contractile responses occurs in a SrcFK-dependent manner, while LY83583 
enhanced SrcFK activity and promoted reversible translocation of eGFP-tagged RhoA and 
ARHGEF1. However, without performing similar experiments to U46619 in the presence of 
LY83583, this may not be the case (see section 6.4, where I discuss future work).   
Furthermore, I would have liked to have performed translocation, CO-IP experiments and 
measured ROS under hypoxic conditions. Due to the systems currently employed in the 
laboratory e.g. plate reader for ROS measurement, there is currently no way to keep samples 
hypoxic for ROS measurements or during visualisation of translocating GFP tagged proteins. 
However, I was able to show that hypoxia activates SrcFK in an ETC dependent manner, which 
subsequently activates Rho-Kinase, although the link between SrcFK and Rho-Kinase 
activation is still unclear. As discussed (in chapter 5), I can hypothesise that SrcFK is indeed 
signalling via ARHGEF1 in response to hypoxia similar to U46619, but again this may vary as 
different agonists and contractile stimuli can activate different ARHGEFs. Performing this set 
of experiments would help elucidate the signalling events involved during hypoxic pulmonary 
vasoconstriction.   
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Throughout my investigation, I used overexpression of eGFP tagged proteins as a way of 
visualising protein movement as a corollary of activation. However, there are a number of 
potential problems with over-expressing proteins and using GFP as a tag. The first being a 
change in phenotype and function of the cell. As RhoA is involved in a number of cellular 
process, overexpression can potentially lead to a fundamental change in how the cell functions. 
Staining of cells however confirmed that the cells were still VSMCs.  
GFP also has the ability to affect the activity of the protein it is attached to either via inhibition 
of over activation of the protein of interest. The main point of these studies was to visualise 
protein movement within the cell in response to stimulation (as a corollary of activation) and 
whether this is affected by prior treatment with inhibitors. Therefore the effect on protein 
function was of secondary consideration.     
Another limitation within this study is that I did not perform experiments in alpha toxin 
permeabilized IPA in Ca2+ clamped conditions. Clamping Ca2+ would allow me to control 
[Ca2+]i levels at my desired level. I would have therefore been able to investigate the sensitivity 
of the contractile machinery without any changes in [Ca2+]i. Currently, changes in calcium do 
need to be taken into consideration. Contractile and phosphorylation studies could therefore be 
influenced by changes in [Ca2+]i and not just calcium sensitization. Previous studies from our 
group, confirmed a role for Src upstream of Rho-Kinase by clamping Ca2+ 41  and LY83583 
nsitive constriction in alpha-toxin-permeabilized IPA88, therefore I did not need to perform 
these experiments myself in Ca2+ clamped conditions. However, I could have investigated the 
interactions between ROS and SrcFK under these conditions by measuring Src 
autophosphorylation at TYR416, Rho-Kinase via MYPT-1 (Thr-850) and MLC20 (ser19) in the 
presence of antioxidants. Thereby, confirming under these conditions, U46619 enhanced SrcFK 
activity and subsequently Rho-Kinase activity in a ROS dependent manner.  
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Ca2+ has not been shown to activate or indeed enhance SrcFK activity, however, JAK2325, 
PYK2538 or PKC539 have been shown to be Ca2+ mediated. SrcFK activity could therefore be 
mediated via an indirect mechanism whereby Ca2+ could regulate SrcFK activity via one of 
these kinases.  
Finally, I would have liked to have performed ROS measurements using another probe or in 
tissue. At present, I have one method showing an increase in ROS production, albeit using 
multiple PASMC lines. If I was able to demonstrate, using two different methods or using the 
same method but using a different biological samples e.g. tissue using L-012, or in cells using 
another method such as Amplex Red, that U46619 and LY83583 enhanced ROS level, this 
would be much more comprehensive and add more weight behind my claim that ROS are 
indeed generated by U46619 in my system. There is currently a debate as to whether H2O2, 
superoxide and peroxynitrite are involved in signalling and what pathways they are acting on, 
as discussed in the introduction and chapter 3.  Having a number of methods in different 
biological samples may allow me to suggest what ROS species are involved e.g. L-012 
measures O2•- and Amplex Red measures H2O2. Therefore, if there is an increase in L-012 signal 
with U46619 which was reduced by SOD, and/or an increase in Amplex Red signal with 
U46619 in the presence of SOD, I could infer that superoxide is being produced and is probably 
the main signalling moiety.     
6.4 Future Work 
 
I would have liked to perform another technique such as Fluorescence resonance energy transfer 
(FRET) in IPA to demonstrate protein interactions. This would further enhance my current 
finding that U46619 enhance SrcFK and ARHGEF1 interactions in IPA. FRET imaging 
methods have been instrumental in determining the compartmentalization and functional 
organization of living cells and for tracing the movement of proteins inside cells540. This has 
allowed for an accurate measurement of molecular proximity. FRET relies on the distance-
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dependent transfer of energy from a donor molecule to an acceptor molecule 541. Due to its 
sensitivity to distance, FRET has been used extensively to investigate molecular interactions 
and biological phenomena that produce changes in molecular proximity542-544. A pair of 
molecules that interact in such a manner, is often referred to as a donor/acceptor pair. The donor 
and acceptor molecules must be in close proximity to one another otherwise energy transfer 
does not occur, suggesting, a close interactions and confirming a close association between 
proteins. 
Although CO-IP and FRET confirm a close interaction between molecules, it does not confirm 
whether this a direct interaction or whether this interaction via other molecules such as other 
kinases or adapter proteins. Furthermore, it does not confirm whether this interaction has an 
effect on activity of the target molecule. Therefore, I can still not categorically say that SrcFK 
is directly phosphorylating ARHGEF1 in IPA. In order to confirm that ARHGEF1 is being 
activated by U46619 or LY83583 in IPA, I would have to follow a similar procedure performed 
by Guilluy et al325, who identify that ARHGEF1 mediates the effects of angiotensin II on 
vascular tone and blood pressure. This is something that I would have performed if I had more 
time, money and expertise. 
Small GTPases act as molecular switches, their activity is controlled by two different 
biochemical reactions, GDP/GTP exchange and GTP hydrolysis. To confirm that ARHGEF1 
activity is being mediated by U46619 in a ROS and SrcFK dependent manner, an in vitro 
guanine nucleotide exchange assay for RhoA would be used in the presence of U46619 and 
pharmacological inhibitors, ebselen, tempol and PP2. GDP/GTP ratios can be measured using 
a number of kits, such as cytoskeleton RhoGEF exchange assay as used by Guilluy et al325. This 
kit measures the uptake of the fluorescent nucleotide analog N-methylanthraniloyl-GTP (mant-
GTP) into GTPases. The uptake is measured due to different fluorescent properties between 
free and GTPase-bound mant-GTP. As mant-GTP gets bound to the GTPase, its fluorescence 
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is increases dramatically. Therefore, the enhancement of mant-GTP fluorescent intensity in the 
presence of a small GTPase indicates nucleotide uptake (or exchange for already bound 
nucleotide) by the GTPase. I would therefore expect, that U46619 and LY83583 would enhance 
the exchange activity which would be blocked by antioxidants and PP2 in IPA.  
To determine that SrcFK directly interacts with ARHGEF1, I would like to investigate the 
phosphorylation status of ARHGEF1. Currently, there are no commercially available phospho-
ARHGEF1 antibodies. However, I would expect an increase in ARHGEF1 phosphorylation in 
response to stimuli which is blocked by inhibitors. This would indicate that phosphorylation of 
ARHGEF is SrcFK and ROS dependent. The data generated, would also complement the data 
already obtained (e.g. SrcFK, MYPT-1 and MLC20 phosphorylation responses) thus providing 
a functional role of ARHGEF1 phosphorylation.  
To further augment these results, I would have liked to have carried out transient knockdown 
of Src or ARHGEF1 using small interference (siRNA) in PASMCs. This could be followed by 
investigating MYPT-1, MLC20 and ARHGEF1 phosphorylation along with eGFP-tagged RhoA 
or eGFP-tagged ARHGEF1 translocation responses. Although pharmacological inhibitors are 
useful at blocking the effects of a proteins or chemically reactive molecules, siRNA knockdown 
of a proteins can reduce proteins activity of the specific proteins. This would be more 
cumbersome and time consuming but offers several advantages including avoiding off-target 
effects and it is easier to determine the level of protein activity by determining the efficiency of 
knockdown. I would expect that if siRNA against Src or ARHGEF1 was transfected into 
PASMCs, then agonist stimulation of MYPT-1, MLC20 and ARHGEF1 phosphorylation along 
with translocation of eGFP-tagged RhoA or eGFP-tagged ARHGEF1 would be inhibited, 
similar to what was already observed. Furthermore, I would have liked to of used ARHGEF1 




Finally, to add more depth to my interaction studies, I would have liked to have performed co-
localisation studies between SrcFK, ARHGEF1, focal adhesion kinase (FAK) and caveolin. 
RhoA and ARHGEF1 translocate to the cell periphery however I do not know where they are 
translocated to i.e. which structure. The primarily structures could be membrane proteins called 
caveolin or focal adhesions. Caveolin act as scaffold proteins and signalling domains whilst 
focal adhesions act as sub-cellular structures that mediate the regulatory effects (i.e., signalling 
events) of a cell in response to ECM adhesion. Therefore, being able to stain for these proteins 




In conclusion, this thesis presents novel finding relating to the upstream regulation of the Rho-
Kinase pathway in rat Pulmonary arteries. The results presented, represent a valuable 
mechanism into smooth muscle contractility in Pulmonary arteries.  
Many of the studies that have been published has focussed on the role of Rho-Kinase in Ca2+ 
sensitization. However, it is only recently that more attention has been paid to the upstream 
regulation of Rho-Kinase. In the context of many vascular diseases and oxidative stress, the 
signalling axis suggested could represent a potential target pathway which should be explored 
further.  
This thesis demonstrates that SrcFK plays an important role as a ROS sensitive mediator acting 
upstream of Rho-Kinase signalling. I have demonstrated that SrcFK interacts with ARHGEF1. 
However, SrcFKs interactions with regards to other RhoGEFs and its role in hypoxia mediated 
Ca2+ sensitization remains unclear. My thesis demonstrates crosstalk between agonist induced 
ROS production, SrcFK and Rho-Kinase activation and therefore shows a new pathway 
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Figure A.1: Comparison between inhibitor responses to U46619 induced contraction +- 
L-NAME  
Bar charts demonstrate that L-NAME has no effect on relaxation responses by (a) ebselen (n=8 
vs. n=7(+L-NAME)), (b) tempol (n=8 vs. n=6(+L-NAME)) or (c) PP2 (n=6 vs. n=8 (L-
NAME)). Paired t test.  
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Cloning of rat RhoA and ARHGEF1 into a C-terminal GFP vector 
Preperation of Luria Bertani (LB) media and LB agar plates. 
 
Before starting the cloning procedure, bacterial medium and agar plates were prepared. Luria 
Bertani (LB) media was made up by mixing 10 g tryptone, 5 g yeast extract (Beckton Dickinson, 
USA), and 10 g NaCl, per litre of ddH2O. Agar medium was made up by adding 15 g of agar 
(Beckton Dickinson, USA) per litre of LB medium.  Both LB and LB-agar were autoclaved to 
sterilise the medium. The required antibiotics (filter sterilised) were added at or below 50ºC for 
LB media. LB-agar was cooled and maintained at 50ºC in a water bath, antibiotic added, and 
plated onto 10 cm sterile Petri-dishes using sterile techniques. 
 
Cloning of RhoA/GEF1 into pcDNA6.2-C-EmGFP-TOPO® vector 
 
The plasmid vector pcDNA™6.2/C-EmGFP/TOPO® is supplied linearised with single 3’-
deoxythymide (T) overhangs for TA cloning. The property of Taq polymerase having a non-
template-dependant terminal transferase activity that adds a single deoxyadenosine (A) to the 




TOPO® cloning exploits the properties of Topoisomerase I, a 314-amino acid enzyme, from 
vaccinia virus (Shuman, 1994). Topoisomerase I binds to duplex DNA at specific sites and 
cleaves the phosphodiester backbone after 5’-CCCTT in one strand. It is thought that the energy 
from the broken phosphodiester backbone is conserved by formation of a covalent bond 
between the 3’-phosphate of the cleaved strand and a tyrosil residue (Tyr 274) of topoisomerase 
I. The resulting topoisomerase-DNA complex, containing 5’-single stranded tail, can religate 
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to an acceptor DNA if the acceptor molecule has a 5’-OH tail complementary to that of the 
activated donor complex (Shuman, 1994). The plasmid vector pcDNA™6.2/C-EmGFP/TOPO® 
exploits this reaction to efficiently clone in PCR products. 
The oligonucleotide primers for each target, listed in Table 1, were designed in accordance with 
the manual for GFP Fusion TOPO® TA expression Kit (Invitrogen Life Technologies, UK) and 
the deposited rat RhoA and GEF1 sequences in the GenBank® database. The Kozak consensus 
sequence is (G/A)NNATGG, where N is any nucleotide (Kozak, 1987;Kozak, 1990). In 











































The RhoA cDNA was obtained by PCR using reverse transcribed RNA from rat PASMC cells 
and cloned into PCR®2.1-TOPO vector. The GEF1 cDNA was obtained from Source 
Bioscience (Source BioScience UK Limited). 
The PCR reaction was carried out using puReTaqTM Ready-To-GoTM Polymerase Chain 
Reaction Beads (Amersham Biosciences UK Ltd.). The beads contain the optimised amount of 
recombinant puReTaq DNA polymerase, nucleotides (dNTPs), buffers, stabilisers and BSA, 
therefore only template DNA and primer were added and made up to 25 µl with 
distilled/deionised water (ddH2O). The concentration of PCR primer mix used in the reactions 
was 0.6 µM. The PCR cycles were carried out as follows: 
95C  8 mins 
 
95C  2 mins 
57C  2 mins  Repeat 19 to give total cycle number of 20 
72C  4 mins 
 
72C  15 mins Final extension  
4C  hold 
 
The PCR samples were run on a 1% agarose gel, 15 µl, with the remaining 10 µl retained for 
the cloning procedure.  GeneRulerTM 1kb DNA Ladder or λ DNA/ EcoRI+HindIII Marker were 
run alongside the samples to determine the size of the PCR product. To reduce carry-over of 
template cDNA, the PCR product using lowest concentration of template cDNA was used for 
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cloning, 50 pg in this case. To 4 µl of PCR product 1 µl of salt solution (1.2 M NaCl, 0.06 M 
MgCl2) and 1 µl (~10 ng) of pcDNA™6.2/C-EmGFP/TOPO® vector were mixed and 
incubated for 30 minutes at room temperature. The reaction mix was then chilled on ice before 
proceeding to One Shot® Chemical Transformation of competent cells (Invitrogen Life 
Technologies, UK). 
To a 50 µl vial of One Shot® TOP10 chemically competent E .coli cells 2 µl of TOPO® cloning 
reaction mix was added, mixed gently and incubated on ice for 30 minutes.  The cells were heat 
shocked for exactly 30 seconds at 42ºC and immediately transferred to ice and then 250 μl of 
sterile SOC medium (20 g tryptone, 5 g yeast extract, 0.5 g NaCl, 10 mM MgCl2, 10 mM 
MgSO4, 0.2 mM glucose, per litre of ddH2O) added.  The tubes were tightly capped and shaken 
horizontally at 225 rpm, 37ºC for 1 hour.  The culture (20-200 μl) was then spread onto pre-
warmed LB-agar-ampicillin (100 μg/ml) selection plates, inverted and incubated overnight at 
37ºC. 
Digestion with restriction endonucleases 
TOPO® TA cloning allows cloning of the PCR insert in the forward and reverse orientation, 
due to identical overhangs in the insert and in the vector. The occurrence of both orientations 
should theoretically be of equal chance. Individual colonies (6-12) were picked and inoculated 
into 5 ml LB-ampicillin (100 μg/ml) media and cultured overnight at 225 rpm and 37ºC.  1ml 
of the culture was stored at 4ºC and the remainder purified for plasmid DNA using QIAprep® 
Miniprep Kit (QIAGEN GmbH, Germany). The bacterial cells were pelleted by spinning at 
3000 rpm for 5 minutes and all the media removed. The plasmid DNA was purified from the 





To identify the clones which have the RhoA/GEF1 PCR insert ligated in the forward 
orientation, each RhoA/GEF1-CT-GFP clone was assessed for their restriction endonuclease 
sites. The samples with the correct digestion products were sent for sequencing (Source 




















Procedure for the Pierce Crosslink Magnetic IP/Co-IP Kit  
A. Binding of Antibody to Protein A/G Magnetic Beads  
Note: The following protocol is optimized for coupling 5μg of antibody, but coupling of 2-
10μg of antibody can be accomplished by adjusting the protocol for the appropriate amounts.  
 
1. Prepare 2mL of 1X Modified Coupling Buffer for each IP reaction by diluting 0.1mL of 20X 
Coupling Buffer and 0.1mL of IP Lysis/Wash Buffer with 1.8mL of ultrapure water.  
2. Vortex the bottle of Pierce Protein A/G Magnetic Beads to obtain a homogeneous suspension. 
Add 25μL of beads into a microcentrifuge tube. Place tube on a magnetic stand to collect beads 
for 1 minute. Remove and discard the storage solution.  
3. Add 500μL of 1X Modified Coupling Buffer prepared in Step 1 to the tube. Gently mix and 
incubate for 1 minute at room temperature on a rotating platform. Collect the beads on a 
magnetic stand, then remove and discard the supernatant. Repeat this step one time.  
4. Dilute antibody 1:20 with 20X Coupling Buffer and 1:20 with IP Lysis/Wash Buffer, so the 
final concentration of antibody is 5μg per 100μL. For example, to prepare 100μL of antibody 
solution, dilute antibody stock into 5μL of 20X Coupling Buffer, 5μL of IP Lysis/Wash Buffer 
and add ultrapure water to bring the final volume to 100μL.  
 
Note: Adjust antibody solution for antibody amounts other than 5μg per IP.  
5. Add 100μL of prepared antibody solution to the beads, gently mix and incubate on a rotating 
platform for 15 minutes at room temperature. Gently vortex the beads every 5-10 minutes 
during incubation to ensure that the beads stay in suspension.  
6. Collect the beads with a magnetic stand. Remove and discard the supernatant  
7. Add 100μL of 1X Modified Coupling Buffer and gently vortex or invert the tube to mix. 
Collect the beads with a magnetic stand, then remove and discard the supernatant.  
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8. Add 300μL of 1X Modified Coupling Buffer and gently vortex or invert the tube to mix. 
Collect the beads with a magnetic stand, then remove and discard the supernatant. Repeat this 
step one time.  
 
B. Crosslinking the Bound Antibody  
Note: Conventional IP can be performed by omitting crosslinking; however, if crosslinking is 
omitted, the antibody will co-elute with the antigen during the elution steps.  
Note: The DSS crosslinker is moisture-sensitive. Keep unused DSS in foil pouch. Dissolve 
DSS in DMSO or DMF immediately before use. DSS is not compatible with amine-containing 
buffers (e.g., Tris, glycine).  
1. Puncture the foil cover of a single tube of DSS with a pipette tip and add 217μL of DMSO 
or DMF to prepare a 10X solution (25mM). Use the pipette to thoroughly mix the solution (i.e., 
draw up and expel the solution) until the DSS is dissolved.  
2. Dilute the DSS 1:100 in DMSO or DMF (10μL of 10X DSS with 990μL solvent) to make 
0.25mM DSS.  
3. Add 2.5μL of 20X Coupling Buffer, 4μL of 0.25mM DSS and 43.5μL of ultrapure water to 
the beads. The total solution volume will be 50μL. The DSS is added at 10X molar excess to 
the Pierce Protein A/G Magnetic Beads at a working concentration of 20μM.  
4. Incubate the crosslinking reaction for 30 minutes at room temperature on a rotator or mixer. 
Gently vortex the beads every 10-15 minutes during incubation to ensure that the beads stay in 
suspension.  
5. Collect the beads with a magnetic stand. Remove and save the flow-through to verify 
antibody crosslinking.  
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6. Add 100μL of Elution Buffer to the beads and gently mix for 5 minutes at room temperature 
on a rotating platform to remove non-crosslinked antibody and quench the crosslinking 
reaction. Collect the beads with a magnetic stand, then remove and discard the supernatant.  
7. Add 100μL of Elution Buffer to the beads and gently vortex or invert to mix. Collect the 
beads with a magnetic stand, then remove and discard the supernatant. Repeat one time.  
8. Add 200μL of cold IP Lysis/Wash Buffer to the beads and gently vortex or invert to mix. 
Collect the beads with a magnetic stand, then remove and discard the supernatant. Repeat one 
time. 
9. Proceed to the Manual or Automated Antigen Immunoprecipitation Protocols. If desired, the 
antibody-crosslinked beads can be stored at 4◦C.  
 
C. Manual Antigen Immunoprecipitation  
1. Dilute the lysate solution to 210μL with IP Lysis/Wash Buffer.  
2. Add 70μL of diluted lysate solution to the tube containing crosslinked magnetic beads and 
incubate for 24 hours at 4oC on a rotator or mixer.  
3. Collect the beads with a magnetic stand, remove the unbound sample and save for analysis.  
4. Add 500μL of IP Lysis/Wash Buffer to the tube and gently mix. Collect the beads and discard 
the supernatant. Repeat this step one time.  
5. Add 500μL of ultrapure water to the tube and gently mix. Collect the beads on a magnetic 
stand and discard the supernatant.  
6. Add 70μL of Elution Buffer to the tube. Incubate for 5 minutes at room temperature on a 
rotator or mixer. Magnetically separate the beads and save the supernatant containing the target 
antigen. To neutralize the low pH add 8μL of Neutralization Buffer for each 70μL of eluate. 
For optimal antigen recovery, repeat this elution one time.  
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The importance of tyrosine kinases in airway smooth muscle (ASM) contraction is not fully understood. The aim of this study
was to investigate the role of Src-family kinases (SrcFK) and focal adhesion kinase (FAK) in GPCR-mediated ASM contraction
and associated signalling events.
EXPERIMENTAL APPROACH
Contraction was recorded in intact or α-toxin permeabilized rat bronchioles. Phosphorylation of SrcFK, FAK, myosin light-chain-
20 (MLC20) and myosin phosphatase targeting subunit-1 (MYPT-1) was evaluated in cultured human ASM cells (hASMC). [Ca
2+]i
was evaluated in Fura-2 loaded hASMC. Responses to carbachol (CCh) and bradykinin (BK) and the contribution of SrcFK and FAK
to these responses were determined.
KEY RESULTS
Contractile responses in intact bronchioles were inhibited by antagonists of SrcFK, FAK and Rho-kinase, while after α-toxin
permeabilization, they were sensitive to inhibition of SrcFK and Rho-kinase, but not FAK. CCh and BK increased phosphorylation
of MYPT-1 and MLC20 and auto-phosphorylation of SrcFK and FAK. MYPT-1 phosphorylation was sensitive to inhibition of
Rho-kinase and SrcFK, but not FAK. Contraction induced by SR Ca2+ depletion and equivalent [Ca2+]i responses in hASMC were
sensitive to inhibition of both SrcFK and FAK, while depolarization-induced contraction was sensitive to FAK inhibition only. SrcFK
auto-phosphorylation was partially FAK-dependent, while FAK auto-phosphorylation was SrcFK-independent.
CONCLUSIONS AND IMPLICATIONS
SrcFK mediates Ca2+-sensitization in ASM, while SrcFK and FAK together and individually inﬂuence multiple Ca2+ inﬂux pathways.
Tyrosine phosphorylation is therefore a key upstream signalling event in ASM contraction and may be a viable target for
modulating ASM tone in respiratory disease.
Abbreviations
ASM, airway smooth muscle; hASMC, cultured human airway smooth muscle cells; KPSS, PSS with 80mM equimolar
substitution of Na+ for K+; MLC20, myosin light-chain 20 KDa subunit; MLCP, myosin light-chain phosphatase; MYPT-1,
myosin phosphatase targeting subunit-1; ROCE, receptor-operated Ca2+ entry; SOCE, store-operated Ca2+ entry; VOCE,
voltage-operated Ca2+ entry
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Introduction
Airway smooth muscle (ASM) tone is subject to regulation by
cholinergic, catecholamine and NANC neurotransmitters as
well as local inﬂammatory mediators. In healthy airways,
muscle tone is normally low, providing a low resistance path
for airﬂow. However, contraction may be enhanced in re-
sponse to chemical irritants or allergens, particularly in lower
respiratory tract bronchioles (Gilbert and Auchincloss, 1989;
Pinelli et al., 2009). In asthma, airway resistance is increased,
partly due to increased basal tone and hypersensitivity to
constrictor stimuli in these bronchioles (Doeing and Solway,
2013; Meurs et al., 2008).
Smoothmuscle contractile force depends on the degree of
myosin light-chain-20 (MLC20) phosphorylation, which is in
turn determined by the balance between Ca2+-dependent ac-
tivation of myosin light-chain kinase (MLCK) and Ca2+-inde-
pendent inhibition of myosin light-chain phosphatase
(MLCP), as well as the formation and recruitment of myoﬁla-
ments (Gunst et al., 2003; Somlyo and Somlyo, 2003).
Increases in [Ca2+]i result from Ca
2+ release from the sarco-
endoplasmic reticulum (SR) and a combination of Ca2+ entry
through receptor-operated, store-operated and voltage-
operated Ca2+ channels (ROCE, SOCE and VOCE, respec-
tively). Inhibition of MLCP occurs via phosphorylation of
myosin phosphatase targeting subunit-1 (MYPT-1), primarily
by Rho-kinase (Feng et al., 1999), resulting in a further
increase in MLC20 phosphorylation and contraction without
the need for a further increase in [Ca2+]i (Somlyo and Somlyo,
2003). Although it is likely that bronchoconstrictors act via a
combination of the above pathways, the precise mechanisms
through which Ca2+ inﬂux and Rho-kinase activity are medi-
ated by GPCRs are not fully understood.
Src family kinases (SrcFK) and focal adhesion kinase (FAK)
are widely expressed non-receptor tyrosine kinases (TKs) im-
portant in many aspects of cellular function, being activated
in response to various stimuli including growth factors,
GPCRs, reactive oxygen species and adhesion. SrcFK and
FAK are often described as beingmutually dependent or recip-
rocally activated, especially when associated with integrin
engagement and/or growth factor receptor activation (Owen
et al., 1999; Ishigaki et al., 2011). An effect of TKs on ASM tone
was ﬁrst suggested by the relaxant effect of non-selective tyro-
sine kinase inhibitors on rat isolated bronchioles (Chopra
et al., 1997). Subsequently, selective inhibition of SrcFK and
FAK was shown to depress GPCR-induced contraction in
human, rodent or canine upper airways (Tang and Gunst,
2001; Katsumoto et al., 2013). FAK was linked to elevated
[Ca2+]i in response to various stimuli in trachea, but the
relative inﬂuence of the kinase on VOCE, ROCE or SOCE or
on Rho-kinase was not determined (Tang et al., 1999; Tang
and Gunst, 2001). SrcFKs have been identiﬁed as upstream
mediators of Rho-kinase in vascular smooth muscle (Nakao
et al., 2002; Knock et al., 2008), but neither this relationship
nor the inﬂuence of SrcFK on GPCR [Ca2+]i responses has
yet been examined in ASM. To our knowledge, only one
previous study has examined the involvement of SrcFK or
FAK speciﬁcally in the contraction of intralobar bronchioles,
and this was limited to the role of SrcFK in mediating
sensitization of rat bronchioles to muscarinic agonists (Sakai
et al., 2010).
In this study, we hypothesized that SrcFK and FAK mediate
GPCR-induced ASM contraction via multiple signalling path-
ways and examined their inﬂuence on Rho-kinase-dependent
MLCP inhibition/Ca2+-sensitization and on SOCE/ROCE and
VOCE Ca2+ entry pathways, in intra-lobar bronchioles of rat
and cultured human ASM cells (hASMC). We found that
SrcFK, most likely c-Src itself, modulate Rho-kinase dependent
Ca2+-sensitization, but FAK does not, and that the two tyrosine
kinases differentially regulate SOCE/ROCE and VOCE. We
also suggest the existence of two subpopulations of GPCR-
activated SrcFK, one being FAK-dependent and the other
FAK-independent.
Methods
Rats and tension measurement by wire
myography
All animal care and experimental procedures complied with
UK legislation under the Animals (Scientiﬁc Procedures) Act
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deemed to be as humane as possible. All results involving an-
imals are reported in accordance with the ARRIVE guidelines
for reporting experiments involving animals (McGrath et al.,
2010). A total of 98 rats were used. Male Wistar rats (~250 g)
had free access to food and water and were maintained on a
12:12 h light/dark schedule. The rats were killed by an i.p.
injection of sodium pentobarbital and the lungs and trachea
were immediately removed. First or second-order intralobar
bronchioles (~2mm length) were dissected free of surround-
ing parenchyma and mounted on a wire myograph (DMT.
dk), bathed in PSS (in mM: 118 NaCl; 24 NaHCO3; 1 MgSO4;
4 KCl; 5.56 glucose; 0.435 NaH2PO4; 1.8 CaCl2, pH 7.4),
gassed with 95% air, 5% CO2 at 37°C. Bronchioles were
incrementally stretched and alternately exposed to PSS con-
taining 80mM [K+] (equimolar substitution for Na+, KPSS)
until the point on the length tension curve at which muscle
length was optimum for active tension development was
achieved, as described previously (Moir et al., 2003). Viability
for contraction experiments was conﬁrmed by a response of
at least 3mN to the last challenge with KPSS. Bronchiole
internal diameter after stretch was typically in the range
300–800 μm.
Speciﬁc examination of the Rho-kinase dependent Ca2+-
sensitization component of contraction was achieved by
permeabilizing myograph-mounted bronchioles with
α-haemolysin (α-toxin). PSS was ﬁrst exchanged for relaxing
solution (pCa = 10, in mM: 200 PIPES; 100Mg(Ms)2; 1000
KMS; 100 K2EGTA; 5 Na2ATP; 10 Na2creatine phosphate,
pH 7.1), gassed with air at 26°C. α-toxin (60 μgml-1) was then
applied in relaxing solution with pCa raised to 6.7 for 30min,
permeabilization being conﬁrmed by the development of
active tension. pCa was adjusted via proportionate substitu-
tion of K2EGTA for CaEGTA, with 100 CaEGTA, 0 K2EGTA
being equivalent to pCa4.5. Contractile responses to
bronchoconstrictors were conducted at pCa 6.5 (~300 nM
[Ca2+]), which induced a contraction equivalent to 10-20%
of that achieved by pCa 4.5. GTP 1 μM and 10 μM
cyclopiazonic acid (CPA) were included to support G-protein
signalling and to prevent the inﬂuence of SR Ca2+ release on
contraction respectively.
Human tissue and cell culture
Donations of human tissue were obtained following written
informed consent and with the approval of the South East
London Research Ethics Committee, REC reference number
10/H0804/66. All clinical procedures conformed to the
standards set by the latest Declaration of Helsinki. hASMC
were obtained from healthy volunteers (n = 11; 7 women, 4
males; age range 22–53 years; life-long absence of respiratory
symptoms; lung functions within normal limits) by deep
endobronchial biopsy. ASM bundles were bathed in DMEM
containing 10% FBS, L-glutamine (2mM), sodium pyruvate
(1mM), non-essential amino acids and amphotericin B
(2 μgml-1), and subjected to enzymatic digestion in nomi-
nally Ca2+-free HEPES buffer containing: 5.56mM glucose,
2mg ml-1 collagenase Type XI, 1mgml-1 papaine, 1mgml-1
trypsin inhibitor and 1mM DTT, for 30min at 37°C. Cells
were then dispersed into culture ﬂasks containing DMEM
(plus supplements) and incubated at 37°C, pH 7.4. Smooth
muscle phenotype was conﬁrmed by positive staining with
anti-smooth muscle α-actin, anti-desmin and anti-calponin,
with Alexa Fluor®488 labelled secondary antibody
(Lifetechnologies) and with TRITC-labelled phalloidin to
conﬁrm the presence of stress ﬁbres in resting cells
(Supporting Information Fig. S1). Cells were used for experi-
ments at passages 4–9, grown to conﬂuence and serum
starved for 7 days in DMEM plus supplements, and the
addition of 1% BSA, 5 μgml-1 transferrin, 1 μM insulin and
100 μM ascorbate.
siRNA design and transfection
Two siRNAs against human SRC (GenBank accession no.
NM_005417) were designed as described previously (Reynolds
et al., 2004; Ui-Tei et al., 2004). The 19 nucleotide target
sequences (SRC-siRNA1: position 1489–1507 and SRC-siRNA2:
position 1684–1702) were synthesized into 64–65 mer oligonu-
cleotides with BamHI/HindIII overhangs (Sigma Aldrich) and
cloned into the expression vector pSilencer 3.0-H1, containing
pmaxGFP (Ambion Inc.). All clones were puriﬁed using an
EndoFree Plasmid Maxi Kit (Qiagen Ltd) and sequenced
(Geneservice Ltd). hASMC were transfected using the Basic
Nucleofector® Kit and nucleofector device (Amaxa Biosystems).
After 72h, the transfection efﬁciency was >90%, conﬁrmed by
ﬂuorescence microscopy.
Protein lysate preparation and western blot
Cultured hASMCs were treated in serum-free DMEM at 37°C.
Preliminary studies showed that phosphorylation responses,
although sustained for at least 5min, peaked at ~30 s, so all
subsequent acute treatments were for 30 s. Cells were imme-
diately washed twice with ice-cold PBS, followed immediately
by application of cell lysis buffer (NEB) containing 1% phos-
phatase inhibitor cocktails 2 and 3 and 1% protease inhibitor
cocktail (all Sigma). Cells were scraped into a tube and
agitated before being placed on ice. Rat trachealis muscle
was dissected free of adjoining cartilage, and epithelium was
removed by scraping. Acute treatments were conducted in
PSS/5% CO2, at 37°C, before the tissue was snap frozen in
liquid nitrogen, pulverized and lysed in cell lysis buffer. All
lysates were centrifuged at 9.2x g, and the supernatants were
stored at 80°C.
Samples were boiled in NuPAGE LDS Sample Buffer
(Invitrogen) at 95°C for 5min before being loaded onto
4–12% NuPAGE Bis-Tris gels (Invitrogen) for SDS-PAGE. Sam-
ple protein content was determined using the bicinchoninic
acid assay, calibrated against BSA protein standards, to enable
loading of ~20 μg of protein per lane. Gels were run at 180V
for 1 h using an Xcell SureLock Mini-Cell (Invitrogen) and
MOPS running buffer (Invitrogen). Protein was transferred
to a nitrocellulose membrane (Amersham) in 25mM Tris,
192mM glycine and 20% methanol, at 35 V for 1 h.
Membranes were blocked with 5% skimmed milk in Tris
buffered saline (TBS) for 1 h at room temperature, followed
by incubation with speciﬁc anti-phospho-protein primary
antibody (typically 1:1000 dilution) in TBS with 1%
skimmed milk and 0.1% Tween-20 (TBS-T), overnight at
4°C. Following washes in TBS-T, HRP-conjugated secondary
antibody (typically 1:5000 dilution) was applied for 1 h at
room temperature, followed by a ﬁnal wash in TBS-T.
‘Phospho’ proteins were visualized with Super-Signal West
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Femto chemi-luminescent Substrate (Thermo scientiﬁc).
Membranes were then stripped in Restore western blot strip-
ping buffer (Thermo Scientiﬁc), re-blocked and re-incubated
with corresponding ‘total’ antibody and appropriate secondary
antibodies, as above. ‘Total’ proteins were visualized with
either ECL plus or ECL prime (Amersham, GE healthcare).
Images were captured and quantiﬁed using the ChemiDoc
XRS+ gel-imaging system (Biorad). An estimate of the propor-
tion of target protein that was phosphorylated was calculated
as a ratio of ‘phospho’ over ‘total’ signal for each protein band
from each gel, and the effects of acute treatments on these
ratios was expressed as a percentage of control (untreated
samples run on the same gel).
[Ca2+]i measurement
Cultured hASMCs were grown on glass cover-slips until 70%
conﬂuent, followed by 7 days of serum starvation. Cells were
loaded with 1 μM Fura PE-3/AM in HBSS (containing in mM:
0.49 MgCl, 0.41 MgSO4, 4 KCl, 0.44 KH2PO4, 4.2 NaHCO3,
120 NaCl, 0.34 Na2HPO4, 20 HEPES and 2 CaCl) at room
temperature for 40min. Coverslips were mounted on an up-
right microscope and cells perfused with HBSS, containing
test reagents as required. Changes in [Ca2+]i were measured
as a ratio of 340 nm over 380 nm emission intensities with
a ×20 oil immersion UV objective and a microspectro-
ﬂuorimeter (CairnResearch Ltd., U.K.). For each coverslip,
ratios obtained in zero [Ca2+]o and the absence of drug
were taken as background ﬂuorescence (auto-ﬂuorescence +
residual basal [Ca2+]i) and subtracted from all subsequent
measurements.
Materials and reagents
Antibodies were obtained from cell signalling (anti-phospho-
Src (tyr416); anti-Src; anti-phospho-FAK (Y397); anti-phospho-
FAK (Y576/577); anti-FAK; anti-phospho-MLC (S19); anti-MYPT1;
anti-MLC), Millipore (anti-phospho-MYPT1 (T696)), Sigma
(anti-rabbit IgG; anti-mouse IgG). Kinase inhibitors were obtai-
ned from Sigma ((1R, 4r)-4((R)-1-aminoethyl)-N-(pyridine-4-yl)





(PF-431396) or Calbiochem: (4-amino-5-(4-chlorophenyl)-7-
(dimethylethyl) pyrazolo[3,4-d]pyrimidine (PP2); 4-amino-
7-phenylpyrazol[3,4-d]pyrimidine (PP3). Cell culture and
western blot materials were obtained from Cell Signalling,
Invitrogen, GE Healthcare or Thermo Scientiﬁc. Nifedipine,
YM58483, and cyclopiazonic acid and α-haemolysin were
from Sigma.
Data analysis and statistics
All values are expressed as mean ± SEM. Non-linear regres-
sion curve ﬁtting was performed with SigmaPlot 10. Carba-
chol (CCh) concentration-response curves were ﬁtted using
the Hill equation for the calculation of PD2 (-LogM EC50)
and maximum response (Max). Bradykinin concentration
responses were biphasic, and were best ﬁtted using a two-
site saturation model, for the characterization of a high
afﬁnity component (PD2-1 and Max-1) and a low afﬁnity
component (PD2-2 and Max-2). Statistical analysis of data
was by Student’s paired or un-paired t-test (two groups of
data, single factor), one-way ANOVA (more than two
groups of data, single factor) or two-way ANOVA (more
than two groups of data, two factors), with Holm–Sidak
post tests where appropriate, and as indicated in ﬁgure or
table legends, using SigmaPlot 10. Differences were consi-
dered signiﬁcant if P < 0.05.
Results
GPCR-mediated contraction of rat bronchioles is dependent on
SrcFK, Rho-kinase and FAK. We examined the contractile
responses to CCh and bradykinin (BK) in rat bronchioles,
whereby the bronchoconstrictors were applied cumulatively
at 5min intervals. Two concentration-response curves were
performed in each bronchiole (0.01–100μM), the ﬁrst acting
as a control and the second after pre-incubation with either
the SrcFK inhibitor PP2 (30 μM), the Rho-kinase inhibitor
Y27632 (10 μM), the FAK inhibitor PF-573228 (10 μM) or no
inhibitor (control). In addition, to account for possible
off-target effects of PP2 and PF-573228, key contractile
responses were also repeated with PP3 (30 μM), the negative
control for PP2 and a dual FAK/PYK2 inhibitor, PF-431396
(10 μM). CCh caused a sustained contraction at each dose
(Figure 1A). The maximum response to CCh was
signiﬁcantly reduced by PP2 (P < 0.01, paired t-test, n = 8),
Y27632 (P < 0.01, paired t-test, n = 6) and PF-573228
(P < 0.05, paired t-test, n = 8), and the PD2 was signiﬁcantly
increased by PP2 (5.55 ± 0.09 vs. control 5.8 ± 0.14,
P < 0.05, paired t-test, n = 8), Y27632 (5.4 ± 0.07 vs. control
5.82 ± 0.07, P < 0.01, paired t-test, n = 6) and PF-573228
(5.21 ± 0.08 vs. control 5.69 ± 0.07, P < 0.001, paired t-test,
n = 8) (Figure 1A–D). PP3 had no signiﬁcant effect on either PD2
(5.6 ± 0.05 vs. control 5.72 ± 0.08, n = 7) or maximum
contraction (144 ± 5% vs. control 149 ± 3%, n = 7).
Conversely, PF-431396 had similar effects as those of
PF-573228, causing a similar increase in PD2 (5.20 ± 0.05
vs. control 5.90 ± 0.07, P < 0.001, paired t-test, n = 7) and
a similar reduction in maximum contraction (139 ± 6.3%
vs. control 176 ± 9.3%, P < 0.001, paired t-test, n = 7)
(Supporting Information Figs. S2A and S3A). In time-
matched control responses, repeated in the absence of
inhibitor, the maximum contraction of the second response
was slightly increased (ﬁrst repeat: 203 ± 22% vs. second
repeat 228 ± 25%, P < 0.01, paired t-test, n=10), but there
was no signiﬁcant change in PD2 (ﬁrst repeat: 5.67 ± 0.11
vs. second repeat 5.63 ± 0.09, n = 10).
Bradykinin caused a prominent transient contraction and
a smaller sustained component at each dose (Figure 1E). The
concentration-dependence of these responses appeared
biphasic. Contraction at all concentrations of BK was
signiﬁcantly inhibited by PP2 (Figure 1F), with maximum
amplitudes of both high and low afﬁnity components being
reduced (Max-1 = 1.66 ± 0.5% vs. control 12.1 ± 4.1%; Max-
2 = 6.81 ± 2.0% vs. control 24.4 ± 6.0%, P < 0.05, n = 11),
while PD2-1 and PD2-2 were both unchanged (PD2-1 = 6.7
± 0.21 vs. control 7.08 ± 0.11; PD2-2 = 4.85 ± 0.27 vs. con-
trol 4.67 ± 0.22, n = 11) (see Supporting Information Fig. S4
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for all BK dose responses curve ﬁt data). BK-induced responses
were nearly abolished by Y27632 (Figure 1G) and abolished
by PF-573228 (Figure 1H), rendering curve ﬁtting impossible.
In time-matched control responses, repeated in the absence
of inhibitor, there were no changes in either Max or PD2
values for either the high or the low afﬁnity component
(not shown).
SrcFKs mediate GPCR-induced Ca2+-sensitization and Rho-kinase
activation, but FAK does not. To clarify whether the effects of
Figure 1
Effects of kinase inhibitors on carbachol and bradykinin-induced contraction in rat bronchioles. Measurement of isometric tension in freshly
isolated rat bronchioles. CCh (A–D) or BK (E–H) was applied cumulatively (0.01–100μM) at 5min intervals. Representative traces show typical
cumulative contractile responses to CCh (A) and BK (E). Arrows indicate the points where the ﬁrst concentration was applied. Two responses were
performed in each bronchiole, the second after application of the Src inhibitor PP2 (30 μM, 10min, B: CCh, n = 8 or F: BK, n = 11), the Rho-kinase
inhibitor Y27632 (10 μM, 10min, C: CCh, n = 6 or G: BK, n = 4), the FAK inhibitor PF-573228 (10 μM, 10min, D: CCh, n = 8 or H: BK, n = 5) or no
inhibitor (not shown). Measurements were taken at the end of each 5min exposure and data ﬁtted by nonlinear regression. Data expressed as a %
of that induced by 80mM KPSS (mean ± SEM); see main text or Supporting Information Fig. S4 for effects on PD2 and max values.
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kinase inhibitors on bronchoconstrictor-induced contraction
is mediated through a Rho-kinase-dependent Ca2+-
sensitization pathway, CCh or BK concentration-response
curves were repeated in α-toxin-permeabilized rat
bronchioles, with [Ca2+]i ﬁxed at pCa 6.5, in the absence or
presence of PP2, Y27632 or PF-573228. After α-toxin-
permeabilization, bronchoconstictor concentration-
response curves were not repeatable (not shown), so
controls and effects of antagonists were compared in
separate bronchioles. CCh-induced contraction was almost
absent in the presence of Y27632 and was signiﬁcantly
smaller in the presence of PP2 (P < 0.05, unpaired t-test,
n = 9), but in the presence of PF-573228 was not different
from controls (Figure 2B). The PD2 was signiﬁcantly greater
after PP2 (4.64 ± 0.13, vs. control -5.08 ± 0.12, P < 0.05,
unpaired t-test, n = 9), but was no different in PF-573228.
The underlying pCa 6.5 contraction was unaffected by either
PP2 or PF-573228, but was partially inhibited by Y27632 (61 ±
8% block, P < 0.05 vs. absence of Y27632, paired t-test, n = 6).
BK also produced a modest (relative to CCh) concentration-
dependent contraction in permeabilized bronchioles (Figure 2A
and C). The concentration-dependence of these responses again
appeared biphasic, but their small amplitude and poor
sustainability rendered curve-ﬁtting impossible. Nevertheless,
peak responses were signiﬁcantly smaller or absent in the
presence of PP2 or Y27632, respectively, and no different in
PF-573228 (Figure 2C).
To conﬁrm that Rho-kinase is being activated by 30 s
exposure to BK (1 μM) or CCh (100 μM), and whether this
activation relates to subsequent activation of MLCK, we
measured phosphorylation of MYPT-1 at T696, a known
phosphorylation target of Rho-kinase (Feng et al., 1999),
and of MLC20 at S19, the main target of MLCK. Furthermore,
in order to reveal a possible interaction between Rho-kinase
and SrcFK or FAK with relation to MLC20 phosphorylation,
we examined the effects of inhibitors of Rho-kinase, SrcFK
or FAK on both phosphorylation responses in hASMC.
Phosphorylation of MLC20 and MYPT-1 were both signiﬁ-
cantly enhanced by BK. This enhancement was signiﬁcantly
reduced by PP2 and abolished by Y27632 at both sites, while
PF-573228 signiﬁcantly reduced the enhancement of MLC20,
but not MYPT-1 phosphorylation (Figure 2D and F). CCh also
enhanced phosphorylation of both proteins, but to a lesser
extent than BK. Basal MLC20 phosphorylation was insensi-
tive to all three inhibitors (Figure 2E), while basal MYPT-1
phosphorylation was partially sensitive to Y27632, but
insensitive to PP2 or PF-573228 (Figure 2G).
Bronchoconstrictors enhance SrcFK and FAK auto-
phosphorylation. In order to conﬁrm that the inﬂuence of
SrcFK and FAK on contraction and Rho-kinase activity
occurs in direct response to bronchoconstrictor stimulation,
we also examined the effects of BK or CCh on SrcFK auto-
phosphorylation at Y416 and FAK auto-phosphorylation at
Y397, as a reﬂection of respective changes in kinase activity
(Calalb et al., 1995; Xu et al., 1999). In hASMC, auto-
phosphorylation of both kinases was signiﬁcantly enhanced
by both agents (Figure 3 A–D). As expected, SrcFK
phosphorylation was almost abolished by PP2, and FAK
phosphorylation was almost abolished by PF-573228, both
conﬁrming the selectivity of the phospho-antibodies and
validating the choice of kinase inhibitor concentrations used.
In rat trachealis muscle, SrcFK and FAK auto-phosphorylation
were also enhanced by BK and CCh, as was phosphorylation
of MLC20 (S19) and MYPT-1 (Y397), (Figure 3E, F).
Bronchoconstrictor-induced FAK Y397 phosphorylation was
noticeably weaker in rat trachealis than in hASMC.
FAK and SrcFK influence SOCE/ROCE and VOCE. We
examined the effects of PP2 and PF-753228 on VOCE-
mediated contraction by sub-maximal depolarization with
40mM KPSS. In control experiments, contraction amplitude
induced by two consecutive KPSS exposures was not
signiﬁcantly different, while when PP2 (30 μM) or PF-
573228 (10 μM) was applied between the ﬁrst and second
exposures, the contractile response was modestly but
signiﬁcantly reduced by PF-573228, but not by PP2
(Figure 4A and B). To rule out a direct Ca2+-channel
antagonist effect of PF-573228, we also examined its effect
on contraction induced by maximal depolarization with
80mM KPSS. This contraction was signiﬁcantly less
sensitive to PF-573228 than the 40mM KPSS contraction
(11.5 ± 2.7% inhibition, n = 6, vs. 30.2 ± 6.3% inhibition of
40mM KPSS, n = 7; P < 0.05 by unpaired t-test). We then
examined the effects of PP2 and PF-573228 on SOCE-
mediated contraction. SR Ca2+ was ﬁrst depleted with
cyclopiazonic acid (CPA, 10 μM) in the absence of
extracellular Ca2+ and presence of 200 μM EGTA, then 2mM
Ca2+ was re-applied. CPA was used here instead of a GPCR
agonist because it would have been difﬁcult to separate
effects of the agonist on Ca2+ entry from those on Rho-
kinase-mediated Ca2+ sensitization. In control experiments,
re-application of 2mM Ca2+ induced a biphasic contraction,
which peaked at ~2min and slowly decayed to ~20% of
80mM KPSS after 30min. In the presence of either PP2 or
PF-573228, the sustained component was signiﬁcantly
smaller, decaying to <10% of 80mM KPSS after 30min
(Figure 4C and D). PP3 was without signiﬁcant effect on this
response, ruling out the possibility of a non-speciﬁc SOCE
blocking effect of PP2 (Supporting Information Fig. S2B),
while PF-431396 inhibited the response in a near-identical
way to that of PF-573228, supporting a speciﬁc role for FAK
in this response (Supporting Information Fig. S3B). To see
whether these effects of PP2 and PF-573228 were due to an
effect of SrcFK or FAK on SOCE itself or on secondary
activation of VOCE, the effect of the SOCE blocker
YM58483 (10 μM) and the Ca2+ channel antagonist
nifedipine (2 μM) on the SOCE-mediated contraction was
also determined. Apart from a small residual transient
contraction, the response was abolished by YM58483, while
nifedipine was without effect, apart from a small reduction
in the peak response (Figure 4D).
To support contraction data and to further eliminate
the possibility that SrcFK and FAK were indirectly
inﬂuencing SOCE via an action on SR Ca2+ release, we
also examine the effects of PP2 and PF-753228 on SOCE
[Ca2+]i responses in Fura-2 loaded hASMC, using BK as
the initial SR-emptying stimulus. After the recording of
an initial baseline in 2mM Ca2+, and then for 5min in
nominally Ca2+-free buffer, the addition of BK (1 μM)
caused a near instantaneous increase in [Ca2+]i. This
decayed back to the baseline within ~2min; a response
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Figure 2
Effects of kinase inhibitors on contraction in α-toxin permeabilized rat bronchioles andMLC20/MYPT-1 phosphorylation in hASMC. (A–C)Measurement
of isometric tension in α-toxin permeabilized rat bronchioles. All responses were performed with pCa ﬁxed at 6.5 and in the presence of 10μMCPA and
1 μMGTP. (A) Representative traces showing CCh (upper panel) or BK (lower panel) being applied cumulatively (0.01–100 μM) at 5min intervals, with
arrows indicating where the ﬁrst dosewas applied. Responses were performed in the absence of inhibitor (control) or after pre-incubation with either the
Src inhibitor PP2 (30 μM, 10min), the Rho-kinase inhibitor Y27632 (10 μM, 10min) or the FAK inhibitor PF-573228 (10 μM, 10min). Measurements
were taken at the end of each 5min exposure. Data are expressed as a%of that induced by pCa 4.5 (mean ± SEM). (B) CCh datawere ﬁtted by nonlinear
regression (control, n = 10; PP2, n = 9; Y27632, n = 4; PF-573228, n = 11); see main text for effects on CCh PD2. (C) BK data could not be ﬁtted by
nonlinear regression so were compared by two-way RM ANOVA (control, n = 6; PP2, n = 6; Y27632, n = 4; PF-573228, n = 6; *P < 0.05, **P < 0.01
vs. control). (D–G)Measurement of phosphorylation of MLC20 at S19 (P-MLC20, D, E) andMYPT-1 at T696 (P-MYPT-1, F, G), in hASMC. Representative
blots show effects of treatment on ‘phospho’ and ‘total’ immunoreactivity for each protein. Bar charts show the effects of treatments on the degree of
phosphorylation (mean ± SEM), expressed as a%of values fromuntreated (control) samples run on the samegels. (D) Effects of BK (1μM30 s) onMLC20
phosphorylation in the absence of inhibitor (n = 16) or after pretreatment with either PP2 (30 μM, 10min, n = 11), Y27632 (10 μM, 10min, n = 9)
or PF-573228 (PF, 10 μM, 10min, n = 11). (E) Effects of inhibitors on basal MLC20 phosphorylation (n = 4–11). (F) Effects of BK (1 μM, 30 s) on
MYPT-1 phosphorylation in the absence of inhibitor (n = 13), or after pre-application of PP2 (30 μM, 10min, n = 13), Y27632 (10 μM, 10min,
n = 13), or PF-573228 (10 μM, 10min, n = 8). (G) Effects of inhibitors on basal MYPT-1 phosphorylation (n = 4–11). Comparisons were by one-
way ANOVA with Holm–Sidak post tests: *P < 0.05 and **P < 0.01 versus control; #P < 0.5 and ##P <0.01 versus BK alone.
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typical of GPCR-induced SR Ca2+-release. 2mM Ca2+ was
then re-applied for 20min, with simultaneous washout
of BK. This induced a biphasic rise in [Ca2+]i with a similar
time course to the SOCE contractile responses. In the
presence of either PP2 or PF-573228, the sustained com-
ponent was reduced by ~50%, while the initial transient
component and the initial BK-induced SR release were both
unaffected (Figure 5).
Interaction between SrcFK and FAK. Because SrcFK and FAK
appear to be sharing some but not all of the contraction
signalling pathways investigated in this study, and in the
Figure 3
Effects of broncoconstrictors on SrcFK and FAK auto-phosphorylation in hASMC and rat trachealis. (A–D) Measurements of auto-phosphorylation
of SrcFK at Y416 (P-SrcFK, A, B) and auto-phosphorylation of FAK at Y397 (P-FAK, C, D) in hASMC. Representative blots show effects of treatments
on ‘phospho’ and ‘total’ immunoreactivity for each protein. Bar charts show the effects of treatments on the degree of phosphorylation (mean ±
SEM), expressed as a % of values from untreated (control) samples run on the same gels. (A) Effect of BK (1 μM, 30 s) in the absence (n = 12) or
presence of PP2 (30 μM, 10min, n = 7) on P-SrcFK (Y416). (B) Effect of CCh (100 μM, 30 s) in the absence (n = 13) or presence of PP2 (n = 8) on
P-SrcFK (Y416). (C) Effect of BK in the absence (n = 15) or presence of PF-573228 (PF, 10 μM, 10min, n = 13) on P-FAK (Y397). (D) Effect of CCh in
the absence (n = 16) or presence of PF-573228 (n = 11) on P-FAK (Y397). Comparisons by one-way ANOVA with Holm–Sidak post tests: **P< 0.01
versus control; ##P< 0.01 versus BK or CCh alone. (E, F) Measurements of phosphorylation of MLC20 (S19), MYPT-1 (T696), SrcFK (Y416) and FAK
(Y397) in rat trachealis muscle. (E) Effects of BK (1 μM, 30 s, n = 8). (F) Effects of CCh (100 μM, 30 s, n = 8). Comparisons by unpaired t-test:
*P<0.05, **P<0.01 versus control.
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light of previous evidence suggesting cooperation between
the two kinases, we investigated the inﬂuence of FAK on
SrcFK auto-phosphorylation and vice versa. Enhancement of
SrcFK (Y416) auto-phosphorylation by BK was inhibited by
PF-573228 by ~50% (Figure 6A), while basally, this
phosphorylation was insensitive to PF-573228 but inhibited
by PP2 (Figure 6B). FAK kinase activity is also reportedly
inﬂuenced by Src-dependent phosphorylation on FAK
Y576/577 (Calalb et al., 1995). Phosphorylation at this dual
site was enhanced by BK, and this enhancement was nearly
abolished by PP2 and partially inhibited by PF-573228
(Figure 6C), while basally, this phosphorylation was inhibited
by PP2, but not PF-573228 (Figure 6D). However, BK-induced
enhancement of FAK (Y397) auto-phosphorylation was
Figure 4
Effects of SrcFK and FAK inhibitors on VOCE- or SOCE-associated contraction in rat bronchioles. (A, B) VOCE-associated contractions induced by
40mM KPSS. Representative traces (A) andmeanmeasurements of peak amplitude (B, ± SEM), showing effects of two contractions in the absence
of inhibitor (left panels, n = 8), the effect of PF-573228 on the second contraction (PF, middle panels, 10 μM, 5min pre-incubation, n = 7) or the
effect of PP2 on the second contraction (30 μM, right panels, 5min pre-incubation, n = 9). Comparisons by paired t-test: **P< 0.01 versus control.
(C, D) SOCE-associated contraction induced by 10 μM CPA/200 μM EGTA/zero Ca2+, followed by re-application of 2mM Ca2+. Representative
traces (C) and mean measurements of amplitude of contractile responses at 2min intervals after re-application of Ca2+ (D, ± SEM), showing
control response (n = 14) and effects of pre-incubation with PF-573228 (n = 9), PP2 (n = 9), nifedipine (n = 10) or YM58483 (n = 5). Comparisons
by two-way ANOVA with Holm–Sidak post tests: *P < 0.05 for control versus PF-573228 or PP2. #P<0.01 for control versus YM58483. ^P < 0.05
for control versus nifedipine at 2min only.
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unaffected by PP2 (Figure 6E). Basal phosphorylation of FAK
(Y397) was also insensitive to PP2, but was inhibited by
PF-53228 (Figure 6F).
c-Src is the principle SrcFK mediating bronchoconstrictor-induced
phosphorylation responses. Multiple members of the Src-
family of kinases are expressed in ASM, including c-Src, Fyn,
Yes and Lyn (Sakai et al., 2010). For this reason, and the fact
that the phospho-SrcFK antibody cannot distinguish
between Src family members, we re-examined the effects of
acute BK treatment on MLC20 (S19), MYPT-1 (T696), SrcFK
(Y416) and FAK (Y576/577) phosphorylation in hASMC after
transfection with c-Src siRNA or scrambled siRNA. Speciﬁcity
of c-Src siRNA was veriﬁed by a ~70% reduction in c-Src
Figure 5
Effects of SrcFK and FAK inhibitors on SOCE/ROCE-associated [Ca2+]i responses in hASMC. A: Representative control trace of [Ca
2+]i in Fura-2
loaded hASMC, as determined by the ratio of ﬂuorescence at 340 nm/380 nm. Arrow indicates the point at which pre-stimulus basal [Ca2+]i
was recorded in 2mM [Ca2+]o (and extrapolated by dashed line). The buffer was then switched to zero [Ca
2+]o until a new baseline was
established, and 1 μM BK added for 5min. Finally, 2mM [Ca2+]o was reapplied for 20min. Responses were performed either in the absence or
presence of FAK inhibitor PF-573228 (B, C: PF, 10 μM, added 5min prior to BK, n = 15 vs. 15 matched controls) or SrcFK inhibitor PP2 (D, E:
30 μM, added 5min prior to BK, n = 10 vs. eight matched controls). Measurements were made of the peak BK-induced transient (B, D:
arbitrary units, mean ± SEM) and of the response to reapplication of 2mM [Ca2+]o (C, E: arbitrary units, measured at 1min intervals, mean ± SEM),
compared with the pre-stimulus basal [Ca2+]i in 2mM [Ca
2+]o (indicated by arrows). Background ﬂuorescence (in zero [Ca
2+]o, prior to the applica-
tion of BK) was subtracted from all other measurements. Comparisons by un-paired t-test (B, D) or two-way ANOVAwith Holm–Sidak post tests (C, E:
*P < 0.05 vs. matched controls).
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protein expression, while expressions of MLC20, MYPT-1 and
FAK were all unaffected (Figure 7A). The scrambled siRNA had
no effect on any of the proteins examined. c-Src siRNA
inhibited BK-induced phosphorylation of MLC20 by ~80%,
while responses of MYPT-1 (T696), SrcFK (Y416) and FAK
(Y576/577) to BK were all inhibited by ~60%, compared with
matched scrambled siRNA transfected cells (Figure 7 B–D).
Discussion
We examined the role of SrcFK and FAK kinase activity in
bronchoconstrictor-induced contraction of rat-isolated
bronchioles and in [Ca2+]i and phosphorylation responses
in hASMC. Contraction was induced and MLC20 phosphor-
ylation was enhanced by the bronchoconstrictors BK and
Figure 6
Interaction between SrcFK and FAK in response to BK in hASMCs. Measurements of auto-phosphorylation of SrcFK at Y416 (P-SrcFK, A, B),
phosphorylation of FAK at the Y576/577 dual site (C, D), and auto-phosphorylation of FAK at Y397 (P-FAK, E, F) in hASMC. Representative blots
show effects of treatments on ‘phospho’ and ‘total’ immunoreactivity for each protein. Bar charts show the effects of treatments on the degree of
phosphorylation (mean ± SEM), expressed as a % of values from untreated (control) samples run on the same gels. (A) Effects of BK (1μM, 30 s) on
P-SrcFK (Y416) in the absence (n = 14) or presence of the FAK inhibitor PF-573228 (PF, 10μM 10 min, n = 7). (B) Effects of PF (n = 4) or the SrcFK
inhibitor PP2 (30μM, 10 min, n = 4) on basal P-SrcFK (Y416). (C) Effects of BK on P-FAK (Y576/577) in the absence (n = 11) or presence of PP2
(n = 6) or PF (n = 7). (D) Effects of PF (n = 4) or PP2 (n = 5) on basal P-FAK (Y576/577). (E) Effect of BK on P-FAK (Y397) in the absence (n = 14)
or presence of PP2 (n = 4). (F) Effects of PF (n = 4) or PP2 (n = 4) on basal P-FAK (Y397). Comparisons by one-way ANOVA with Holm–Sidak post
tests: **P < 0.01 versus control or ##P < 0.01 versus BK alone.
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CCh, and these responses were sensitive to inhibition of
both SrcFK and FAK. Using auto-phosphorylation as an in-
dication of kinase activity, both SrcFK and FAK were acti-
vated by both agents in hASMC and rat trachealis,
suggesting an important role for these kinases in GPCR-
induced ASM contraction in both humans and rodents.
PP3, the negative control for PP2, was without effect on
contraction, while PF-431396, another inhibitor of FAK,
had similar effects as PF-573228, reducing the likelihood
of our results being inﬂuenced by non-speciﬁc effects of PP2
or PF-573228. Amongst the several Src family members, both
c-Src and Fyn have been implicated in vascular smooth mus-
cle contraction (Nakao et al., 2002; Knock et al., 2008), and
Lyn is activated by muscarinic agonists in ASM (Pertel et al.,
2006). Here however, the effects of c-Src siRNA suggest that
60–80% of all the bronchoconstrictor-induced phosphoryla-
tion responses investigated herein were speciﬁcally mediated
by c-Src.
Figure 7
Effects of c-Src siRNA on bronchoconstrictor-induced MLC20, MYPT-1, SrcFK and FAK phosphorylation in hASMCs. Measurement of protein
expression and phosphorylation responses to BK (1 μM, 30 s) in hASMCs after transfection with c-Src siRNA or scrambled siRNA (scram). (A) Effect
of c-Src siRNA on c-Src protein expression and (lack of) effect onMLC20, MYPT-1 and FAK expression. Data normalized to GAPDH expression in the
same samples (arbitrary units, n = 8–12). Comparisons by unpaired t-test: **P < 0.01 versus scram siRNA. (B) Effect of BK on MLC20 phosphory-
lation at S19 (P-MLC20) after transfection with scram siRNA (n =16) or c-Src siRNA (n = 16). (C) Effect of BK on MYPT-1 phosphorylation at T696
(P-MYPT-1) after transfection with scram siRNA (n = 14) or c-Src siRNA (n = 14). (D) Effect of BK on SrcFK phosphorylation at Y416 (P-SrcFK) after
transfection with scram siRNA (n = 16) or c-Src siRNA (n = 16). (E) Effect of BK on FAK phosphorylation at Y576/577 (P-FAK) after transfection with
scram siRNA (n = 10) or c-Src siRNA (n = 10). Comparisons by two-way ANOVA: **P < 0.01 versus control; ##P < 0.01 versus scram siRNA.
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To further characterize the signalling pathways through
which SrcFK and FAK mediate ASM contraction, we ﬁrst fo-
cussed on their role in Rho-kinase dependent Ca2+-sensitiza-
tion, a process whereby inhibition of MLCP results in
enhanced MLC20 phosphorylation, and hence force genera-
tion, without the requirement for an increase in [Ca2+]i
(Somlyo and Somlyo, 2003). Both BK and CCh-induced con-
traction were highly sensitive to Rho-kinase inhibition with
Y27632. Furthermore, a component of the contractile re-
sponse to both BK and CCh persisted when bronchioles were
permeabilized with α-toxin to prevent changes in intracellu-
lar Ca2+. We found that these contractile responses were
dependent on Rho-kinase and SrcFK, but not FAK. Further-
more, we found that MYPT-1 phosphorylation on T696, an
indicator of Rho-kinase-mediated MLCP inhibition (Feng
et al., 1999), is also enhanced by BK and CCh and that this
enhancement is sensitive to inhibition of Rho-kinase and
SrcFK, but not of FAK. This inﬂuence of SrcFK on Rho-kinase
activity occurred speciﬁcally in response to agonist stimula-
tion, because baseline phosphorylation of MYPT-1 and
MLC20 and baseline pCa6.5 contraction in permeabilized
bronchioles were not affected by SrcFK inhibition. Clearly,
these results indicate that SrcFK mediates GPCR-induced
smooth muscle contraction in part via activation of Rho-
kinase. Importantly, this is the ﬁrst direct demonstration of
an interaction between SrcFK and Rho-kinase in ASM and in
vessels of a size relevant to the control of airway resistance,
consistent with the implied importance of Rho-kinase in
airway hyper-responsiveness from studies in whole animal
or isolated upper airways (Yoshii et al., 1999; Schaafsma
et al., 2006). Interestingly, receptor TK stimulation also
induces Rho-kinase-dependent ASM contraction (Gosens
et al., 2004), and other responses of ASM to growth factor
stimulation are also SrcFK-dependent (Krymskaya et al., 2005).
Thus SrcFK may be a point of convergence for the activation of
Rho-kinase in response to either GPCR or growth factors.
Rho-kinase is directly activated by the small G-protein
RhoA, which is itself activated by guanine nucleotide
exchange factors (RhoGEFs). RhoGEFs are known to be acti-
vated or modulated by various non-receptor TKs (Chikumi
et al., 2002; Ying et al., 2009; Guilluy et al., 2010), in addition
to G12/13 binding. It is therefore conceivable that SrcFK may
be activating RhoA/Rho-kinase via direct phosphorylation
of a RhoGEF. Alternatively, they may do so via the prior acti-
vation of another kinase, such as FAK, PYK2 or JAK2 (Calalb
et al., 1995; Andreev et al., 2001; Singh et al., 2011). Our
results are not inconsistent with this hypothesis, but exclude
FAK as the intermediary kinase in this instance.
We next focussed on the role of SrcFK and FAK in Ca2+ sig-
nalling. Gq/PLC-β-coupled GPCRs induce Ca2+ entry through
three main pathways: DAG-sensitive TRP channel opening
(ROCE), IP3-dependent depletion of SR Ca
2+ and subsequent
STIM1/Orai1/TRP-dependent inﬂux (SOCE), and subsequent
depolarization-induced opening of L-type Ca2+ channels
(VOCE) (Kawasaki et al., 2006; Wang et al., 2008). Several
members of the TRPC family of channels, in addition to being
modulated by DAG, are subject to modulation by phosphory-
lation, and tyrosine phosphorylation of TRPC channels is
SrcFK-dependent, contributing to either ROCE or SOCE
(Kawasaki et al., 2006). Moreover, association of STIM1 with
Orai1 in response to SR depletion, and subsequent Ca2+
inﬂux, is partially dependent on SrcFK-mediated phosphory-
lation of STIM1 (Lopez et al., 2012). In accord with these pre-
vious studies, we found that CPA-induced SOCE-dependent
contraction in rat bronchioles and BK-induced Ca2+ inﬂux
in hASMC were both similarly sensitive to SrcFK inhibition.
Interestingly, we found that these responses were also
similarly sensitive to FAK inhibition. This, to our knowledge,
is the ﬁrst indication that FAK may be contributing to GPCR-
induced Ca2+ responses and contraction in human and
rodent ASM, via upstreammodulation of SOCE and/or ROCE.
Some GPCR agonists, notably angiotensin II, also mediate SR
Ca2+ release via SrcFK-dependent tyrosine phosphorylation
of PLC-γ (Schmitz et al., 1997). However, there is no indi-
cation that this is occurring in our study, because we found
that neither PP2 nor PF-573228 altered the BK-induced Ca2+
transients indicative of SR release.
Our ﬁnding that the CPA-induced SOCE contraction
was minimally affected by the Ca2+ channel antagonist
nifedipine suggests that VOCE secondary to SOCE-induced
depolarization was not contributing substantially to this
response. However, VOCE may also be activated more
directly via a number of signalling pathways including
stretch-activated phosphatidylcholine-speciﬁc PLC-derived
DAG (Mauban et al., 2015) or integrin-directed tyrosine
phosphorylation. Regarding the latter, engagement of
integrin α5β1 induces SrcFK and FAK-dependent phosphory-
lation of the α1c subunit of the L-type Ca2+ channel in
vascular smooth muscle, with the likeliest sequence of
events being integrin-induced FAK auto-phosphorylation
followed by SrcFK recruitment by FAK (Owen et al., 1999;
Salazar and Rozengurt, 2001) and subsequent direct phos-
phorylation of the channel by SrcFK (Wu et al., 2001; Gui
et al., 2006). Similarly in ASM, VOCE may also be enhanced
via stretch or adhesion-induced FAK activity (Smith et al.,
1998; Tang et al., 1999). In bronchioles, we found that
contraction induced by depolarization with sub-maximal
(40mM) K+ was sensitive to PF-573228 but not PP2, which
suggests that FAK may be activating VOCE independently
of SrcFK. However, contraction induced by maximum depo-
larization with 80mMK+ was considerably less sensitive to
PF-573228, ruling out a non-speciﬁc effect of PF-573228 on
Ca2+ channel opening per se. We did not systematically
examine the effects of stretch on contractile responses, as
carried out previously in trachea (Tang et al., 1999), but
applied a standard degree of stretch to maximize active
tension responses to bronchoconstrictors or KPSS. Similarly,
adherent hASMC are assumed to be under a degree of
self-induced basal tension (Deguchi et al., 2005). In light of
this, it is worth noting that the relatively weak FAK auto-
phosphorylation observed in trachealis samples treated with
BK or CCh, compared with similarly treated hASMC, may
have been because no stretch was applied to trachealis
samples during BK or CCh treatment prior to snap freezing
for protein extraction.
In smooth muscle contraction, it has been assumed that
the mutual dependence between SrcFK and FAK relates pri-
marily to the recruitment of contractile ﬁbres through actin
polymerization and focal attachment formation (Gerthoffer
and Gunst, 2001; Tang et al., 1999; Gunst et al., 2003). It is
therefore of note that we only see possible evidence of such
mutuality with regard to SOCE/ROCE activity, but not in
Tyrosine kinases in airway smooth muscle BJP
British Journal of Pharmacology (2015) 172 5265–5280 5277
relation to Rho-kinase activation (SrcFK only) or VOCE
activity (FAK only). The selective sensitivity of basal SrcFK
auto-phosphorylation to PP2 and of basal FAK auto-
phosphorylation to PF-537228 conﬁrms the speciﬁcity of
these two antagonists for their intended targets at the
concentrations used in this study. Therefore, our ﬁnding that
BK-induced SrcFK auto-phosphorylation is partially PF-
537228-sensitive suggests a partial dependence of GPCR-
induced SrcFK activity on FAK. This is probably because SrcFK
can be activated via disruption of intramolecular auto-
inhibition by association of the SH2 domain with the phos-
phorylated Y397 of FAK (Xing et al., 1994). Conversely, we
show that BK-induced FAK auto-phosphorylation is wholly
independent of SrcFK activity. In response to adhesion, in
non-muscle cells, FAK auto-phosphorylation is enhanced by
SrcFK-mediated phosphorylation on Y576/577 (Calalb et al.,
1995; Salazar and Rozengurt, 2001). However, despite the fact
that we show that FAK Y576/577 phosphorylation is also
induced by BK and almost entirely SrcFK-mediated, this
phosphorylation does not correlate with enhanced FAK auto-
phosphorylation. A similar discrepancy was observed in
ﬁbroblasts where adhesion-induced FAK auto-phosphorylation
was SrcFK-dependent but GPCR-induced FAK auto-
phosphorylation was not, despite both stimuli inducing
SrcFK-dependent Y576/577 phosphorylation (Salazar and
Rozengurt, 2001). Taken together, our results imply two
things about these interactions in ASM: ﬁrstly, that GPCR
can induce FAK activation without prior activation of SrcFK,
and secondly, that there may be two sub-populations of
BK/CCh-activated SrcFK; one FAK-dependent, resulting in
modulation of SOCE/ROCE, and the other FAK-independent,
resulting in activation of Rho-kinase (as summarized in
Figure 8).
In conclusion, our data suggest an important role for
SrcFK and FAK in bronchoconstrictor-mediated contraction
in ASM, with the two kinases acting together to induce
SOCE/ROCE, and independently to mediate Rho-kinase-
dependent Ca2+ sensitization and VOCE respectively. These
ﬁndings may inform the search for new drug targets for the
treatment of obstructive lung diseases such as asthma, and
in particular, support the suggested key role for SrcFK in
experimental airway hyper-responsiveness (Sakai et al.,
2010; Katsumoto et al., 2013).
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Figure 8
Proposed role for SrcFK and FAK in bronchoconstrictor or depolarization-induced ASM contraction, based on the results of the current study and
existing literature. (A) GPCR activate both SrcFK and FAK, presumably via interaction with heterotrimeric G-protein sub-units (e.g. Gαq, Gα12/13
or Gβγ) or downstream signalling molecules. Activated SrcFK forms two distinct sub-populations: one FAK-independent and one FAK-dependent.
(B) FAK-independent SrcFK induces Rho-kinase to phosphorylate MYPT-1, thus enhancing myosin light-chain phosphorylation (P-MLC) through
inhibition of myosin light-chain phosphatase (MLCP). SrcFK are perhaps activating Rho-kinase via the tyrosine phosphorylation of RhoA-
associated proteins such as RhoGEFs. (C) A FAK/Src complex may be mediating store-operated and/or receptor-operated Ca2+ entry (SOCE/
ROCE) via the tyrosine phosphorylation of TRP channels, or associated signalling proteins, such as STIM1, in association with DAG. (D) FAK is also
independently enhancing voltage-operated Ca2+ entry (VOCE), perhaps via direct phosphorylation of voltage-dependent Ca2+ channels, in
response to the additional stimulus of stretch or cellular adhesion, via integrin engagement.
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Control of vascular smooth muscle function by Src-family
kinases and reactive oxygen species in health and disease
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Abstract Reactive oxygen species (ROS) are now recognised as secondmessenger molecules that
regulate cellular functionby reversibly oxidising specific amino acid residues of key target proteins.
Amongst these are the Src-family kinases (SrcFKs), a multi-functional group of non-receptor
tyrosine kinases highly expressed in vascular smooth muscle (VSM). In this review we examine
the evidence supporting a role for ROS-induced SrcFK activity in normal VSM contractile
function and in vascular remodelling in cardiovascular disease. VSM contractile responses to
G-protein-coupled receptor stimulation, as well as hypoxia in pulmonary artery, are shown to
be dependent on both ROS and SrcFK activity. Specific phosphorylation targets are identified
amongst those that alter intracellular Ca2+ concentration, including transient receptor potential
channels, voltage-gated Ca2+ channels and various types of K+ channels, as well as amongst
those that regulate actin cytoskeleton dynamics and myosin phosphatase activity, including
focal adhesion kinase, protein tyrosine kinase-2, Janus kinase, other focal adhesion-associated
proteins, and Rho guanine nucleotide exchange factors. We also examine a growing weight of
evidence in favour of a key role for SrcFKs in multiple pro-proliferative and anti-apoptotic
signalling pathways relating to oxidative stress and vascular remodelling, with a particular focus
on pulmonary hypertension, including growth-factor receptor transactivation and downstream
signalling, hypoxia-inducible factors, positive feedback between SrcFK and STAT3 signalling and
positive feedback between SrcFK and NADPH oxidase dependent ROS production. We also
discuss evidence for and against the potential therapeutic targeting of SrcFKs in the treatment of
pulmonary hypertension.
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Introduction: SrcFKs as ROS effectors in VSM
The purpose of this review is to highlight the inter-
actions between reactive oxygen species (ROS) and
Src-family kinases (SrcFKs), a family of non-receptor
tyrosine kinases, in the regulation of vascular smooth
muscle (VSM) function. We will examine evidence
supporting an important role for this interaction in
normal excitation–contraction coupling. We will also
provide details of the role of SrcFKs in oxidative
stress-related VSM proliferation and migration signalling
associated with vascular remodelling, with a focus on
pulmonary hypertension, and briefly comment on the
potential therapeutic use of SrcFK inhibitors against this
group of diseases. Firstly, however, we will set the scene by
describing ROS production in VSM, their role as second
messengers and mechanism of action on target proteins,
and evidence supporting SrcFKs as key proximal ROS
effectors in VSM.
Vascular ROS production. ROS are now considered as
bona fide second messenger molecules, being produced
within cells in response to physiological and patho-
physiological stimuli, acting on cellular target proteins
to reversibly alter cellular function. There are two
main sources of ROS in VSM. Firstly from cyto-
plasmic oxidoreductase enzymes, most notably NADPH
oxidase (NOX), which transfers an electron from cyto-
solic NADPH to molecular oxygen, generating super-
oxide (O2•−) (Bedard&Krause, 2007). Secondly, electrons
leaking from the mitochondrial electron transport chain
form superoxide in the mitochondrial inter-membrane
space (Turrens, 2003; Waypa et al. 2013). Super-
oxide readily reacts with nitric oxide (NO•), producing
peroxynitrite (ONOO−), or is converted to the more
stable hydrogen peroxide (H2O2) by superoxide dismutase
(SOD) (Bedard & Krause, 2007). H2O2 is in turn
fully reduced to H2O by catalase or converted to the
highly reactive hydroxyl radical via the Fenton reaction
(Fig. 1).
Vascular NOX activity is stimulated by various
G-protein-coupled receptor (GPCR) agonists including
angiotensin II, endothelin-1, thrombin, ATP and
thromboxane (Banes-Berceli et al. 2005; Madamanchi
et al. 2005; El-Awady et al. 2011; Chakraborti et al. 2012).
It is generally agreed that mitochondrial ROS production
is enhanced by hypoxia both in the short term and the long
term and, acutely, this is considered an important trigger
for the normal physiological vasoconstrictor response
to regional hypoxia in the pulmonary vascular bed
(Waypa et al. 2013). GPCR-induced arterial constriction is
generally relaxed by antioxidant enzymes,NOX inhibitors,
or small molecule antioxidants (El-Awady et al. 2011;
Connolly et al. 2013), while hypoxic pulmonary vaso-
constriction is enhanced by inhibitors of endogenous SOD
(Abdalla & Will, 1995) and inhibited by antioxidants and
inhibitors of mitochondrial electron transport function
(Connolly et al. 2013; Waypa et al. 2013). Conversely,
exogenous ROS generally enhance VSM proliferation
(Wedgwood et al.2001;Madamanchi et al.2005) and cause
constriction, especially inpulmonary artery, although they
may relax other vascular beds depending perhaps on the
nature of the pre-constricting agent (Knock et al. 2009;
Snetkov et al. 2011).
REDOX regulation of SrcFKs. ROS alter protein function
by chemically modifying specific amino acid residues.
Cysteine is relatively readily oxidised by superoxide and
H2O2, and S-nitrosylated by peroxynitrite. Peroxynitrite
also nitrates serine, threonine and tyrosine residues
(Fig. 1). Oxidation of paired cysteine residues within a
protein or in adjacent proteins may also result in the
formation of disulphide bridges, but is not an abso-
lute requirement for a change in protein function
(Janssen-Heininger et al. 2008). Cysteine oxidation
and nitrosylation, and to a lesser extent nitration, is
readily reversible through the action of REDOX buffer
systems, most notably glutathione reductase/peroxidase
(Janssen-Heininger et al. 2008). The susceptibility of
individual cysteine residues to oxidation varies between
proteins and between residues within the same protein,
depending on the ionisation pKa of the residue in
question (Chiarugi et al. 2003; Gusan&Anand-Srivastava,
2013).
c-Src is the principle member of a family of closely
related tyrosine kinases collectively known as the
Src-family kinases (SrcFKs). There are nine in total, of
which three (c-Src, Fyn and Yes) are highly expressed in
VSM (Nakao et al. 2002; Knock et al. 2008a). Note that
in this review we will refer to these kinases collectively
as SrcFKs, since Src, Fyn and Yes are difficult to separate
pharmacologically, and rarely has genetic manipulation
been used to determine their individual contributions to
VSM function. SrcFKs feature prominently among the
various classes of proteins that possess cysteine residues
with a pKa low enough for them to be oxidised by physio-
logical levels of ROS (Knock & Ward, 2011). Although
there may be specific exceptions, cysteine oxidation is
generally stimulatory of tyrosine kinase activity and
inhibitory of protein tyrosine phosphatase (PTP) activity
(Knock & Ward, 2011; Funato & Miki, 2014). Thus, it is
no surprise that increased ROS production in response
to various vasoactive stimuli is associated with an early
increase in total cellular tyrosine phosphorylation (Uzui
et al. 2000; Chiarugi et al. 2003; Knock et al. 2008a,b) and
that exogenous ROS enhance tyrosine phosphorylation
in vascular preparations, whilst antioxidants do the
opposite (Frank et al. 2001, 2003). Correspondingly, PTP
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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inhibitors tend to promote constriction, while tyrosine
kinase inhibitors, including those selective for SrcFKs,
tend to relax pre-constricted arteries (Jin & Rhoades,
1997; Knock et al. 2008a, 2009). SrcFKs are normally
activated by de-phosphorylation of the auto-inhibitory
C-terminal phospho-tyrosine (Tyr-527 in c-Src), and
subsequent auto-phosphorylation of the catalytic sub-
unit activation loop (Tyr-418 in c-Src) (Xu et al. 1999).
ROS activate SrcFKs throughmultiple mechanisms, firstly
by oxidising cysteine residues in the SH2 domain,
causing inter-molecular disulphide bridge formation and
disruption of internal Tyr-527–SH2 domain interaction,
secondly by oxidising cysteine residues on the SH2 and
kinase domains of the already active kinase, further
activating it, and thirdly by inhibiting their inactivation
through oxidative inhibition of an Src-specific PTP, and
of C-terminal Src-kinase (CSK) (Akhand et al. 1999;
Giannoni et al. 2005; Roskoski, 2005; Mills et al. 2007)
(Fig. 2).
SrcFKs are activated in smooth muscle by various vaso-
constrictor stimuli including GPCR agonists (Nakao et al.
2002;Knock et al.2008a), stretch (Gui et al.2010;Gonzales
et al. 2014) and hypoxia (Knock et al. 2008b), while VSM
contraction induced by exogenously applied H2O2, or by
artificially enhanced superoxide production, is sensitive to
SrcFK inhibition (Oeckler et al. 2003; Knock et al. 2009).
Thus, VSM responses to various stimuli may be mediated
via an interaction between ROS and SrcFKs. Indeed, as
discussed in the following sections, many of the numerous
SrcFK phosphorylation targets, including various classes
of ion channel, cytoskeletal proteins associated with small
G-proteins of the Rho family, growth-factor receptors,
other tyrosine kinases, and transcription regulators, are
phosphorylated in a ROS-dependent manner.
Figure 1. Generation, metabolism and action of ROS in VSM
Superoxide (O2•−) is generated by oxido-reductase enzymes in the plasma membrane, such as NADPH oxidase
(NOX). A reducing substrate, in this case NADPH, donates an electron which is transferred to molecular oxygen on
the extracellular surface (Bedard & Krause, 2007). Superoxide is generated in a similar manner by the mitochondrial
electron transport chain, principally complex III (Waypa et al. 2013). Superoxide can re-enter the cell or exit the
mitochondria through non-selective anion channels (NSAC), or is converted to H2O2 by cytosolic or mitochondrial
superoxide dismutase (SOD). Alternatively, superoxide may react with nitric oxide (NO•) to form the similarly reactive
peroxynitrite (ONOO−). H2O2 is converted to the highly reactive hydroxyl radical (OH•) via the Fe2+-catalysed Fenton
reaction or is fully reduced to H2O by catalase (CAT). Superoxide and H2O2 reversibly modify protein function
principally via oxidation of the sulfhydryl (R-SH) group of cysteine residues to sulfenic acid (R-SOH). Peroxynitrite
S-nitrosylates cysteine (R-SH → R-SOH + NO2−) and nitrates the hydroxyl groups of serine, threonine and tyrosine
residues (R-OH → R-NO2), and the latter is less readily reversible (Janssen-Heininger et al. 2008). OH• is highly
reactive, much less discriminating, and therefore potentially damaging to the cell.
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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SrcFKs and ROS in normal contractile function
The principle function of vascular smooth muscle is
to contract or relax in response to circulating or local
factors, thus contributing to the control of tissue blood
flow and mean arterial blood pressure. Smooth muscle
contraction is caused by the ratchet-like movement of
the molecular motor myosin along actin fibres. Myosin
ATPase activity, which triggers this movement, is initiated
by Ca2+/calmodulin-dependent phosphorylation of myo-
sin light-chain-20 (MLC20) by myosin light-chain kinase
(MLCK). Polymerisation of actin filaments and their
bundling with myosin into contractile fibres is also
dynamically regulated, as is the association of these fibres
with integrin-rich focal adhesions which permit the trans-
mission of contractile force to the extracellular matrix, as
well as acting as platforms formultiple signalling pathways
(Ridley & Hall, 1992; Min et al. 2012; Sreenivasappa et al.
2014). In this section, we describe how ROS and SrcFKs
regulate contractile force via changes to the free intra-
cellular Ca2+ concentration ([Ca2+]i) to influence MLCK
activity, by inhibiting the activity of myosin light-chain
phosphatase (MLCP) which de-phosphorylates MLC20,
and by regulating actin polymerisation and focal adhesion
signalling through the activation of the small monomeric
G-protein RhoA and various adaptor proteins associated
with integrins.
Regulation of ion channels. Many vasoconstrictors
that bind Gq-coupled receptors activate phospholipase
C-β (PLC-β) to induce inositol 1,4,5-trisphosphate
(IP3)-dependentCa2+ release from the sarco-endoplasmic
reticulum and open diacylglycerol (DAG)-sensitive trans-
ient receptor potential (TRP) non-selective cation
channels. The resultant depolarisation then triggers influx
through voltage-dependent Ca2+ channels. Exogenous
ROS enhance agonist-induced increases in [Ca2+]i and
contraction in pulmonary artery (Snetkov et al. 2011)
and these effects may be in part via activation of
SrcFKs, since GPCRs stimulate SrcFKs to further activate
TRP channels through tyrosine phosphorylation of
PLC-γ (Vazquez et al. 2004; Gonzales et al. 2014),
or via direct phosphorylation of canonical TRP family
members on the cytosolic N-terminus, which has
been shown as an obligatory step in their activation
(Kawasaki et al. 2006). Alternatively, SrcFKs also directly
phosphorylate voltage-gated Ca2+ channels, specifically
Figure 2. Activation of Src by ROS in VSM
Src activation is normally promoted by de-phosphorylation of the auto-inhibitory Tyr-527, disrupting intra-molecular
binding with the SH2 domain. This promotes auto-phosphorylation of Tyr-418 on the activation loop, opening up
the kinase domain for substrate binding. Additionally, SrcFKs are both directly and indirectly REDOX sensitive, being
activated by: (i) ROS-induced intermolecular disulphide bridge formation which promotes trans-phosphorylation
of Tyr-418 (Akhand et al. 1999), (ii) oxidation of cysteine residues in the SH2 (Cys-245) and kinase (Cys-487)
domains, which further activates an already active Src (Giannoni et al. 2005), (iii) via oxidative inactivation of the
inhibitory c-Src kinase (CSK), which phosphorylates the auto-inhibitory C-terminal Tyr-527 (Mills et al. 2007), or
(iv) oxidative inactivation of Src-specific PTPs which de-phosphorylate Tyr-418 on the activation loop (Roskoski,
2005). Specific amino acid numbers given refer to the sequence in human c-Src.
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the α1C pore-forming subunit of CaV1.2, which facilitates
its binding to α5β1 integrin, a step which is necessary for
its contribution to myogenic contraction (Gui et al. 2010)
(Fig. 3).
K+ channels are also phosphorylation targets for
SrcFKs and in the systemic circulation there is
evidence that this phosphorylation may be stimulatory
or inhibitory. In mesenteric artery, serotonin-induced
SrcFK activity results in inhibition of KV current, thus
contributing to contraction (Sung et al. 2013). There is
conflicting evidence over the effects of SrcFK-dependent
phosphorylation on large conductance Ca2+-activated
potassium (BKCa) channels, with inhibition being
reported in rat aorta (Alioua et al. 2002) and activation
being reported in rat cremaster VSM,which also promotes
association of the channel with integrins (Gui et al.
2010). The reasons for these discrepancies are unclear,
but perhaps relate to differences in vascular bed or
experimental conditions. In some vascular beds where
K+ channel activity has a particularly strong influence
on vascular tone, a stimulatory effect of SrcFKs on K+
currents may account at least in part for the occasionally
observed relaxing effects of ROS. For example, H2O2
enhances large conductance Ca2+-activated K+ (KCa)
channel activity in coronary VSM, accounting for its
endothelium-derived hyperpolarising factor-like activity
in that vascular bed (Barlow et al. 2000), and mesenteric
artery pre-constricted with a GPCR agonist, but not with
30 mM KCl, is relaxed by superoxide and this is associated
with reduced [Ca2+]i and enhanced voltage-gatedK+ (KV)
current (Snetkov et al. 2011) (Fig. 3).
As described in the introductory section, pulmonary
artery differs from most systemic vascular beds by
constricting in response to hypoxia and this constriction
is generally considered to occur as a result of increased
mitochondrial ROS production (Waypa et al. 2013).
Coupled with this, SrcFKs are activated by hypoxia (Sato
et al. 1999, 2005; Knock et al. 2008b), and SrcFK inhibition
Figure 3. SrcFKs and ROS modulate ion channel activity and contraction in VSM
GPCR stimulation activates Gq and phospholipase C-β (PLC-β) to generate diacylglycerol (DAG), which opens
C-type transient receptor potential (TRP) channels. GPCRs also induce ROS-dependent activation of SrcFKs which
phosphorylate and activate phospholipase C-γ (PLC-γ ) or directly phosphorylate TRP channels on the cytoplasmic
N-terminal domain (e.g. Tyr-226 on TRPC3; Kawasaki et al. 2006), further enhancing their activity. Resultant
cationic influx depolarises the cell (+Vm), which in turn opens voltage-gated Ca2+ channels (VGCC). SrcFKs
also phosphorylate and further activate VGCCs (e.g. Tyr-2122 on the α1C pore-forming subunit of CaV1.2; Gui
et al. 2010), promoting their association with integrins (e.g. α5β1; Gui et al. 2010). VGCC opening elevates
intracellular [Ca2+] ([Ca2+]i); Ca2+ binds calmodulin (CAM), which activates myosin light-chain kinase (MLCK)
which in turn phosphorylates myosin light-chain-20 (MLC) to initiate contraction. SrcFKs may also phosphorylate
K+ channels of the Ca2+-activated (BKCa), voltage-gated (KV) and two-pore acid-sensitive (TASK) types, thus
limiting depolarisation. This phosphorylation may be stimulatory or inhibitory and in pulmonary artery, whether
hypoxia enhances (Waypa et al. 2013) or inhibits (Wu et al. 2007) ROS production, determines whether SrcFKs are
activated or inhibited by hypoxia, thus enhancing or limiting cell depolarisation, which is of potential importance
in pulmonary hypoxic vasoconstriction (see main text for explanation).
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reduces hypoxic constriction in pulmonary artery (Knock
et al. 2008b). A recent study on the two-pore acid-sensitive
K+ channel TASK-1 in pulmonary VSM has shown this
channel to be phosphorylated and opened by SrcFKs, and
using this model to explain how SrcFKs contribute to
hypoxic pulmonary vasoconstriction, SrcFKs are shown to
be inhibited by hypoxia thus reducing TASK-1 current and
causing depolarisation (Nagaraj et al. 2013). Paradoxically,
this latter study is only consistent with the wealth of
evidence that SrcFKs are activated by ROS if hypoxia
inhibits mitochondrial ROS production (Wu et al. 2007),
contradicting the aforementioned work of Waypa et al.
Perhaps direct evidence for an involvement of SrcFKs
in the relationship between ROS and K+ channels in
pulmonary VSM, and the relative importance of K+
channels to pulmonary vascular tonewould help to resolve
this apparent discrepancy. Interestingly, ROS do not relax
pre-constricted pulmonary artery, despite K+ current
being enhanced by ROS to a degree similar to that in
mesenteric VSM (Snetkov et al. 2011), perhaps due to a
relative dominance of ROS-inducedRho-kinase activity in
pulmonary VSM (Knock et al. 2009; Snetkov et al. 2011),
as discussed below.
Regulation of RhoA/ROCK. The monomeric G-protein
RhoA and its effector kinase, Rho-kinase (ROCK),
are essential regulators of actin polymerisation, focal
adhesion assembly and MLCP activity. Many contra-
ctile stimuli, including various GPCR agonists, hypo-
xia and exogenous ROS, activate RhoA/ROCK in VSM,
and there is pharmacological evidence that this activity
is in part dependent on SrcFKs (Nakao et al. 2002;
Knock et al. 2008a,b), presumably downstream of RhoA
activation. RhoA is activated by exchange of bound GDP
forboundGTPand this is promotedbyguaninenucleotide
exchange factors (GEFs) (Bos et al. 2007). Several
RhoA-specific GEFs (ARHGEFs) are expressed in VSM
(Cario-Toumaniantz et al. 2012) and they are activated
directly by G12/13 and/or by tyrosine phosphorylation,
which may be promoted by ROS (Chandra et al. 2012).
It has been hypothesised that SrcFKs may activate
RhoA via GEF phosphorylation (Knock et al. 2008a;
Sreenivasappa et al. 2014), but to date this has not been
demonstrated directly. Instead, RhoGEFs are known to be
phosphorylated and activated by three other non-receptor
tyrosine kinases, focal adhesion kinase (FAK), protein
tyrosine kinase-2 (PYK2) or Janus kinase (JAK2) (Lim
et al. 2008; Guilluy et al. 2010; Gadepalli et al. 2012).
Although these three kinases are not known to be directly
ROS sensitive, they are activatable byGPCR agonists in the
vascular wall in a NOX-dependent manner, as well as by
exogenous ROS (Vepa et al. 1999; Frank et al. 2003; Daou
& Srivastava, 2004) and through SrcFK-mediated tyrosine
phosphorylation (Calalb et al. 1995; Andreev et al. 2001;
Singh et al. 2011). JAK additionally appears to require
prior ROS-dependent activation of PYK2 (Frank et al.
2002) (Fig. 4).
Active RhoA promotes actin fibre nucleation, poly-
merisation and bundling into contractile fibres in
association with SrcFKs, FAK, paxillin and other adapter
proteins at focal attachments as well as chaperone
proteins such as mDia (Geneste et al. 2002; Lim
et al. 2008). Also, ROCK phosphorylates and activates
LIM-kinase,which in turnphosphorylates and inhibits the
actin-severing protein cofilin, thus promoting actin fibre
stability (Geneste et al. 2002) (Fig. 4). Contractile stimuli
induce SrcFKs to phosphorylate several proteins at focal
adhesions, including FAK (Tyr-925), paxillin (Tyr-118)
and Cas (Tyr-165) (Min et al. 2012). MLCP activity
is constitutive and does not require active stimulation,
but contractile stimuli that raise [Ca2+]i can further
enhance MLC20 phosphorylation by actively inhibiting
MLCP. The resultant further enhancement of MLC20
phosphorylation above that induced by raising [Ca2+]i is
known as ‘Ca2+ sensitisation’. Rho-kinase phosphorylates
myosin phosphatase targeting subunit-1 (MYPT-1) on at
least two threonine residues, which result in disassembly
of the MLCP holoenzyme (Thr-850), or a reduction in
its phosphatase activity (Thr-696), respectively (Ichikawa
et al. 1996; Velasco et al. 2002) (Fig. 4).
SrcFKs and ROS in pulmonary hypertension
Pulmonary hypertension is a spectrum of diseases which
includes pulmonary hypertension due to hypoxia and/or
respiratory disease (PH) and pulmonary arterial hyper-
tension (PAH) which has various causes, both known
and unknown. Both PH and PAH are characterised
by remodelling of the pulmonary vasculature and
hyper-responsiveness to constrictor stimuli, resulting
in increased pulmonary vascular resistance and sub-
sequent right heart failure and death (Simonneau et al.
2009). Vascular remodelling includes smooth muscle
proliferation and migration which normally contribute
to tissue growth and repair, but otherwise are usually
suppressed in favour of a contractile phenotype. Occlusive
cardiovascular diseases on the other hand, are associated
with excessive or dysregulated VSM proliferation and
migration. These changes have been strongly linked
with excessive and poorly regulated ROS production,
with contributions from altered expression of oxidant
and antioxidant enzymes, endothelial dysfunction and
increased sensitivity to, or increased availability of
ROS-stimulating factors, resulting in an abnormal shift
in smooth muscle REDOX state in favour of oxidation,
commonly described as ‘oxidative stress’. Enhanced
mitochondrial and/or NOX-derived ROS coupled with
reduced expression of antioxidant enzymes have been
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implicated in the pathogenesis of both PH and PAH
(Liu et al. 2006; Crosswhite & Sun, 2010; Reis et al.
2013).
SrcFKs, as key ROS targets in VSM, and known
mediators of smooth muscle proliferation and migration
(Krymskaya et al. 2005; Pullamsetti et al. 2012),
are therefore well placed to contribute to oxidative
stress-related vascular remodelling. ROS promote cell
migration (Wang et al. 2014), acting in part through
activation of SrcFKs and FAK at focal adhesions
(Timpson et al. 2001; Chiarugi et al. 2003; Giannoni
et al. 2005). As discussed in the previous section, and
shown in Fig. 4, SrcFKs promote actin contractile fibre
formation through tyrosine phosphorylation of multiple
protein targets including paxillin, Cas, RhoGEFs and
activation of RhoA. This is also important in cell
migration, but occurs alongside disassembly of cell–cell
junctions (Frame et al. 2002) and activation of the mono-
meric G-proteins cdc42 and Rac-1, which generate cycles
of filopodia formation and cell spreading, respectively, at
the leading edge of themigrating cell (Nobes&Hall, 1995).
In the remaining sections of this review, with a particular
focus on pulmonary hypertension, we will examine how
ROS and SrcFKs interact to induce VSM proliferation, via
transactivation of growth factor receptors, signal trans-
ducer and activator of transcription-3 (STAT3) and hypo-
xic inducible factors, and through positive feedback,
further enhance ROS production. Finally, we will discuss
evidence for and against targeting SrcFKs as treatments
for PH/PAH.
SrFK, ROS and growth factor transactivation. ROS-
generating stimuli use multiple signalling pathways to
induce VSM growth and proliferation. An early step
following activation of SrcFKs is the activation of receptor
tyrosine kinases, and here we will focus on two of the
most important of these, the epidermal growth factor
receptor (EGFR) and the platelet-derived growth factor
Figure 4. SrcFKs mediate ROS-induced activation of RhoA and Rho-kinase in VSM
(i) GPCRs and hypoxia induce ROS production (via NOX and mitochondrial electron transport chain, respectively,
see Fig. 1), which activate SrcFKs. GPCRs also activate G12/13. RhoA is activated by exchange of bound GDP for
bound GTP and this is promoted by guanine nucleotide exchange factors (RhoGEFs). RhoGEFs may be activated
by G12/13 and/or by tyrosine phosphorylation. SrcFKs activate other non-receptor tyrosine kinases focal adhesion
kinase (FAK), protein tyrosine kinase-2 (PYK2) or Janus kinase (JAK2), all of which may activate RhoGEFs. SrcFKs
may also directly activate RhoGEFs but this has not been clearly demonstrated (dotted line). JAK2 activity may also
require prior PYK2 activity. (ii) Contraction requires polymerisation and bundling of actin filaments into contractile
fibres and their attachment at focal adhesions, which are composed in part of integrins, talin and vinculin, and
various adapter proteins including FAK, paxillin and Cas, which are phosphorylated by SrcFKs. RhoA at focal
adhesions promotes actin polymerisation and bundling, in part through association with paxillin and activation
of the actin chaperone protein mDia. (iii) RhoA also activates Rho-kinase (ROCK) which further promotes actin
polymerisation by activating LIM-kinase (LIMK), which in turn prevents cofilin from severing actin filaments. ROCK
also phosphorylates the myosin targeting subunit of myosin phosphatase (MLCP) resulting in reduced myosin
light-chain de-phosphorylation, thus enhancing net MLC phosphorylation and contraction.
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receptor (PDGFR). In response to ROS-generating
stimuli, receptor tyrosine kinases are activated in the
absence of their natural ligands through a process
known as transactivation (Saito & Berk, 2001). After
growth factor binding, the receptor forms homodimers
and auto-phosphorylates multiple tyrosine residues
on its cytoplasmic regions. During transactivation in
response to GPCR agonists such as endothelin-1 and
angiotensin II, these residues are instead phosphorylated
in a ROS-dependent manner by SrcFKs (Heeneman et al.
2000; Oeckler et al. 2003; Chen et al. 2006; Nakashima
et al. 2006). The resultant phospho-tyrosines then act
as docking sites for multiple SH2-domain-containing
proteins, which in turn trigger multiple downstream
signalling events. Here and in Fig. 5, using PDGFR as an
example,wedescribe fourof themost fully characterisedof
these signalling pathways. Transactivated PDGFR recruits
the adapter proteins Shc and growth-factor receptor
boundprotein-2 (GRB2) (Ward et al. 1996; Ravichandran,
2001). SrcFKs subsequently phosphorylated Shc to
provide further binding sites for GRB2 (Ravichandran,
2001). GRB2 can then bind and activate the guanine
nucleotide exchange factor for Ras, son-of-sevenless
(SOS). Activated Ras then initiates the Raf/MEK/ERK
mitogen-activated protein (MAP) kinase cascade,
promoting cell division. PLC-γ also binds PDGFR in
VSM and is activated by ROS-dependent SrcFK-mediated
phosphorylation (Saito et al. 2002; ten Freyhaus et al.
2011), and the subsequent sustained elevation in
[Ca2+]i contributes to sustained ERK activation (Egan
et al. 2005). Phosphatidyl inositol-3-kinase (PI3K) is
also phosphorylated by SrcFKs following binding to
the transactivated PDGFR (ten Freyhaus et al. 2011;
Karoor et al. 2013) and this phosphorylation relieves
intra-molecular PI3K auto-inhibition (Cuevas et al. 2001;
Choudhury et al. 2006). PI3K then generates phosphatidyl
inositol trisphosphate (PIP3), which through membrane
localisation and activation of Akt (protein kinase B) and
PDK initiates the Bad and S6 kinase anti-apoptotic and
protein synthesis pathways (Eguchi et al. 1999). SrcFKs
further enhance this signalling by phosphorylating and
inhibiting phosphatase and tensin homologue (PTEN),
preventing it from de-phosphorylating PIP3 (Lu et al.
2003; Karoor et al. 2013).
Figure 5. Role of SrcFKs in growth factor receptor transactivation and mitogenic signalling in VSM
(i) GPCR-induced or hypoxia-induced ROS stimulate SrcFKs to phosphorylate platelet-derived growth factor
receptor (PDGFR) on multiple tyrosine residues. This occurs in the absence of native PDGF ligand (trans-
activation). (ii) PDGFR recruits the adapter proteins Shc and growth factor receptor bound protein-2 (GRB2)
on phosphorylated Tyr-557 and Tyr-684, respectively (Ward et al. 1996). SrcFKs subsequently phosphorylate Shc
to provide further binding sites for GRB2. GRB2 can then bind and activate the guanine nucleotide exchange
factor for Ras, son-of-sevenless (SOS). Activated Ras then initiates the Raf/MEK/ERK mitogen-activated protein
kinase cascade, promoting cell division. In addition, PLC-γ binds PDGFR at phosphorylated Tyr-1021 (Saito et al.
2002) and is then itself phosphorylated and activated by SrcFK. Activated PLC-γ induces a sustained elevation in
[Ca2+]i which contributes to sustained ERK activation. (iii) Phosphatidyl inositol-3-kinase (PI3K) binds PDGFR at
phosphorylated Tyr-751 (Karoor et al. 2013), followingwhich it is phosphorylated and activated by SrcFKs. PI3K then
phosphorylates phosphatidyl inositol bisphosphate (PIP2) to generate phosphatidyl inositol trisphosphate (PIP3).
SrcFKs also phosphorylate and inhibit phosphatase and tensin homologue (PTEN), preventing de-phosphorylation
of PIP3. PIP3 promotes the membrane localisation of Akt and PDK, allowing PDK to phosphorylate and activate
Akt. Activated Akt initiates the Bad and S6 kinase (S6K) anti-apoptotic and protein synthesis pathways.
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Reciprocal relationship between SrcFKs and ROS.
Chronic hypoxia triggers a sustained enhancement in
mitochondrial ROS production in VSM, resulting in
enhanced SrcFK activity (Sato et al. 2005). However, as
well as being a key downstream effector of ROS, SrcFKs
also contribute to the activation of NOX. In response to
GPCR stimulation, SrcFKs phosphorylate the p47phox sub-
unit of NOX and trigger the activation of Rac-1, which is
required for holoenzyme assembly (Seshiah et al. 2002;
Chowdhury et al. 2005). Coupled with the steady increase
in basal mitochondrial ROS production described above,
increased expression of NOX, and reduced expression of
antioxidant enzymes in PH and PAH (Liu et al. 2006; Reis
et al. 2013), this apparent positive feedback relationship
between ROS and SrcFK activity could not only facilitate
the prolonged sustained increases in ROS characteristic of
oxidative stress in PH/PAH, but may also be required for
the long-term changes in VSM phenotype, migration and
proliferation induceddownstreamof SrcFKs (Seshiah et al.
2002) characteristic of pulmonaryhypertension, acting via
growth-factor receptor transactivation, and as discussed
below, hypoxia-inducible factor (HIF)-1α/2α and STAT3
activation (Fig. 6).
ROS, SrcFKs and altered gene expression via hypoxia-
inducible factor and STAT3. SrcFKs are implicated
in several additional signalling pathways considered
important in VSM remodelling in PH/PAH. For example,
they also contribute to VSM migration and proliferation
by increasing the availability of hypoxia-inducible factors
(HIF-1α andHIF-2α) (Sato et al. 2005). In normoxia, HIF
levels are kept low by prolyl hydroxylation and subsequent
proteolysis; however, in response to chronic hypoxia,
ROS-induced SrcFKs phosphorylate and inhibit prolyl
hydroxylase (PLH) and/or von Hippel-Lindau tumour
suppressor protein (VHL), thus increasing the availability
of HIF (Chan et al. 2002; Sato et al. 2005; Chou et al.
2010). ActivatedHIF alters the expression of awide variety
of proteins that contribute to the enhanced proliferation,
Figure 6. Role of SrcFKs in pulmonary hypertension
(i) Pulmonary hypertension induced by chronic hypoxia (PH) is associated with enhanced mitochondrial ROS
production. PH and pulmonary arterial hypertension (PAH) are both also associated with enhanced NOX expression
and activity and reduced antioxidant expression and activity, further elevating ROS production. In addition to being
activated by ROS, SrcFKs also in turn enhance NOX activity through phosphorylation of the p47phox subunit and
activation of Rac-1 which is required for NOX holo-enzyme assembly, therefore generating a positive feedback
loop between ROS and SrcFKs. (ii) SrcFKs phosphorylate and inactivate two enzymes, prolyl hydroxylase (PLH) and
von Hippel-Lindau tumour suppressor protein (VHL), thus preventing the prolyl hydroxylation and degradation
of hypoxia inducible factor-1α or -2α (HIF1α/2α). HIF enhances the expression of platelet-derived growth factor
(PDGF) and its receptor (PDGFR) and inhibits the expression of tyrosine phosphatases that oppose the activity of
SrcFKs and PDGFR. (iii) SrcFKs phosphorylate and activate the transcription factor, signal transducer and activator
of transcription-3 (STAT3). STAT3 inhibits the expression of microRNA-204 (miR-204) and bone morphogenetic
protein receptor-II (BMPRII) which inhibit the expression and activity of SrcFKs, respectively. STAT3 therefore
indirectly enhances expression and activity of SrcFKs, generating a second positive feedback loop. STAT3 also
up-regulates three additional mitogenic signals: nuclear factor of activated T-cells (NFAT), Survivin and Pim-1. This
activity, coupled with HIF activation, oxidative stress and direct SrcFK transactivation of PDGFR (Fig. 5), results in
greatly enhanced VSM proliferation, migration and inhibition of apoptosis.
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migration and hyper-contractility associated with PH,
including increases in expression of growth factors and
their receptors (Shimoda & Laurie, 2014; Smith & Yuan,
2014) and decreases in expression of protein tyrosine
phosphatases that oppose the actions of SrcFKs and
PDGFR (ten Freyhaus et al. 2011) (Fig. 6).
STATs are activated by tyrosine phosphorylation,
which triggers their dimerisation and translocation
to the nucleus. This phosphorylation is typically
mediated by Janus kinase following cytokine receptor
activation. However, in PH, ROS-induced SrcFKs may
also phosphorylate and activate STAT3 independently
of JAK, perhaps in association with growth-factor
receptors. Activated STAT3 subsequently up-regulates the
expression of nuclear factor of activated T-cells (NFAT),
Pim-1 and Survivin, promoting VSM proliferation
and inhibiting apoptosis (Paulin et al. 2011). STAT3
also inhibits the expression of the anti-proliferative
bone morphogenetic protein receptor-II (BMPRII) and
micro-RNA-204 (miR-204) (Paulin et al. 2011), and since
BMPRII normally inhibits SrcFK auto-phosphorylation
(Wong et al. 2005), while miR-204 inhibits its expression,
STAT3 indirectly stimulates expression and activity of
SrcFKs. Furthermore, some forms of familial PAH are
also associated with a constitutive deficiency in miR-204
levels and/ormutations in BMPRII that render it unable to
inhibit SrcFKs (Wong et al. 2005; Courboulin et al. 2011).
Thus, through STAT3, there is the potential for a second
positive feedback loop enhancing the activation of SrcFKs
and downstream signalling in both PH and PAH (Fig. 6).
SrcFKs as a therapeutic target in pulmonary hyper-
tension? Considering the evidence in support of a
key role for SrcFKs in smooth muscle function, both
normal (constriction) and abnormal (oxidative stress,
vascular remodelling), one might expect them to be
potential therapeutic targets for the treatment of cardio-
vascular disease in general and pulmonary hypertension
in particular. SrcFK-selective inhibitors have been tested
against some cancers but so far the focus of the search
for effective treatments against pulmonary hypertension
has been on a group of mixed specificity inhibitors
exemplified by imatinib and related compounds that
target PDGFR, c-Kit and c-Abl, originally designed as
anti-cancer drugs (Iqbal & Iqbal, 2014). These have
been tested against animal models of PAH and PH with
promising results (Schermuly et al. 2005; Berghausen et al.
2013), and a recent clinical trial also suggests that imatinib
improves cardiac function in a cohort of patients with
PAH (Shah et al. 2014). Interestingly, although specific
SrcFK inhibitors have yet to be tested in this context,
a comparison of two PDGFR antagonists, imatinib and
dasatinib, showed dasatinib to be the most potent against
hypoxia-induced VSM migration and proliferation and
morphological changes associated with PH, and the
difference was attributed to the additional inhibition of
SrcFKs by dasatinib (Pullamsetti et al. 2012). However,
the impact of this finding has been muddled somewhat by
recent reports that dasatinib, while in use as an anti-cancer
drug actually induces pulmonary hypertension in human
subjects, presumably throughvasoconstriction rather than
remodelling since it is readily reversible (Godinas et al.
2013; Seferian et al. 2013). This is consistent with a
reported acute enhancement of pulmonary perfusion
pressure in isolated mouse lung by both dasatinib and the
selective SrcFK inhibitor PP2 (Godinas et al. 2013; Nagaraj
et al. 2013) and consistent with the finding that SrcFKs
phosphorylate and activate TASK channels in pulmonary
VSM (Nagaraj et al. 2013), but not with the weight
of evidence showing SrcFK to be both pro-contractile
and pro-proliferative in its actions. Nevertheless, whether
these unwanted effects of dasatinib in the clinical setting
are indeed mediated through SrcFKs or are independent
of tyrosine kinase inhibition remains to be confirmed,
considering that no reports of selective SrcFK inhibitors
inducing PH in humans have been made.
Conclusions
In summary, there is clear evidence placing SrcFKs as
key ROS effectors in VSM, acting both as mediators
of normal smooth muscle contractile responses, via
modulation of ion channel and RhoA/Rho-kinase activity,
and as mediators of uncontrolled VSM proliferation
and migration in response to oxidative stress, acting
upon multiple downstream signalling pathways including
growth-factor receptor transactivation, STAT3 and
hypoxia-inducible factors. More specifically, there is
also considerable evidence implicating SrcFKs in the
pathogenesis of pulmonary hypertension, but more
research is required to attribute the experimental and
clinical effects of mixed-specificity kinase inhibitors to
specific tyrosine kinases such as SrcFKs.
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